Compound for selectively degrading smarca2 / 4 and use thereof

By designing PROTAC compounds with structures of Formula I and Formula II, the problem of selective degradation of SMARCA2/4 in the prior art has been solved, achieving effective treatment of SMARCA4-deficient cancers, enhancing the therapeutic effect and reducing the impact on normal cells.

WO2026233437A1PCT designated stage Publication Date: 2026-11-12GAN & LEE PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095753
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-02-14
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing technologies have difficulty selectively degrading SMARCA2/4 proteins, posing a challenge to the treatment of SMARCA4-deficient cancers. Furthermore, traditional small molecule drugs lack selectivity and stability, making it difficult to effectively inhibit tumor cell proliferation.

Method used

PROTAC compounds with Formula I and Formula II structures were developed to selectively degrade SMARCA2/4 by linking part L with specific PTM and ULM. SMARCA2/4 protein was degraded using protein degradation targeted chimeras (PROTACs) technology.

Benefits of technology

It achieves selective degradation of SMARCA2/4, enhances the therapeutic effect on SMARCA4-deficient cancers, reduces side effects on normal cells, and improves the selectivity and stability of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026095753-FTAPPB-I100001
    Figure PCTCN2026095753-FTAPPB-I100001
  • Figure PCTCN2026095753-FTAPPB-I100002
    Figure PCTCN2026095753-FTAPPB-I100002
  • Figure PCTCN2026095753-FTAPPB-I100003
    Figure PCTCN2026095753-FTAPPB-I100003
Patent Text Reader

Abstract

The present disclosure relates to a compound useful as an SMARCA2 / 4 modulator. Specifically, the compound involved in the present disclosure contains a ligand that binds to E3 ubiquitin ligase on one end, and a ligand that binds to a target protein (SMARCA2 / 4) on the other end, such that the target protein is placed near the ubiquitin ligase to achieve degradation (or inhibition) of the target protein.
Need to check novelty before this filing date? Find Prior Art

Description

A compound that selectively degrades SMARCA2 / 4 and its applications

[0001] This application claims priority to Chinese Patent Application No. 202510588010X, filed May 8, 2025; Chinese Patent Application No. 2025106688155, filed May 23, 2025; Chinese Patent Application No. 2025108013667, filed June 16, 2025; Chinese Patent Application No. 2025118453339, filed December 9, 2025; Chinese Patent Application No. 2025120374284, filed December 31, 2025; Chinese Patent Application No. 2026101218660, filed January 29, 2026; and Chinese Patent Application No. 202610215902X, filed February 14, 2026, all of which are incorporated herein by reference in their entirety. Technical Field

[0002] This invention relates to the pharmaceutical field, and more specifically to a compound that can selectively degrade SMARCA2 / 4, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, or polymorph thereof, and its use in the prevention or treatment of diseases or conditions mediated by SMARCA2 / 4. Background Technology

[0003] SMARCA2 / 4 are important subunits of the SWI / SNF chromatin remodeling complex, also known as the BAF complex. Chromatin, the carrier of genetic information in eukaryotes, is composed of DNA and nucleosomes and is usually in a highly dense state. When a gene at a specific site needs to be transcribed, the chromatin changes from a dense to a loose state; this process requires the participation of the chromatin remodeling complex. The chromatin remodeling complex uses the energy from ATP hydrolysis to reposition, assemble, migrate, and reorganize nucleosomes, altering chromatin structure and thus changing the "accessibility" of transcription factors and cellular proteins to local DNA. When the chromatin structure tends to be loose under the influence of chromatin remodeling factors, the accessibility of RNA polymerase II, transcription factors, etc., to chromatin DNA increases, thereby initiating gene transcription; conversely, when the chromatin structure tends to be dense, the accessibility of RNA polymerase II and transcription factors to chromatin DNA decreases, thereby inhibiting the transcription of related genes. Chromatin remodeling, a crucial aspect of epigenetic regulation, plays a vital role in eukaryotic DNA replication, transcription, recombination, and DNA repair, thereby controlling cell proliferation, division, and maturation. SWI / SNF can alter chromatin disassembly and the replacement of nucleosome stabilizing proteins, thus regulating gene expression. SMARCA4 (BRG1 protein) and SMARCA2 (BRM protein) are two mutually exclusive catalytic subunits constituting the SWI / SNF complex. They share 75% homology at the protein level and both possess ATPase activity, providing energy for chromatin remodeling. The ATP-dependent chromatin remodeling activity of SMARCA2 or SMARCA4 is essential, primarily involved in double-strand break and nucleotide excision repair, playing a crucial role in double-strand damage repair. Therefore, SMARCA mutations can lead to uncorrected or inappropriate DNA damage repair, constituting a driving factor in tumorigenesis and development.

[0004] In certain tumor types, mutations within the SWI / SNF complex lead to specific background vulnerabilities, such as the requirement of SMARCA2 for tumor cells lacking SMARCA4 to survive. This finding of a lethal relationship in SMARCA2 / 4 synthesis has been translated in vivo, highlighting SMARCA2 as a promising therapeutic target for SMARCA4-deficient cancers. Furthermore, the SMARCA4-deficient patient population typically lacks targetable oncogenes (such as mutant EGFR or ALK translocations), further emphasizing the potential for developing SMARCA2 inhibitors. SMARCA4 functional characterization in tumors with high SMARCA4 levels has revealed its role in signaling pathways leading to increased proliferation and survival. Knockdown of SMARCA4, which shows elevated levels in known tumors, is known to suppress proliferation and other cancer cell properties. The study also showed that SMARCA4 knockdown / modulation increases sensitivity to known chemotherapeutic agents, suggesting that SMARCA4 targeting may also be an adjunct therapy to existing chemotherapeutic treatments (PNAS February 25, 2014.111(8)3128-3133; J Pathol.2016Feb;238(3):389–400).

[0005] In contrast to the genetic silencing of SMARCA2, which leads to potent antiproliferative activity in SMARCA4-deficient cancer cell lines, pharmacological studies of PFI-3 (a selective, cell-penetrating SMARCA2 / 4 bromodomain inhibitor that binds to both SMARCA2 and SMARCA4 bromodomains) have failed to demonstrate an antiproliferative phenotype, suggesting that bromodomain function of SMARCA2 / 4 is unnecessary for tumor cell proliferation, while catalytic ATPase activity is essential (Cancer Res. 2015 Sep 15; 75(18):3865–3878). Therefore, to mimic the phenotype achieved through genetic silencing, methods to reduce or completely eliminate SMARCA2 / 4 may be necessary.

[0006] Protein degradation-targeting chimeras (PROTACs) are a promising emerging technology that holds the potential to transform many umdruggable potential targets into druggable ones. Traditional small-molecule drugs are often ineffective against proteins that constitute approximately 80% of human protein and lack enzymatic function, as these drugs typically require binding to enzymes or receptors to exert their effects. PROTACs consist of three parts: a warhead that recruits an amchor to an E3 ubiquitin ligase to bind to the target protein (POI), and a linker that connects the two parts. Traditional small molecules exert their pharmacological effects through occupancy-driven mechanisms at key sites on the target protein, thus requiring a certain in vivo drug concentration and demanding high-quality binding sites. PROTACs, however, achieve their pharmacodynamic effects by degrading the target protein, theoretically without requiring very high drug concentrations.

[0007] SMARCA2 and SMARCA4 have two main functional regions: an ATPase region and a bromodomain. The amino acid residue homology between these two functional regions is greater than 90%. Small molecule inhibitors often struggle to achieve selectivity for SMARCA4 and SMARCA2, and they typically also exhibit strong cytotoxicity against normal cells. Clinically, there is an urgent need for PROTAC molecules with excellent stability and activity, and good selectivity for either SMARCA2 or SMARCA4. Summary of the Invention

[0008] In view of this, one aspect of the present disclosure provides a compound having the structure of Formula I: PTM-L-ULM (Formula I),

[0009] Or its pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, or polymorphs.

[0010] in:

[0011] L is the chemical linker connecting ULM and PTM;

[0012] The PTM is selected from the following structures:

[0013] in,

[0014] R b2 For N or CR a2 ;

[0015] R b3 For N or CR a3 ;

[0016] R b4 For N or CR a4 ;

[0017] R b5 For N or CR a5 ;

[0018] R a7 R a8 and R a9 Each occurrence is independently selected from N and CR. b ;

[0019] R b R a1 R a2 R a3 R a4 and R a5 Each occurrence is independently selected from hydrogen, deuterium, halogen, nitro, amino, cyano, hydroxyl, alkyl, alkoxy, haloalkyl, haloalkoxy, deuterated alkyl, heteroalkyl, alkenyl, alkynyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -C 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)H and -O-cycloalkyl;

[0020] ULM is selected from the following structure:

[0021] in:

[0022] W3 is independently C (=O) or C (=S) each time it appears;

[0023] Z is either N or CR each time it appears. m ;

[0024] G1 and G2 are each independently selected from O, S, and Se each time they appear;

[0025] R3, R4, R5, and R6, each when appearing independently, are each selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, heteroalkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein each of the alkyl, heteroalkyl, alkenyl, alkoxy, cycloalkyl, heterocyclic, aryl, amino, and heteroaryl groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl groups;

[0026] Each occurrence of A1, A2, A3, A4, A5, and A6 is independently C(R). m 2. NR m C (=O), O or S;

[0027] Each occurrence of X is independently either N or CR. m ;

[0028] Each occurrence of m3 is independently 0, 1, 2, 3, 4, 5, 6 or 7, and each occurrence of m4 is independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and m3 + m4 ≤ 8;

[0029] Each time m5 appears, it is independently 0, 1, 2, 3, 4, 5, 6 or 7; each time m6 appears, it is independently 1, 2, 3, 4, 5, 6 or 7; and m5 + m6 ≤ 7.

[0030] Each time m9, m10, and m11 appear, they are each independently selected from 0, 1, 2, and 3, and m9 + m10 + m11 ≤ 3;

[0031] R m Each of the following groups is independently selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, heteroalkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein each of the alkyl, heteroalkyl, alkenyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl groups;

[0032] R1, R2, and R8 are each independently selected from hydrogen, halogens, deuterium, and carbon each time they appear. 1-6 Alkyl, C 1-6 Alkoxy, hydroxyl, 3-7 membered cycloalkyl, C 1-6 Haloalkyl, C1-6 Hydroxyalkyl, -C 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 alkyl)2, and -C 1-6 Alkylene-N(C) 1-6 Alkyl)H; and

[0033] Each occurrence of n is independently 0, 1, 2, or 3;

[0034] In some further embodiments, in the aforementioned compounds having the structure of Formula I:

[0035] 1) When PTM is selected from Formula 1-1 and ULM is selected from Formula 2-11, Formula 2-12 and Formula 2-13, at least one H on the compound of Formula I is R aa Replace, R aa -C 1-6 Alkylene-N(C) 1-6 Alkyl)2, -OC 1-6 Alkylene-N(C) 1-6 Alkyl)2, -C 1-6 Alkylene-OC 1-6 Alkylene-N(C) 1-6 alkyl)2 or -C 1-6 An alkylene-3-7-membered heterocyclic group, wherein the 3-7-membered heterocyclic group contains 1, 2, or 3 N, O, or S heteroatoms; or

[0036] When PTM is selected from Equation 1-1, ULM is selected from Equations 2-11, 2-12, and 2-13, and Equation 2-12 has the structure shown in Equation 2-12a, L is selected from... or

[0037] When PTM is selected from Equation 1-1 and ULM is selected from Equations 2-11, 2-12 and 2-13, R b3 R b4 R b5 R a7 Or R a8 One and only one of them is selected from the N atom; or

[0038] 2) When PTM is selected from Equation 1-2, ULM is selected from Equations 2-11, 2-12, and 2-13, L is selected from...

[0039] Another aspect of this disclosure provides compounds having the structure of formula III:

[0040] PTM-L-ULM (Formula II),

[0041] Or its pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, or polymorphs.

[0042] in:

[0043] L is the chemical linker connecting ULM and PTM;

[0044] The PTM is selected from the following structures:

[0045] in,

[0046] R b2 For N or CR a2 ;

[0047] R b3 For N or CR a3 ;

[0048] R b4 For N or CR a4 ;

[0049] R b5 For N or CR a5 ;

[0050] R a7 R a8 and R a9 Each occurrence is independently selected from N and CR. b ;

[0051] R b R a1 R a2 R a3 R a4 and R a5 Each occurrence is independently selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, deuterated alkyl, heteroalkyl, alkenyl, alkynyl, amino, haloalkoxy, hydroxyalkyl, alkoxy, cyano, hydroxyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -C 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)H and -O-cycloalkyl;

[0052] ULM is selected from the following structure:

[0053] in:

[0054] W3 is independently C (=O) or C (=S) each time it appears;

[0055] Z is either N or CR each time it appears. m ;

[0056] G1 and G2 are each independently selected from O, S, and Se each time they appear;

[0057] R3, R4, R5, and R6, each when appearing independently, are each selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, heteroalkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein each of the alkyl, heteroalkyl, alkenyl, alkoxy, cycloalkyl, heterocyclic, aryl, amino, and heteroaryl groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl groups;

[0058] Each of A1, A2, A3, A4, A5, and A6 is independently C(R) when it appears. m 2. NR m C (=O), O or S;

[0059] Each occurrence of X is independently either N or CR. m ;

[0060] Each time m3 appears, it is independently 0, 1, 2, 3, 4, 5, 6 or 7, and m4 is 0, 1, 2, 3, 4, 5, 6, 7 or 8, and m3 + m4 ≤ 8;

[0061] Each occurrence of m5 is independently 0, 1, 2, 3, 4, 5, 6 or 7, and each occurrence of m6 is independently 1, 2, 3, 4, 5, 6 or 7, and m5 + m6 ≤ 7.

[0062] Each time m9, m10, and m11 appear, they are each independently selected from 0, 1, 2, and 3, and m9 + m10 + m11 ≤ 3;

[0063] R m Each time it appears, it is independently selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, heteroalkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein each of the alkyl, heteroalkyl, alkenyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl groups;

[0064] R1, R2, and R8 are each independently selected from hydrogen, halogen, deuterium, and carbon each time they appear. 1-6 Alkyl, C 1-6 Alkoxy, hydroxyl, 3-7 membered cycloalkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, -C 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 alkyl)2, and -C 1-6 Alkylene-N(C) 1-6 Alkyl)H; and

[0065] n is 0, 1, 2 or 3 each time it appears;

[0066] The conditions are:

[0067] 1) When PTM is selected from Formula 1-1 and ULM is selected from Formula 2-1, Formula 2-2 and Formula 2-3, at least one H in the compound of Formula III is R aa Replacement, R aa -C 1-6 Alkylene-N(C) 1-6 Alkyl)2, -OC 1-6 Alkylene-N(C) 1-6 Alkyl)2, -C 1-6 Alkylene-OC 1-6 Alkylene-N(C) 1-6 alkyl)2 or -C 1-6 An alkylene-3-7-membered heterocyclic group, wherein the 3-7-membered heterocyclic group contains 1, 2, or 3 N, O, or S heteroatoms; or

[0068] 2) When PTM is selected from Equation 1-1, ULM is selected from Equations 2-1, 2-2, and 2-3, L is selected from...

[0069] 3) When PTM is selected from Equation 1-1 and ULM is selected from Equations 2-1, 2-2 and 2-3, R b3 R b4 R b5 R a7 、or R a8 One and only one of them is selected from the N atom;

[0070] 4) When PTM is selected from Equation 1-2, ULM is selected from Equation 2-1, Equation 2-2, and Equation 2-3, L is selected from...

[0071] Another aspect of this invention discloses a compound having the structure of Formula I:

[0072] PTM-L-ULM (Formula I),

[0073] Or its pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, or polymorphs.

[0074] in:

[0075] L is the chemical linker connecting ULM and PTM;

[0076] The PTM is selected from the following structures:

[0077] in,

[0078] R a7 R a8 and R a9 Each occurrence is independently selected from N or CR. b ;

[0079] R a R b R a1 R a2 R a3 R a4 R a5 Each occurrence is independently selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, deuterated alkyl, heteroalkyl, alkenyl, alkynyl, amino, haloalkoxy, hydroxyalkyl, alkoxy, cyano, hydroxyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -C 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)H and -O-cycloalkyl;

[0080] Each occurrence of p1, p2, and p3 is independently selected from 0, 1, 2, and 3;

[0081] The ULM is selected from the following structures:

[0082] in:

[0083] W 11 It is C (=O) or C (=S);

[0084] G and Z are each independently selected from O, S, and Se;

[0085] R 3a1 R 3b1 R 3c1 and R 3d1Each of the following groups is independently selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, heteroalkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, heteroalkyl, alkenyl, alkoxy, cycloalkyl, heterocyclic, aryl, amino, and heteroaryl groups are each independently and optionally substituted by one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl groups;

[0086] R D1 R E1 R F1 R G1 Each occurrence is independently C(R) m 2. NR m C (=O), O or S;

[0087] R T1 Each occurrence is independently either N or CR. m ;

[0088] Each time m3 appears, it is independently 0, 1, 2, 3, 4, 5, 6 or 7, and m4 is 1, 2, 3, 4, 5, 6, 7 or 8, and m3 + m4 ≤ 8;

[0089] Each time m7 and m8 appear, they are each an independent integer of 0, 1, 2, 3, 4, 5, 6 or 7, and m7 + m8 ≤ 7;

[0090] R m Each of the following groups is independently selected from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, heteroalkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein each of the alkyl, heteroalkyl, alkenyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl groups;

[0091] R 21 R 11 and R N Each is independently selected from hydrogen, halogen, deuterium, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, 3-7 membered cycloalkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, -C 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C)1-6 alkyl)2, and -C 1-6 Alkylene-N(C) 1-6 Alkyl)H; and

[0092] n is 0, 1, 2, or 3;

[0093] When PTM is selected from formula 1-1, at least one H of the compound of formula I is reacted with R. aa Replacement, R aa The heterocyclic group is a -C1-C6 alkylene-N(C1-C6 alkyl)2, an -O-C1-C6 alkylene-N(C1-C6 alkyl)2, an -C1-C6 alkylene-O-C1-C6 alkylene-N(C1-C6 alkyl)2, or a -C1-C6 alkylene-3-7 membered heterocyclic group, wherein the heterocyclic group contains 1, 2, or 3 N, O, or S heteroatoms.

[0094] In one embodiment, when PTM is selected from formula 1-1, at least one H of the formula I compound is R aa Replacement, R aa It is -C1-C6 alkylene N(C1-C6 alkyl)2.

[0095] In some implementations, L is a covalent bond or -(B) L ) q -;

[0096] In some implementations, q is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; in some implementations, q is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0097] In some implementation schemes, B L Each time it appears, it is selected independently from CR. L1 R L2 O, S, S(O), S(O)2, NR L1 C(O)NR L1 C(O), a monocyclic alkyl group, a monoheterocyclic alkyl group, a monoheterocyclic partially unsaturated cyclic hydrocarbon group, a bridged cyclic group, a heterobridged cyclic group, a spirocyclic group, a heterospirocyclic group, an aryl group, and a heteroaryl group, wherein the monocyclic alkyl group, a monoheterocyclic alkyl group, a monoheterocyclic partially unsaturated cyclic hydrocarbon group, a bridged cyclic group, a heterobridged cyclic group, a spirocyclic group, a heterospirocyclic group, a monocyclic aryl group, and a monocyclic heteroaryl group are optionally selected by 1, 2, 3, 4, 5, or 6 independently selected from R L1 The group substitution; in some embodiments, B L Each occurrence is independently selected from: CR L1 R L2 O, S, S(O), S(O)2, NRL1 C(O)NR L1 C(O), 3-8 membered monocycloalkylene, 3-8 membered monoheterocycloalkylene, 3-8 membered monoheterounsaturated cycloalkylene, 5-15 membered bridged cycloalkylene, 5-15 membered heterobridged cycloalkylene, 5-15 membered spirocycloalkylene, 5-15 membered heterospirocycloalkylene, 6-15 membered arylene and 5-15 membered heteroarylene, wherein the 3-8 membered monocycloalkylene, 3-8 membered monoheterocycloalkylene, 3-8 membered monoheterounsaturated cycloalkylene, 5-15 membered bridged cycloalkylene, 5-15 membered heterobridged cycloalkylene, 5-15 membered spirocycloalkylene, 5-15 membered heterospirocycloalkylene, 6-15 membered arylene and 5-15 membered heteroarylene are optionally selected independently by 1, 2, 3 or 4 members from R L1 The group substitution; the 3-8 membered heterocyclic alkyl group, the 3-8 membered heterocyclic partially unsaturated cyclic hydrocarbon group, the 5-15 membered heterobridged cyclic group, the 5-15 membered heterospirocyclic group, and the 5-15 membered heteroaryl group contain 1, 2, 3, 4 or 5 heterocyclic atoms each independently selected from N, O, and S.

[0098] In some implementation schemes, R L1 and R L2 Each time it appears, it is independently selected from hydrogen, halogen, and C. 1-8 Alkyl, -OC 1-8 Alkyl, -SC 1-8 Alkyl, -NH-C 1-8 Alkyl, -N(C) 1-8 Alkyl) 2, 3-11 membered cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 3-11 membered heterocycloalkyl, -O-3-8 membered cycloalkyl, -O-3-11 membered heterocycloyl, -O-6-10 membered aryl, -O-5-10 membered heteroaryl, -S-3-8 membered cycloalkyl, -NH-3-8 membered cycloalkyl, -N(3-8 membered cycloalkyl)(C 1- 8-alkyl), -NH-3-8-membered heterocyclic group, -N(3-8-membered heterocyclic group) (C 1-8 alkyl), -NH-6-10 aryl, -N(6-10 aryl) (C 1-8 alkyl), -NH-5-10 heteroaryl, -N(5-10 heteroaryl) (C 1-8 Alkyl groups, -OH, -NH2, -SH, -SO2, P(O)(OC) 1-8 Alkyl)(C 1-8 Alkyl), -P(O)(OC 1-8 Alkyl)2、-C≡CC 1-8 Alkyl group, -C≡CH, -CH=CH-(C 1-8 alkyl), -C(C 1-8 Alkyl)=CH-(C 1-8 alkyl), -C(C1-8 Alkyl) = C(C 1-8 Alkyl group 2, -Si(OH)3, -Si(C) 1-8 Alkyl)3、-Si(OH)(C 1-8 Alkyl)2、-C(O)-C 1-8 Alkyl, -C(O)OH, -CN, -CF3, -CHF2, -CH2F, -NO2, -SO2H, -SF5, -S(O)2NH-C 1-8 Alkyl group, -S(O)2N(C) 1-8 Alkyl)2、-S(O)NH-C 1-8 Alkyl, -S(O)N(C) 1-8 Alkyl)2、-C(O)NH-C 1-8 Alkyl, -C(O)N(C) 1-8 Alkyl)2, -N(C 1-8 alkyl)C(O)NH(C 1-8 alkyl), -N(C) 1-8 alkyl)C(O)N(C 1-8 alkyl)2、-NHC(O)NH(C 1-8 Alkyl), -NHC(O)N(C 1-8 Alkyl)2, -NHC(O)NH2, -N(C 1-8 alkyl)S(O)2NH(C 1-8 alkyl), -N(C) 1-8 alkyl)S(O)2N(C 1-8 alkyl)2、-NHS(O)2NH(C 1-8 Alkyl), -NHS(O)2N(C 1-8 alkyl)2 and -NHS(O)2NH2, the C 1-8 Alkyl, 3-11 membered cycloalkyl, 3-11 membered heterocycloalkyl, 6-10 membered aryl, and 5-10 membered heteroaryl are each independently and optionally selected from halogen, alkyl, heteroalkyl, alkenyl, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocycloyl, halocycloalkyl, haloheteroalkyl, -N(C 1-6 Alkyl) 2, 6-10 aryl, 5-10 heteroaryl, halogenated C 6-10 The aryl group is substituted with one or more substituents of a 5-10 halogenated heteroaryl group; in some embodiments, R L1 and R L2 Each time it appears, it is independently selected from hydrogen, halogen, and C. 1-6 Alkyl, -OC 1-6 Alkyl, -C(O)-C 1-6Alkyl groups, -C(O)OH, -CN, -CF3, -CHF2, -CH2F, -NO2, -SO2, 3-6 membered cycloalkyl groups, and 3-6 membered heterocycloalkyl groups, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl groups and 3-6 membered heterocyclic alkyl groups are each independently selected from halogens, C 1-6 Alkyl, C 2-6 Heteroalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, hydroxy, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, cyano, amino, nitro, 3-6 membered cycloalkyl, 3-6 membered heterocyclic, 3-6 membered halocycloalkyl, 3-6 membered haloheteroalkyl, -N(C 1-3 It is substituted by one or more substituents of alkyl)2, 6-10 aryl, 5-10 heteroaryl, 6-10 haloaryl and 5-10 haloheteroaryl;

[0099] In some implementation schemes, R a7 R a8 and R a9 Each occurrence is independently selected from N, CH, and -C. 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)H and -C 1-6 Alkylene-N(C) 1-6 alkyl)2; in some embodiments, R a7 R a8 and R a9 Each occurrence is independently selected from N, CH, CH2N(CH3)2 and (CH2)2-N(CH3)2;

[0100] In some implementation schemes, R a7 For CH;

[0101] In some implementation schemes, R a8 Selected from N, CH and CH2N(CH3)2;

[0102] In some implementation schemes, R a9 For CH;

[0103] In some implementation schemes, R b R a1 R a2 R a3 R a4 and R a5 Each group is independently selected from hydrogen, halogen, deuterium, cyano, nitro, amino, carboxyl, hydroxyl, and C. 1-6Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, 3-7 membered heterocyclic alkyl, 3-6 membered cycloalkyl, -O-3-5 membered cycloalkyl, -C 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 alkyl)2, and -C 1-6 Alkylene-N(C) 1-6 Alkyl)H;

[0104] In some implementation schemes, R b R a1 R a2 R a3 R a4 and R a5 Each group is independently selected from hydrogen, F, Cl, Br, I, deuterium, nitro, cyano, amino, carboxyl, hydroxyl, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, 3-7 membered heterocyclic alkyl, 3-6 membered cycloalkyl, -O-3-5 membered cycloalkyl, -C 1-3 Alkylene -NH2, -C 1-3 Alkylene-N(C) 1-3 alkyl)2, and -C 1-3 Alkylene-N(C) 1-3 Alkyl)H;

[0105] In some implementations, both G1 and G2 are 0;

[0106] In some implementations, W3 is C (=O);

[0107] In some implementations, Z is N or CH;

[0108] In some implementations, R3, R4, R5, and R6 are each independently selected from hydrogen, deuterium, halogen, and C each time they appear. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2- 6 heteroalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, hydroxyl, C 1-6Hydroxyalkyl, nitro, cyano, amino, C 1-6 Alkylamino, 3-7 membered cycloalkyl, 3-7 membered heterocyclic group containing 1, 2 or 3 heteroatoms independently selected from N, O and S, 6-8 membered aryl, and 6-8 membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein the C 1-6 Alkyl, C 2-6 Heteroalkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 The alkoxy, 3-7 membered cycloalkyl, 3-7 membered heterocyclic, 6-8 membered aryl, amino, and 6-8 membered heteroaryl are each independently and optionally substituted by one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl.

[0109] In some implementations, R3, R4, R5, and R6 are each independently selected from hydrogen, halogen, and C each time they appear. 1-6 Alkyl, C 1-6 Alkoxy, hydroxy, C 1- 6-Hydroalkyl, C 1-6 Halogenated alkoxy groups, -NH-C 1-3 Alkyl, -NH-C(O)-C 1-3 Alkyl and C 1-6 Hydroxyalkyl;

[0110] In some implementations, R3, R4, R5, and R6 are each independently selected from hydrogen, F, Cl, Br, I, and C each time they appear. 1-3 Alkyl, C 1-3 Alkoxy, hydroxy, C 1-3 Haloalkyl, C 1-3 Halogenated alkoxy groups, -NH-C 1-3 Alkyl, -NH-C(O)-C 1-3 Alkyl and C 1-3 Hydroxyalkyl;

[0111] In some implementations, A1, A2, A3, A4, A5, and A6 are each independently C(R) each time they appear. m 2. NR m C (=O) or -O-;

[0112] In some implementations, X is N independently each time it appears;

[0113] In some implementations, m3 is independently 0, 1, 2, 3 or 4 each time it appears, and m4 is independently 0, 1, 2, 3, 4 or 5 each time it appears, and m3 + m4 ≤ 5; in some implementations, m3 is independently 0, 1, 2 or 3 each time it appears, and m4 is independently 0, 1, 2, 3 or 4 each time it appears, and m3 + m4 = 2, m3 + m4 = 3, or m3 + m4 = 4;

[0114] In some implementations, m5 is independently 0, 1, 2, 3 or 4 each time it appears, and m6 is independently 1, 2, 3 or 4 each time it appears, and m5 + m6 ≤ 4; in some implementations, m5 is independently 0, 1, 2 or 3 each time it appears, and m6 is independently 1, 2 or 3 each time it appears, and m5 + m6 = 2, m5 + m6 = 3 or m5 + m6 = 4;

[0115] In some implementation schemes, R m Each time it appears, it is independently selected from hydrogen, halogen, and C. 1-6 Alkyl, C 1-6 Alkoxy, hydroxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, -NH-C 1-3 Alkyl and C 1-6 Hydroxyalkyl; in some embodiments, R m Each time it appears, it is independently selected from hydrogen, F, Cl, Br, I, C. 1-3 Alkyl, C 1-3 Alkoxy, hydroxy, C 1-3 Haloalkyl, C 1-3 Halogenated alkoxy groups, -NH-C 1-3 Alkyl and C 1-3 Hydroxyalkyl; in some embodiments, R m Each occurrence is independently selected from H, F, Cl, Br, I, C. 1-3 Alkyl, C 1-3 Alkoxy, hydroxy, C 1-3 Halogenated alkyl groups and C 1-3 Hydroxyalkyl; in some embodiments, R m Each time it appears, it is independently selected from H and methyl;

[0116] In some implementation schemes, R1 and R2 are each independently selected from H, F, Cl, Br, I, and C each time they appear. 1-3 Alkyl, C 1-3 Alkoxy, hydroxy, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, -C 1-3 Alkylene -NH2, -C 1-3 Alkylene-N(C) 1-3 alkyl)2, and -C1-3 Alkylene-N(C) 1-3 Alkyl)H;

[0117] In some implementations, R8 is independently selected from H and -C each time it appears. 1-3 Alkyl, -C 1-3 Alkylene -NH2, -C 1-3 Alkylene-N(C) 1-6 Alkyl)H and -C 1-3 Alkylene-N(C) 1-6 Alkyl)2;

[0118] In some implementations, R8 is independently selected from H, -CH3, -CH2N(CH3)2 and -(CH2)2-N(CH3)2 each time it appears;

[0119] In some implementations, n is 0 or 1;

[0120] In some implementations, n is 1;

[0121] In some implementation schemes, R aa -C 1-3 Alkylene-N(C) 1-3 Alkyl)2, -OC 1-3 Alkylene-N(C) 1-3 Alkyl)2, -C 1-3 Alkylene-OC 1-3 Alkylene-N(C) 1-3 alkyl)2, or -C 1-3 Alkylene-4-6-membered heterocyclic group, wherein the heterocyclic group contains 1, 2 or 3 N, O or S heteroatoms;

[0122] In some implementation schemes, R aa -C 1-3 Alkylene-N(C) 1-3 alkyl)2; in some embodiments, R aa -OC 1-3 Alkylene-N(C) 1-3 alkyl)2; in some embodiments, R aa -C 1-3 Alkylene-OC 1-3 Alkylene-N(C) 1-3 alkyl)2; in some embodiments, R aa -C 1-3 Alkylene-4-6-membered heterocyclic group, wherein the heterocyclic group contains 1, 2 or 3 N, O or S heteroatoms;

[0123] In some implementation schemes, R aa Selected from:

[0124] In some implementation schemes, R aa for In some implementation schemes, R aa for In some implementation schemes, R aa for

[0125] In some implementation schemes, R b For H; in some implementations, R a1 It is cyclopentyl; in some embodiments, R b2 For C-Br; in some implementations, R b3 For CH; in some implementations, R b4 For CH; in some implementations, R b5 For CH; in some implementations, R a7 For CH; R a8 For CH; in some implementations, R a9 For CH;

[0126] In some implementations, A1, A2, A3, A4, A5, and A6 are each independently CH2 each time they appear.

[0127] In some implementations, the ULM is selected from the following structures:

[0128] In some implementations, L is a covalent bond or -(B) L ) q -;B LEach time it appears, it is independently a divalent linker selected from one or more of the following groups: -O-, -S-, -S(O)-, -S(O)2-, -CH2-, -C(O)-, -NH-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxacyclobutyl, aziridine, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 7-azaspiro[3.5]nonane, 6-azaspiro[4.4]octane, 2-azaspiro[4.5]decane, 2-azacyclospiro[3.3]heptane, 3-azaspiro[5.5]undecane, spiro[3.5]nonane, spiro[4.4]octane, spiro[4.5]decane, spiro[4.5]decane, spiro[3.5]nonane, spiro[4.4]octane, spiro[4.5]decane, spiro[4.5]decane, spiro[4.5]decane, spiro[4.5]decane, spiro[4.5]undecane, spiro[4.5]nonane, spiro[4.5]octane, spiro[4.5]decane, spiro[4.5]decane, spiro[4.5]un ... [3.3]Heptane, spiro[5.5]undecane, 2,5-diazabicyclo[2.2.2]octane, 2-oxa-4,9-diazabicyclo[5.5]undecane, 3-azabicyclo[3.1.0]hexane, 1-oxa-8-azabicyclo[4.5]decane, 4-azabicyclo[2.5]octane, 3-azabicyclo[3.2.1]octane, 8-azabicyclo[3.2.1]octane, 6-azabicyclo[3.1.1]heptane, 3-azabicyclo[3.1.1]heptane, 2-azabicyclo[2.2.2]octane, and phenylene; wherein the divalent linker is optionally selected from one or more R L1 Substitution of groups;

[0129] In some embodiments, the divalent linker is optionally composed of 1, 2, 3, 4, or 5 independently selected from halogen, cyano, hydroxyl, C 1-6 Alkyl, C 1- 6-alkoxy, fluorine-substituted C 1-6 Alkoxy, C 3-6 The cycloalkyl group is substituted with substituents of 3 to 6 oxecycloalkyl groups; in some embodiments, the divalent linker is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from fluorine, chlorine, cyano, hydroxyl, methyl, ethyl, isopropyl, methoxy, ethoxy, difluoromethoxy, cyclopropyl and oxecyclobutane.

[0130] In some implementation schemes, B L Selected from one or more of the following structural segments: -O-, -S-, -S(O)-, -S(O)2-, -CH2-, -C(CH3)2-, -C(O-, -NH-,

[0131] q is 1, 2, 3, 4, 5, 6, 7, or 8; in some implementations, q is 1, 2, 3, 4, 5, or 6; and

[0132] This is the connection site.

[0133] In some implementations, L is selected from the following structures:

[0134] Covalent bond, -C(O)-, -C(O)-(CH2) ja -、-(CH2) ja -、-(CH2) pa -NH-(CH2) sa -、-(CH2) ya -NH-(CH2) ja -NH-(CH2) sa -、-(CH2) pa -C(O)-(CH2) sa -、-(CH2) pa -O-(CH2) sa -、-(CH2) ya -C(O)-(CH2) ja -C(O)-(CH2) sa -、-(CH2) ya -O-(CH2) ja -O-(CH2) sa -、-(CH2) ya -O-(CH2) ja -C(O)-(CH2) sa -、-(CH2) ya -C(O)-(CH2) ja -O-(CH2) sa -、-(CH2) pa -NH-(CH2) ya -O-(CH2) ja -C(O)-(CH2) sa -、-(CH2) ya -C(O)-(CH2) ja -O-(CH2) sa -NH-(CH2) pa -、

[0135] Each of the following characters, ja, pa, sa, and ya, is selected independently from 1, 2, 3, and 4 when it appears.

[0136] In some implementations, the PTM is selected from the following structures:

[0137] In some embodiments, the compound is selected from the compounds shown in Formulas 3-1, 3-2, 3-3, 3-4, and 3-5:

[0138] In the formula, R b R b2 R b3 R b4 R b5 R a1 R a7 R a8 R a9 R1, R2, R3, R4, R5, R6, R8, R1, n and R2 are as defined in any of the aforementioned implementation schemes.

[0139] In some further implementation schemes:

[0140] 1) When the compound is selected from Formula 3-1, at least one H in the compound shown in Formula 3-1 is reacted with R. aa Replace, R aa -C 1-6 Alkylene-N(C) 1-6 Alkyl)2, -OC 1-6 Alkylene-N(C) 1-6 Alkyl)2, -C 1-6 Alkylene-OC 1-6 Alkylene-N(C) 1-6 alkyl)2 or -C 1-6 Alkylene-3-7-membered heterocyclic group, wherein the 3-7-membered heterocyclic group contains 1, 2 or 3 N, O or S heteroatoms;

[0141] 2) When PTM is selected from Formula 3-2, in the compound shown in Formula 3-2, L is selected from...

[0142] In some implementation schemes, R b2 It is CBr;

[0143] In some implementation schemes, R b3 R b4 R b5 R a7 R a8 and R a9 Each is CH; in some implementations, R b3 For hydrogen; in some implementations, R b4 For hydrogen; in some implementations, R b5 For hydrogen; in some implementations, R a7 For hydrogen; in some implementations, R a8 It is hydrogen; R a9 For CH;

[0144] In some implementation schemes, R a1 It is cyclopentyl;

[0145] In some implementations, R5, R6, R1, and R2 are H;

[0146] In some implementations, R8 is C 1-6 Alkyl group; in some embodiments, R8 is CH3;

[0147] In some implementations, n is 1;

[0148] In some further implementation schemes:

[0149] 1) When the compound is selected from formula 3-1, at least one H of the compound is reacted with R. aa Replacement, R aa Selected from Or, when the compound is selected from formula 3-1, L is selected from...

[0150] 2) When PTM is selected from Equation 3-2, L is selected from...

[0151] In another aspect, this disclosure provides compounds represented by formulas 3-6, or pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, or polymorphs thereof.

[0152] In the formula, R a1 Selected from hydrogen, F, Cl, Br, I, deuterium, nitro, cyano, amino, carboxyl, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, 3-7-membered heterocyclic alkyl, 3-6-membered cycloalkyl and -O-3-5-membered cycloalkyl containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0153] R b2 For CR a2 ;R b3 For CR a3 ;R b4 For CR a4 ;R b5 For CR a5 ;R a2 R a3 R a4 and R a5 Each group is independently selected from hydrogen, F, Cl, Br, I, deuterium, nitro, cyano, amino, carboxyl, hydroxyl, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6Halogenated alkoxy groups and C 1-6 Hydroxyalkyl;

[0154] In some implementations, R8 is selected from H and -C. 1-6 alkyl;

[0155] R5 and R6 are each independently selected from hydrogen, halogen, and C each time they appear. 1-6 Alkyl, C 1-6 Alkoxy, hydroxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, -NH-C 1-3 Alkyl, -NH-C(O)-C 1-3 Alkyl and C 1-6 Hydroxyalkyl;

[0156] L is selected from B L3 -B L4 Among them, B L3 and B L4 Each is independently selected from C(O), C 1-6 Alkylene, 3-8 member monoheterocyclic alkylene, 5-15 member heterobridged cycloalkylene, 5-15 member heterospirocyclic cycloalkylene

[0157] In some implementation schemes, R a1 It is cyclopentyl;

[0158] R b2 CBr; R b3 For CH; R b4 For CH; R b5 For CH; R a7 For CH; R a9 R8 is CH; R5 is H; R6 is H;

[0159] In some implementations, n is 1;

[0160] L is selected from 3-8 membered submonoheterocyclic alkyl-C(O); in some embodiments, L is selected from

[0161] Another aspect of this disclosure provides a compound, or an isomer, isotopic derivative, polymorph, prodrug, or pharmaceutically acceptable salt or solvation thereof, wherein said compound is selected from any of the following structures:

[0162] Another aspect of this disclosure provides compounds having the structure of Formula II:

[0163] CLM a ―L a PTM a (Formula II)

[0164] Or its pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, or polymorphs.

[0165] in:

[0166] PTM a It is the target protein binding portion;

[0167] L a It is a covalently connected CLM a and the PTM a The chemical bonding part, and

[0168] CLM a It is the cerebellar protein (CRBN) binding moiety, which is selected from any of the following structures:

[0169] Indicates CLM a With L a The connection site.

[0170] In some implementations, L a Is it a key or -(B) La ) qa -;

[0171] B La Each occurrence may be the same or different, and each is independently selected from: CR L1a R L2a O, S, SO, SO2, NR L3a SO2NR L3a SONR L3a C(O)NR L3a NR L3a C(O)NR L4a NR L3a SO2NR L4a C(O), CR L1a =CR L2a C≡C, SiR L1a R L2a P(O)R L1a P(O)OR L1a NR L3a C(=NCN)NR L4a NR L3a C(=NCN), NR L3a C(=CNO2)NR L4a , cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally surrounded by 1, 2, 3, 4, 5, or 6 R groups. L1aand / or R L2a Group substitution;

[0172] R L1a R L2a R L3a and R L4a Each time it appears, it is independently selected from H, halogen, C. 1-8 Alkyl, OC 1-8 Alkyl, SC 1-8 Alkyl, NH-C 1-8 Alkyl, N(C) 1-8 Alkyl)2, C 3-11 cycloalkyl, aryl, heteroaryl, C 3-11 Heterocyclic groups, OC 3-8 cycloalkyl, OC 3-11 Heterocyclic, O-aryl, O-heteroaryl, SC 3- 8-cycloalkyl, NH-C 3-8 cycloalkyl, N(C) 3-8 cycloalkyl)2, N(C) 3-8 cycloalkyl)(C 1-8 Alkyl), NH-C 3-8 Heterocyclic groups, N(C) 3-8 Heterocyclic group)2, N(C 3-8 Heterocyclic group)(C 1-8 Alkyl), NH-aryl, N(aryl) (C 1-8 Alkyl), NH-heteroaryl, N(heteroaryl) (C 1-8 Alkyl), OH, NH2, SH, SO2, P(O)(OC) 1- 8alkyl)(C 1-8 Alkyl), P(O)(OC 1-8 Alkyl)2、C≡CC 1-8 Alkyl, C≡CH, CH=CH-(C 1-8 Alkyl), C(C) 1-8 Alkyl)=CH-(C 1-8 Alkyl), C(C) 1-8 Alkyl) = C(C 1-8 Alkyl)2, Si(OH)3, Si(C 1-8 Alkyl)3, Si(OH)(C 1-8 Alkyl)2, C(O)-C 1-8 Alkyl, C(O)OH, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NH-C 1-8 Alkyl, SO2N(C) 1-8 Alkyl)2, SONH-C 1-8 Alkyl, SON(C) 1-8 Alkyl)2、C(O)NH-C 1-8Alkyl, C(O)N(C) 1- 8-alkyl)2, N(C) 1-8 alkyl)C(O)NH(C 1-8 alkyl), N(C) 1-8 alkyl)C(O)N(C 1-8 Alkyl)2、NHC(O)NH(C 1-8 Alkyl), NHC(O)N(C 1-8 Alkyl)2, NHC(O)NH2, N(C) 1-8 alkyl)SO2NH(C 1-8 alkyl), N(C) 1-8 Alkyl)SO2N(C 1-8 Alkyl)2, NHSO2NH(C 1-8 Alkyl), NH SO2 N(C 1- 8-alkyl)2, and NHSO2NH2, optionally, the C 1-8 Alkyl, C 3-11 cycloalkyl, C 3-11 Heterocyclic group, C 6-10 Aryl and C 5-10 Each heteroaryl group is independently substituted by one or more substituents selected from halogen, alkyl, heteroalkyl, alkenyl, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, halocycloalkyl, haloheteroalkyl, alkylamino, aryl, heteroaryl, haloaryl, and haloheteroaryl; and

[0173] qa is an integer greater than or equal to 1; in some implementations, qa is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0174] In some implementation schemes, B La Selected from one or more of the following structures:

[0175] -O-, -S-, -S(O)-, -S(O)2-, -CH2-, -C(O)-, -NH-,

[0176] This is the connection point.

[0177] In some implementations, L a Selected from the following structures:

[0178] Covalent bond, -(CH2) j -、-(CH2) p -NH-(CH2) s -、-(CH2)y -NH-(CH2) j -NH-(CH2) s -、-(CH2) p -C(O)-(CH2) s -、-(CH2) p -O-(CH2) s -、-(CH2) y -C(O)-(CH2) j -C(O)-(CH2) s -、-(CH2) y -O-(CH2) j -O-(CH2) s -、-(CH2) y -O-(CH2) j -C(O)-(CH2) s -、-(CH2) y -C(O)-(CH2) j -O-(CH2) s -、-(CH2) p -NH-(CH2) y -O-(CH2) j -C(O)-(CH2) s -、-(CH2) y -C(O)-(CH2) j -O-(CH2) s -NH-(CH2) p -、

[0179] Where j is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0180] k, s, p, and y are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0181] For CLM a or PTM a The connection point;

[0182] In some implementations, L aselected from a covalent bond, -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -NH-CH2-, -NH-(CH2)2-, -NH-(CH2)3-, -NH-(CH2)4-, -NH-(CH2)5-, -NH-(CH2)6-, -NH-(CH2)7-, -NH-(CH2)8-, -C(O)-NH-CH2-, -C(O)-NH-(CH2)2-, -C(O)-NH-(CH2)3-, -C(O)-NH-(CH2)4-, -C(O)-NH-(CH2)5-, -C(O)-NH-(CH2)6-, -C(O)-NH-(CH2)7-, -C(O)-NH-(CH2)8-, -CH2-NH-, -(CH2)2-NH-, -(CH2)3-NH-, -(CH2)4-NH-, -(CH2)5-NH-, -(CH2)6-NH-, -(CH2)7-NH-, -(CH2)8-NH-, -NH-CH2-NH-, -NH-(CH2)2-NH-, -NH-(CH2)3-NH-, -NH-(CH2)4-NH-, -NH-(CH2)5-NH-, -NH-(CH2)6-NH-, -NH-(CH2)7-NH-, -NH-(CH2)8-NH-, -(CH2-CH2-O)-CH2-CH2-, -(CH2-CH2-O)2-CH2-CH2-, -(CH2-CH2-O)3-CH2-CH2-, -NH-(CH2-CH2-O)-CH2-CH2-, -NH-(CH2-CH2-O)2-CH2-CH2-, -NH-(CH2-CH2-O)3-CH2-CH2-, -C(O)-NH-(CH2-CH2-O)-CH2-CH2-, -C(O)-NH-(CH2-CH2-O)2-CH2-CH2-, -C(O)-NH-(CH2-CH2-O)3-CH2-CH2-, -(CH2-CH2-O)-CH2-CH2-NH-, -(CH2-CH2-O)2-CH2-CH2-NH-, -(CH2-CH2-O)3-CH2-CH2-NH-, -NH-(CH2-CH2-O)-CH2-CH2-NH-, -NH-(CH2-CH2-O)2-CH2-CH2-NH-, -NH-(CH2-CH2-O)3-CH2-CH2-NH-, -C(O)-NH-(CH2-CH2-O)-CH2-CH2-NH-, -C(O)-NH-(CH2-CH2-O)2-CH2-CH2-NH-,-C(O)-NH-(CH2-CH2-O)3-CH2-CH2-NH-、-CH2-CH2-(O-CH2-CH2)-、-CH2-CH2-(O-CH2-CH2)2-、-CH2-CH2-(O-CH2-CH2)3-、-NH-CH2-CH2-(O-CH2-CH2)-、-NH-CH2-CH2-(O-CH2-CH2)2-、-NH-CH2-CH2-(O-CH2-CH2)3-、-C(O)-NH-CH2-CH2-(O-CH2-CH2)-、-C(O)-NH-CH2-CH2-(O-CH2-CH2)2-、-C(O)-NH- CH2-CH2-(O-CH2-CH2)3-,-CH2-CH2-(O-CH2-CH2)-NH-,-CH2-CH2-(O-CH2-CH2)2-NH-,-CH2-CH2-(O-CH2-CH2)3-NH-,-NH-CH2-CH2-(O-CH2-CH2)-NH-,-NH-CH2-CH2-(O-CH2-CH2)2-NH-,-NH-CH2-CH2-(O-CH2-CH2)3-NH-,-NH-CH2-CH2-O-CH2-CH2-C(O)-,-C(O)-CH2-CH2-O-CH2-CH2-NH-,-NH-(CH2) 4-C(O)-,-NH-(CH2)5-C(O)-,-NH-(CH2)6-C(O)-,-C(O)-(CH2)4-NH-,-C(O)-(CH2)5-NH-,-C(O)-(CH2)6-NH-,-NH-(CH2-CH2-O)-(CH2)3-,-NH-(CH2-CH2-O)-(CH2)4-,-NH-(CH2-CH2-O)-(CH2)5-,-NH-(CH2-CH2-O)-(CH2)6-,-(CH2)3-(O-CH2-CH2)-NH-,-(CH2)4-(O-CH2-CH2)-NH-,-(CH2)5-(O-C H2-CH2)-NH-,-(CH2)6-(O-CH2-CH2)-NH-,-CH2-CH2-O-(CH2)2-C(O)-,-CH2-CH2-O-(CH2)3-C(O)-,-CH2-CH2-O-(CH2)4-C(O)-,-C(O)-(CH2)2-O-CH 2-CH2-, -C(O)-(CH2)3-O-CH2-CH2-, -C(O)-(CH2)4-O-CH2-CH2-, -C(O)-(CH2)2-, -C(O)-(CH2)3-, -C(O)-(CH2)4-, -C(O)-(CH2)5-, -C(O)-(CH2)6--(CH2)2-C(O)-,-(CH2)3-C(O)-,-(CH2)4-C(O)-,-(CH2)5-C(O)-,-(CH2)6-C(O)-,-C(O)-(CH2)2-C(O)-,-C(O)-(CH2)3-C(O)-,-C(O)-(CH2)4-C(O)-,-C(O)-(CH2)5-C(O)-,-C(O)-(CH2)6-C(O)-,-CH2-C(O)-CH2-,-CH2- C(O)-(CH2)2-,-CH2-C(O)-(CH2)3-,-CH2-C(O)-(CH2)4-,-(CH2)2-C(O)-CH2-,-(CH2)2-C(O)-(CH2)2-,-(CH2)2-C(O)-(CH2)3-,-(CH2)2-C(O)-(CH2)4-,-(CH2)3-C(O)-CH2-,-(CH2)3-C(O)-(CH2)2-,-(CH2)3-C(O)-(CH2) 2)3-、-(CH2)3-C(O)-(CH2)4-、-(CH2)4-C(O)-CH2-、-(CH2)4-C(O)-(CH2)2-、-(CH2)4-C(O)-(CH2)3-、-(CH2)4-C(O)-(CH2)4-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-CH2-O-(CH2)3-、-CH2-O-(CH2)4-、-(CH2)2-O-CH2-、-(CH2) 2-O-(CH2)2-,-(CH2)2-O-(CH2)3-,-(CH2)2-O-(CH2)4-,-(CH2)3-O-CH2-,-(CH2)3-O-(CH2)2-,-(CH2)3-O-(CH2)3-,-(CH2)3-O-(CH2)4-,-(CH2)4-O-CH2-,-(CH2)4-O-(CH2)2-,-(CH2)4-O-(CH2)3-,-(CH2)4-O-(CH2)4-,

[0183] In some embodiments, PTM is the portion that binds to a target protein or polypeptide, wherein the target protein is selected from: B7.1, B7, TNFR2, NADPH oxidase, Bcl / Bax and other mates in the apoptosis pathway, C5a receptor, HMG-CoA reductase, PDE5 (phosphodiesterase type 5), PDE4 (phosphodiesterase type 4), PDE1, PDE2, PDE3, squalene cyclooxygenase, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclooxygenase 1, cyclooxygenase 2, 5-HT receptor, dopamine receptor, G protein (such as Gq), histamine receptor, 5-lipoxygenase, trypsin-like serine protease, thymidine... Nucleotide synthase, purine nucleoside phosphorylase, trypanosome GAPDH, glycogen phosphorylase, carbonic anhydrase, chemokine receptor, JAK, STAT, RXR and their analogues, HIV-1 protease, HIV-1 integrase, influenza neuraminidase, hepatitis B reverse transcriptase, sodium channels, multidrug resistance-associated protein P-glycoprotein, tyrosine kinase, CD23, CD124, tyrosine kinase p56lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-α receptor, ICAM-1, calcium channels (Ca2+ channels), VCAM, VLA-4 integrin, selectin, CD40 / CD40L, inosine monophosphate dehydrogenase, p38 MAP kinase, Ras / Raf / MEK / ERK pathway, interleukin-1β convertase, caspase, HCV NS3 protease, HCV NS3RNA helicase, glycine ribonucleotide formyltransferase, rhinovirus 3C protease, herpes simplex virus-1 (HSV-1) protease, cytomegalovirus (CMV) protease, poly(ADP-ribose) polymerase, cyclin-dependent kinase 4 / 6, vascular endothelial growth factor, oxytocin receptor, microsomal triglyceride transfer protein, bile acid transporter, 5α-reductase, angiotensin II, glycine receptor, norepinephrine reuptake receptor, endothelin receptor, neuropeptide Y and its receptor, adenosine receptor, adenosine kinase, AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferase, geraniol-geraniol transferase, NGF receptor TrkA, β-amyloid, VEGF receptor Flk-1 / KDR, vitrinin Receptors, integrin receptors, Her-2 / neu, telomerase, cytosolic phospholipase A2, EGF receptor tyrosine kinase, ecdysone 20-monooxygenase, GABA-gated chloride channels, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channels, chloride channels, acetyl-CoA carboxylase, adenylate succinate synthase, protoporphyrinogen oxidase, enolpyruvylshikimate phosphate synthase, MYC protein, androgen receptor, estrogen receptor, aurora kinase A, Bcr-Abl protein, epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Bruton's tyrosine kinase (BTK), bromide domain protein 4 (BRD4), SMARCA2 / 4, IRAK4 protein, STAT6, IKZF2, IRF5, CDK2, ActRⅡ, and KAT6.

[0184] In some embodiments, the PTM is a portion that binds to a target protein or polypeptide, wherein the target protein is selected from: structural proteins, receptors, enzymes, cell surface proteins; proteins associated with cellular integration functions, including proteins involved in catalytic activity, aromatase activity, motility, helicase activity, metabolic processes, antioxidant activity, proteolysis, and biosynthesis; proteins having kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulatory activity, signal transduction activity, structural molecule activity, binding activity, receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, and stimulus response; behavioral proteins; cell adhesion proteins; proteins involved in cell necrosis; and proteins involved in transport, including proteins with protein transport activity, nuclear transport activity, ion transport activity, channel transport activity, carrier activity, permease activity, secretory activity, electron transport activity, pathogenesis, chaperone protein regulator activity, nucleic acid binding activity, transcription factor activity, extracellular tissue and biological origin activity, and translation regulator activity.

[0185] In some embodiments, PTM is an Hsp90 inhibitor, a kinase inhibitor, a phosphatase inhibitor, an MDM2 inhibitor, a compound that binds to a protein containing a human BET bromo domain, an HDAC inhibitor, a human lysine methyltransferase inhibitor, a compound that binds to a RAF receptor, a compound that binds to FKBP, an angiogenesis inhibitor, an immunosuppressive compound, a compound that binds to an aryl hydrocarbon receptor, a compound that binds to an androgen receptor, a compound that binds to an estrogen receptor, a compound that binds to a thyroid hormone receptor, a compound that binds to an HIV protease, or a compound that binds to an HIV integrase. Compounds that bind to HCV protease, compounds that bind to acyl protein thioesterase 1 and / or 2, compounds that bind to c-MYC protein, compounds that bind to laser kinase A, compounds that bind to Bcr-Abl protein, compounds that bind to bromodomain protein 4 (BRD4), compounds that bind to anaplastic lymphoma kinase (ALK), compounds that bind to Bruton's tyrosine kinase (BTK), compounds that bind to cyclin-dependent kinase 4 / 6 (CDK4 / 6), compounds that bind to SMARCA2 / 4, compounds that bind to IRAK4 protein, or compounds that bind to epidermal growth factor receptor.

[0186] In some implementations, PTM a Selected from a structure combining SMARCA2 / 4;

[0187] In some implementations, PTM a Selected from:

[0188] R b2 For N or CR a2 In some implementation schemes, R b2 For CH;

[0189] R b3 For N or CR a3 In some implementation schemes, R b3 For CH;

[0190] R b4 For N or CR a4 In some implementation schemes, R b4 For N or CH;

[0191] R b5 For N or CR a5 In some implementation schemes, R b5 For CH;

[0192] R a7 R a8 and R a9 Each occurrence is independently selected from N and CR. b In some implementation schemes, Ra7 R a8 and R a9 Each occurrence is independently selected from N, CH, and -C. 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)H and -C 1-6 Alkylene-N(C) 1-6 alkyl)2; in some embodiments, R a7 R a8 and R a9 Each occurrence is independently selected from N, CH, CH2N(CH3)2, and (CH2)2-N(CH3)2; in some embodiments, R a7 For CH; R a8 Selected from N, CH and CH2N(CH3)2; R a9 For CH;

[0193] R b R a1 R a2 R a3 R a4 R a5 Each occurrence is independently selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, deuterated alkyl, heteroalkyl, alkenyl, alkynyl, amino, haloalkoxy, hydroxyalkyl, alkoxy, cyano, hydroxyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -C 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)2, -C 1-6 Alkylene-N(C) 1-6 Alkyl)H and -O-cycloalkyl; in some embodiments, R b R a1 R a2 R a3 R a4 and R a5 Each occurrence is independently selected from hydrogen, halogen, deuterium, cyano, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, nitro, amino, carboxyl, hydroxyl, 3-7 membered heterocyclic alkyl groups containing 1, 2 or 3 heteroatoms independently selected from N, O and S, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, 3-6 membered cycloalkyl, -O-3-5 membered cycloalkyl, -C 1-6 Alkylene -NH2, -C 1-6 Alkylene-N(C) 1-6 alkyl)2, and -C 1-6 Alkylene-N(C)1-6 Alkyl)H; in some embodiments, R b R a1 R a2 R a3 R a4 R a5 Each occurrence is independently selected from hydrogen, F, Cl, Br, I, deuterium, cyano, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, nitro, amino, carboxyl, hydroxyl, 3-7 membered heterocyclic alkyl groups containing 1, 2 or 3 heteroatoms independently selected from N, O and S, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl 3-6 membered cycloalkyl, -O-3-5 membered cycloalkyl, -C 1-3 Alkylene -NH2, -C 1-3 Alkylene-N(C) 1-3 alkyl)2, and -C 1-3 Alkylene-N(C) 1-3 Alkyl)H;

[0194] In some implementations, the PTM is selected from the following structures:

[0195] Another aspect of this disclosure provides a ligand-drug conjugate that uses the aforementioned compound as the toxic portion of the drug.

[0196] Another aspect of this disclosure provides the use of the foregoing compounds or pharmaceutically acceptable salts thereof for the preparation of ligand-drug conjugates.

[0197] In some implementations, the ligand is an antibody or its antigen-binding fragment.

[0198] In another aspect of this disclosure, a pharmaceutical composition is provided, the pharmaceutical composition comprising an effective amount of the aforementioned compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0199] Another aspect of this disclosure provides the use of the aforementioned compounds or pharmaceutically acceptable salts thereof, or the aforementioned pharmaceutical compositions, in the preparation of a medicament for treating or preventing diseases or conditions mediated by SMARCA2 / 4.

[0200] In another aspect of this disclosure, the aforementioned compound or a pharmaceutically acceptable salt thereof, or the aforementioned pharmaceutical composition, is provided for the treatment or prevention of diseases or conditions mediated by SMARCA2 / 4.

[0201] Another aspect of this disclosure provides a method for treating or preventing diseases or conditions mediated by SMARCA2 / 4, comprising administering to a subject in need an effective amount of the aforementioned compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described above.

[0202] In some implementations, the condition is cancer; in other implementations, the cancer is lung cancer or cervical cancer.

[0203] In another aspect of this disclosure, the use of the aforementioned compound or its isomers, isotope derivatives, polymorphs, prodrugs, or pharmaceutically acceptable salts or solvates thereof in the preparation of medicaments for treating or preventing conditions that are treated by binding to cerebellar proteins in vivo is provided.

[0204] In another aspect of this disclosure, the use of the aforementioned compound or its isomers, isotope derivatives, polymorphs, prodrugs, or pharmaceutically acceptable salts or solvates thereof as CRBN binding moieties in the preparation of protein degradation-targeting chimeric (PROTAC) drugs is provided. Detailed Implementation

[0205] The following detailed description of specific implementation schemes illustrates the content of this disclosure, but does not imply any adverse limitation thereof. Various specific implementation schemes of this disclosure have been described in detail herein, and it will be apparent to those skilled in the art that various changes and modifications can be made to these specific implementation schemes without departing from the spirit and scope of this disclosure.

[0206] Terms and Definitions

[0207] As used herein, the term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms, and more preferably an alkyl group containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and their various branched isomers, etc. More preferably, lower alkyl groups containing 1 to 6 carbon atoms (C 1-6 Alkyl group. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any usable connection point. The substituent is preferably selected independently from one or more substituents chosen from the following groups: D atom, halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

[0208] SMARCA2 / 4 refers to the SMARCA2 or SMARCA4 protein.

[0209] The term "heteroalkyl" refers to an alkyl group in which one or more -CH2- atoms are substituted by heteroatoms selected from NH, O, and S, or where one or more -CH- atoms are substituted by N atoms; wherein the alkyl group is as defined above; the heteroalkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any usable connection point, wherein the substituent is preferably independently selected independently from one or more substituents selected from D atoms, halogens, alkyl groups, alkoxy groups, haloalkyl groups, hydroxy groups, hydroxyalkyl groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, and heteroaryl groups.

[0210] The term "alkoxy" refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), wherein the definition of alkyl or cycloalkyl is given herein. Alkoxy is preferably C-. 1-6 Alkoxy, further preferably C 1-3 Non-limiting examples of alkyl and alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, O-cyclopropyl, O-cyclobutyl, O-cyclopentyl, and O-cyclohexyl. The alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of a D atom, halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

[0211] The term "alkenyl" refers to an alkyl compound containing a carbon-carbon double bond in its molecule, wherein the definition of alkyl is as described above. Alkenyl is preferably an alkyl group having 2 to 8 carbon atoms and at least one (e.g., 1 to 2) carbon-carbon double bond. 2-8 "Alkenyl" is preferred; more preferably, C is preferred. 2-6 Alkenyl (i.e., alkenyl groups having 2 to 6 carbon atoms and 1 to 2 carbon-carbon double bonds). More preferably, C 2-4 Alkenyl (i.e., an alkenyl group having 2 to 4 carbon atoms and 1 to 2 carbon-carbon double bonds). Alkenyl groups can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents.

[0212] The term "alkynyl" refers to an alkyl compound containing a carbon-carbon triple bond in its molecule, wherein the alkyl group is defined as described above. The alkynyl group is preferably a "C" group having 2 to 8 carbon atoms and at least one (e.g., 1 to 2) carbon-carbon triple bond. 2-8 "Alkyne group". Preferably C 2-6 Alkynyl (i.e., alkynyl group having 2 to 6 carbon atoms and 1 to 2 carbon-carbon triple bonds). More preferably C 2-4 The alkynyl group (i.e., an alkynyl group having 2 to 4 carbon atoms and 1 to 2 carbon-carbon triple bonds). The alkynyl group can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from alkyl, alkoxy, halogen, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents.

[0213] The term "cycloalkyl" refers to a cyclic hydrocarbon substituent of a saturated or partially unsaturated monocyclic, bicyclic, or more rings, including, for example, fused, bridged, or spirocyclic groups. The cycloalkyl ring may contain 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 8 (e.g., 3, 4, 5, 6, 7, and 8) carbon atoms, and even more preferably 4 to 7 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, cyclooctyl, etc. The cycloalkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any usable connection point. The substituent is preferably independently selected from one or more substituents chosen from halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

[0214] The term "heterocyclic alkyl" or "heterocyclic group" refers to a saturated or partially unsaturated monocyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, or S(O)m (where m is an integer from 0 to 2), but excluding the ring portion of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) ring atoms, wherein 1 to 4 (e.g., 1, 2, 3, and 4) are heteroatoms; more preferably, it contains 3 to 8 ring atoms, wherein 1 to 3 are heteroatoms; even more preferably, it contains 3 to 6 ring atoms, wherein 1 to 3 are heteroatoms; most preferably, it contains 5 or 6 ring atoms, wherein 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclic alkyl groups include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc. Heterocyclic alkyl or heterocyclic groups may be substituted or unsubstituted; when substituted, the substituent may be substituted at any usable connection point, and the substituent is preferably independently and optionally selected from one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl.

[0215] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (fused polycyclic) group having a conjugated π-electron system, preferably 6- to 10-membered, such as phenyl and naphthyl. The aryl ring comprises an aryl ring fused to a heteroaryl, heterocyclic, or cycloalkyl ring as described above, wherein the ring attached to the parent structure is an aryl ring. The aryl group can be substituted or unsubstituted; when substituted, the substituent can be substituted at any usable connection point, and the substituent is preferably independently selected independently from one or more substituents chosen from halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.

[0216] The term "heteroaryl" refers to a heteroaryl system comprising 1 to 4 (e.g., 1, 2, 3, and 4) heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. The heteroaryl group is preferably 5 to 10-membered (e.g., 5, 6, 7, 8, 9, or 10-membered), more preferably 5- or 6-membered, such as furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc. The heteroaryl ring comprises a heteroaryl group fused to an aryl, heterocyclic alkyl, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heteroaryl ring. The heteroaryl group can be substituted or unsubstituted. When substituted, the substituent can be substituted at any usable connection point. The substituent is preferably independently selected independently from one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

[0217] The term "haloalkyl" refers to an alkyl group that has been substituted with one or more halogens, wherein the alkyl group is as defined above.

[0218] The term "hydroxyalkyl" refers to an alkyl group that is substituted with one or more hydroxyl groups, wherein the alkyl group is as defined above.

[0219] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0220] The term "amino" refers to -NH2. The term "cyano" refers to -CN. The term "nitro" refers to -NO2.

[0221] The term "bond" refers to a covalent bond between two atoms or two parts. Unless otherwise specified, a bond can be a single bond, a double bond, or a triple bond.

[0222] The term "chemical bond" should be understood as a connection between atoms through an attractive force strong enough to allow the bonded aggregate to function as a unit. This includes, but is not limited to, chemical bonds such as covalent bonds, non-covalent bonds such as ionic bonds, metallic bonds, and bridging bonds, hydrophobic interactions, hydrogen bonds, and van der Waals interactions.

[0223] The term "part" refers to a specific segment or functional group of a molecule. A chemical part is generally considered a chemical entity embedded in or attached to a molecule.

[0224] The term "target protein" refers to proteins and peptides that have any biological function or activity (including structural, regulatory, hormonal, enzymatic, genetic, immune, contractile, storage, transport, and signal transduction). In some implementations, target proteins include structural proteins, receptors, enzymes, cell surface proteins, and proteins involved in integrated cellular functions, including proteins involved in: catalytic activity, aromatase activity, motility activity, helicase activity, metabolic processes (anabolism and catabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transduction factor activity, structural molecule activity, binding activity (proteins, lipids, carbohydrates), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, stimulation response, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transport activity, nuclear transport, ion transport activity, channel transport activity, carrier activity), permease activity, secretory activity, electron transport activity, pathogens, associated protein regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular structure and biological origin activity, and translation regulator activity. The proteins include proteins derived from eukaryotes and prokaryotes, which include microorganisms, viruses, fungi, and parasites, as well as numerous others, including humans, microorganisms, viruses, fungi, and parasites that are targets for drug therapy, other animals including domestic animals, microorganisms and other antimicrobial drugs used to determine the targets of antibiotics, plants, and even viruses, as well as numerous others.

[0225] "Optional" or "optionally" means that the event or situation described below may but does not have to occur, and the description includes the circumstances in which the event or situation occurs or does not occur. For example, "optionally substituted cyclopropyl" means that the cyclopropyl group may be substituted but is not required to be present, and the description includes the cases where the cyclopropyl group is substituted and the cases where the cyclopropyl group is not substituted.

[0226] "Substituted" refers to one or more hydrogen atoms in a group, preferably five, more preferably one to three hydrogen atoms, which are independently substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine possible or impossible substitutions without much effort (through experiment or theory).

[0227] "Pharmaceutically acceptable salt" means a salt of the compounds disclosed herein that is safe and effective when used in mammals and has the intended biological activity.

[0228] Indicates the connection site.

[0229] Examples The following examples pertain to the intermediate compounds and final products identified in the specification and synthetic regimens. The preparation of the compounds of the present invention is described in detail using the following examples, but the chemical reactions described are disclosed in accordance with their general applicability to the preparation of the compounds of the present invention. Sometimes, the reactions may not be applicable to every compound within the scope of the present invention as described. Compounds in which this may occur are readily identifiable to those skilled in the art. In these cases, the reactions can be successfully carried out with conventional modifications known to those skilled in the art. In all preparation methods, all starting materials are known or can be readily prepared using known starting materials.

[0230] The starting materials, chemical reagents, and solvents used in this disclosure are all commercially available and were purchased from companies such as Anaiji Chemical, Shanghai Bide Pharmaceutical, Beijing Innocare, Jiangsu Aikon, Sinopharm Group, Beijing Bailingwei, and Yunnan Xinlanjing.

[0231] The structures of all compounds synthesized in this application were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS).

[0232] Nuclear magnetic resonance (NMR) measurements were performed using a Bruke AVANCE-400 / 600 NMR spectrometer. The deuterated solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), with tetramethylsilane (TMS) as the internal standard.

[0233] Mass spectrometry (MS) measurements were performed using Waters Acquity Plus device implementation.

[0234] High-performance liquid chromatography (HPLC) preparation was carried out using a Waters 2489 system.

[0235] The medium-pressure rapid preparative chromatograph is a COMBIFLASH NEXTGEN 300+.

[0236] The thin-layer chromatography silica gel plates used are Silica gel 60 thin-layer chromatography silica gel plates (aluminum plates, containing fluorescence).

[0237] The silica gel (100-200 mesh, 200-300 mesh) used in silica gel thin-layer chromatography was purchased from Inokai.

[0238] The reaction process in the examples was detected using thin-layer chromatography (TLC). The systems used to monitor the developing solvent and the eluent used to purify the compounds by column chromatography included: petroleum ether / ethyl acetate system and dichloromethane / methanol system.

[0239] Example 1: Synthesis of Intermediate S1

[0240] Step 1: Synthesis of N-cyclopentyl-5-iodo-2-nitroaniline (intermediate S1a)

[0241] 2-Fluoro-4-iodo-1-nitrobenzene (5 g, 18.73 mmol, 1 eq.) was dissolved in THF (50 ml), and DIPEA (7.26 g, 56.18 mmol, 3 eq.) and cyclopentanamine (4.78 g, 58.18 mmol, 3 eq.) were added sequentially. The mixture was stirred at room temperature for 2 h. After the reaction was completed, the reaction solution was concentrated and slurried twice with petroleum ether to obtain a yellow solid intermediate S1a (6.20 g, 99.68%).

[0242] LC-MS(ESI):[M+H] + =333.20

[0243] 1 H NMR (400MHz, DMSO-d6) δ7.93(d,J=6.8Hz,1H),7.76(d,J=8.9Hz,1H),7.44(d,J=1.7Hz,1H),7.01( dd,J=9.0,1.7Hz,1H),4.18–3.92(m,1H),2.13–1.99(m,2H),1.84–1.75(m,2H),1.69–1.63(m,4H).

[0244] Step 2: Synthesis of 1-cyclopentyl-5-iodobenzene-1,2-diamine (intermediate S1b)

[0245] Intermediate S1a (4.45 g, 13.40 mmol, 1 eq.) was dissolved in a mixed solvent of acetic acid (20 ml) and water (2 ml). Zinc powder (4.38 g, 66.99 mmol, 5 eq.) was added in portions, and the mixture was stirred at room temperature for 1 h. After the reaction was complete, the zinc powder was filtered off, the reaction solution was concentrated, and purified by silica gel column chromatography (PE:EA = 5:1) to obtain a yellow solid intermediate S1b (2 g, 49.40%).

[0246] LC-MS(ESI):[M+H] + =303.20

[0247] 1 H NMR (400MHz, DMSO-d6) δ6.66(dd,J=8.0,2.0Hz,1H),6.60(d,J=2.0Hz,1H),6.33(d,J=8.0Hz,1H),4. 75(s,2H),4.49(s,1H),3.75–3.60(m,1H),1.98–1.87(m,2H),1.78–1.61(m,2H),1.59–1.41(m,4H).

[0248] Step 3: Synthesis of cyclopentyl-6-iodo-1H-benzo[d]imidazol-2-amine (intermediate S1c)

[0249] Intermediate S1b (1 g, 3.31 mmol, 1 eq.) was dissolved in methanol (8 mL). A methanol solution of cyanogen bromide (0.53 g, 4.96 mmol, 1.5 eq.) was slowly added dropwise to the reaction system. After stirring at 50 °C for 1 h, triethylamine (0.33 g, 3.31 mmol, 1 eq.) was added, and stirring was continued at 50 °C for another 1 h. After the reaction was complete, the reaction system was concentrated under reduced pressure to obtain a brown solid crude intermediate S1c (1.5 g, 100%).

[0250] LC-MS(ESI):[M+H] + =328.13

[0251] Step 4: Synthesis of 2-bromo-N-(1-cyclopentyl-6-iodo-1H-benzo[d]imidazol-2-yl)-6-fluorobenzamide (intermediate S1d)

[0252] 2-Bromo-6-fluorobenzoic acid (0.7 g, 3.2 mmol, 1 eq.) and CDI (0.57 g, 3.52 mmol, 1.1 eq.) were dissolved in 1,4-dioxane solvent (10 ml) and stirred at 95 °C for 1 h. After the reaction system cooled to room temperature, HOBT (0.52 g, 3.84 mmol, 1.2 eq.) and intermediate S1c (1.05 g, 3.20 mmol, 1 eq.) were added, and the mixture was stirred at 95 °C overnight. After the reaction was completed, the reaction solution was concentrated and purified by silica gel column chromatography (PE:EA = 3:1) to obtain a yellow solid intermediate S1d (0.96 g, 56.87%).

[0253] LC-MS(ESI):[M+H] + =528.15

[0254] 1 H NMR (400MHz, DMSO-d6) δ12.92(s,1H),7.87(s,1H),7.59(d,J=8.3,1.4Hz,1H),7.48(d,J=7.4Hz,1H),7.39(d, J=8.3Hz,1H),7.36–7.25(m,2H),5.21–5.02(m,1H),2.24–2.06(m,2H),2.06–1.76(m,4H),1.76–1.48(m,2H).

[0255] Step 5: Synthesis of 4-bromo-7-cyclopentyl-9-iodobenzo[4,5]imidazo[1,2-a]quinazolin-5(7H)-one (intermediate S1)

[0256] Intermediate S1d (0.92 g, 1.74 mmol, 1 eq.) was dissolved in DMF (8 ml), and potassium phosphate (0.55 g, 2.61 mmol, 1.5 eq.) was added. The mixture was stirred at 120 °C for 1 h. After the reaction was complete, the reaction system was cooled to room temperature, and ice water (10 ml) was added and the mixture was stirred for 10 min. The mixture was filtered to obtain a white solid intermediate S1 (0.73 g, 82.02%).

[0257] LC-MS(ESI):[M+H] + =508.10

[0258] 1 H NMR(400MHz,Chloroform-d)δ8.09(d,J=8.4,1.0Hz,1H),7.85-7.81(m,2H),7.74(d,J=1.6Hz,1H),7.69(dd,J=8. 7,1.6Hz,1H),7.56(t,J=8.2Hz,1H),5.60–5.43(m,1H),2.26–2.10(m,4H),2.10–1.97(m,2H),1.89–1.76(m,2H).

[0259] Example 2: Synthesis of Intermediate S2

[0260] Step 1: N 1 -(2-bromo-3-fluoro-6-nitrophenyl)-N 2 N 2 -Dimethylethane-1,2-diamine (intermediate S2a)

[0261] 2-Bromo-1,3-difluoro-4-nitrobenzene (5.00 g, 21.01 mmol) was dissolved in acetonitrile (50 mL), and then potassium carbonate (8.71 g, 63.03 mmol) was added to the flask. The mixture was stirred at room temperature for 5 hours. The mixture was filtered through diatomaceous earth and then concentrated under vacuum to obtain a yellow solid S2a (5.78 g, 90%).

[0262] LC-MS(ESI):[M+H] + =306.18.

[0263] 1 H NMR (600MHz, Chloroform-d) δ7.93(dd,J=9.3,5.8Hz,1H),7.18(s,1H),6.56(dd,J=9.3,7.1Hz,1H),3.34–3.28(m,2H),2.48(t,J=5.8Hz,2H),2.26(s,6H).

[0264] Step 2: Tert-butyl 4-((2-bromo-3-((2-(dimethylamino)ethyl)amino)-4-nitrophenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylic acid ester (intermediate S2b)

[0265] 6.04 g (28.32 mmol) of tert-butyl-4-(hydroxymethyl)-3,6-dihydropyridine-1(2H)-carboxylic acid ester was dissolved in ultra-dry tetrahydrofuran (50 mL), and the reaction was cooled to -10 °C under nitrogen protection. Sodium hydride (1.13 g, 28.32 mmol) was added to the reaction system at -10 °C, and the system was transferred to room temperature and stirred for 30 minutes. Subsequently, S2a (5.78 g, 18.88 mmol) was added to the system at -10 °C, and the system was returned to room temperature and stirred for 3 hours. After the reaction was completed, the reaction system was concentrated, and the crude product was purified by column chromatography to obtain a yellow solid S2b (9.43 g, 99%).

[0266] LC-MS(ESI):[M+H] + =499.29.

[0267] 1 H NMR(400MHz,Chloroform-d)δ8.00(d,J=9.4Hz,1H),6.41(d,J=9.4Hz,1H),5.84(s,1H),4.56(s,2H),3.98–3.94(m ,2H),3.63–3.54(m,2H),3.41(t,J=6.3Hz,2H),2.63(t,J=6.3Hz,2H),2.35(s,6H),2.25–2.19(m,2H),1.47(s,9H).

[0268] Step 3: Tert-butyl 4-((4-amino-2-bromo-3-((2-(dimethylamino)ethyl)amino)phenoxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylic acid ester (intermediate S2c)

[0269] S2b (9.43 g, 18.88 mmol) and zinc powder (6.17 g, 94.41 mmol) were dissolved in acetic acid (50 mL), and the mixture was stirred overnight at room temperature. After the reaction was complete, the mixture was poured into saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by column chromatography to give a black oily substance S2c (6.62 g, 75%).

[0270] LC-MS(ESI):[M+H] + =469.39.

[0271] 1 H NMR(400MHz,Chloroform-d)δ6.58(d,J=8.6Hz,1H),6.50(d,J=8.6Hz,1H),5.78(s,1H),4.39–4.32(m,2H),3.97–3.88 (m,2H),3.58–3.51(m,2H),3.15(t,J=6.1Hz,2H),2.71(t,J=6.1Hz,2H),2.46(s,6H),2.26–2.18(m,2H),1.46(s,9H).

[0272] Step 4: Tert-butyl 4-(((4-bromo-3-(2-(dimethylamino)ethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)oxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylic acid ester (intermediate S2d)

[0273] Intermediate S2c (3.50 g, 7.46 mmol) was dissolved in tetrahydrofuran (30 mL), and carbonyl diimidazole (2.42 g, 14.91 mmol) was added under ice bath conditions. The reaction was allowed to proceed overnight at room temperature. The reaction mixture was concentrated, and the crude product was purified by column chromatography to give intermediate S2d (3.23 g, 87%) as a white solid.

[0274] LC-MS(ESI):[M+H] + =495.39.

[0275] 1H NMR(400MHz, DMSO-d6)δ10.96(s,1H),6.89(d,J=8.5Hz,1H),6.76(d,J=8.5Hz,1H),5.83(s,1H),4.51–4.43(m,2H), 4.18(t,J=7.1Hz,2H),3.88–3.79(m,2H),3.44(t,J=5.8Hz,2H),2.53–2.50(m,2H),2.24–2.12(m,8H),1.40(s,9H).

[0276] Step 5: Tert-butyl 1-(2-(dimethylamino)ethyl)-2-oxo-2,3-dihydro-1H,7H-spiro[benzofurano[4,5-d]imidazol-8,4'-piperidine]-1'-carboxylic acid ester (intermediate S2e)

[0277] Intermediate S2d (3.23 g, 6.52 mmol) was dissolved in toluene (40 mL), and azobisisobutyronitrile (3.21 g, 19.56 mmol) and tributyltin hydride (3.80 g, 13.04 mmol) were added. The mixture was reacted at 110 °C for 15 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to give a white solid intermediate S2e (150 mg, 6%).

[0278] LC-MS(ESI):[M+H] + =417.49.

[0279] 1 H NMR (400MHz, DMSO-d6) δ10.80(s,1H),6.74(d,J=8.2Hz,1H),6.45(d,J=8.3Hz,1H),4.43(s,2H),4.07– 3.88(m,4H),2.96–2.71(m,2H),2.25–2.07(m,8H),1.81–1.72(m,2H),1.64–1.53(m,2H),1.40(s,9H).

[0280] Step 6: Tert-butyl 1-(2-(dimethylamino)ethyl)-3-(1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydro-1H,7H-spiro[benzofurano[4,5-d]imidazol-8,4'-piperidin]-1'-carboxylic acid ester (intermediate S2f)

[0281] Intermediate S2e (110 mg, 0.26 mmol) and potassium tert-butoxide (59.27 mg, 0.53 mmol) were dissolved in ultra-dry tetrahydrofuran (5 mL). The mixture was stirred at 0 °C for 2 hours under nitrogen protection. Then, a solution of intermediate 1-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yltrifluoromethanesulfonate (201 mg, 0.53 mmol) dissolved in ultra-dry tetrahydrofuran (1 mL) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to obtain a yellow solid intermediate S2f (55 mg, 32%).

[0282] LC-MS(ESI):[M+H] + =648.57.

[0283] 1 H NMR(600MHz,Chloroform-d)δ7.38–7.33(m,2H),6.84–6.80(m,2H),6.41(d,J=8.3Hz, 1H),6.23(d,J=8.5Hz,1H),5.22–5.11(m,1H),4.95(s,2H),4.52–4.41(m,2H),4.34–4 .06(m,4H),3.79(s,3H),3.02–2.96(m,1H),2.86–2.73(m,3H),2.72–2.63(m,2H),2.6 4–2.52(m,1H),2.40–2.26(m,8H),2.17–2.11(m,1H),1.89–1.81(m,2H),1.47(s,9H).

[0284] Step 7: 3-(1-(2-(dimethylamino)ethyl)-2-oxo-1,2-dihydro-3H,7H-spiro[benzofurano[4,5-d]imidazol-8,4'-piperidin]-3-yl)piperidin-2,6-dione (intermediate S2)

[0285] Intermediate S2f (55 mg, 0.08 mmol) was dissolved in trifluoroacetic acid (0.1 mL), and trifluoromethanesulfonic acid (0.01 mL) was added at room temperature. The reaction was carried out at 70 °C for 3 hours under nitrogen protection. The reaction system was concentrated, and the crude product was purified by high-pressure pre-liquid chromatography to obtain a white solid intermediate S2 (13 mg, 36%).

[0286] LC-MS(ESI):[M+H] + =428.49.

[0287] 1H NMR (400MHz, DMSO-d6) δ11.15(s,1H),7.04(d,J=8.5Hz,1H),6.65(d,J=8.4Hz,1H),5.43–5.35(m,1H),4.57–4.49(m,2H),4.42–4.34( m,2H),3.54–3.42(m,4H),3.14–3.04(m,2H),2.97(s,6H),2.92–2.80(m,1H),2.72–2.60(m,1H),2.21–2.09(m,2H),2.05–1.94(m,4H).

[0288] Example 3: Synthesis of intermediate S4

[0289] Step 1: 2-(2-bromo-3-nitrophenoxy)tetrahydro-2H-pyran (intermediate S4a)

[0290] 2-Bromo-3-nitrophenol (10 g, 45.9 mmol) was dissolved in 80 mL of dichloromethane, and 3,4-dihydro-2H-furan (8.4 mL, 91.7 mmol) and pyridine 4-methylbenzenesulfonic acid (1.09 g, 4.59 mmol) were added. The reaction system was reacted at 50 °C for 5 h. After the reaction was completed, the reaction system was concentrated under reduced pressure and purified by silica gel column chromatography to obtain a pale yellow solid S4a (7.4 g, 53%).

[0291] 1 H NMR (400MHz, DMSO-d6) δ7.56 (q, J=4.1, 3.5Hz, 2H), 7.48 (dd, J=6.7, 3.2Hz, 1H), 3.75–3.5 4(m,3H),1.85(q,J=5.6,4.7Hz,2H),1.65(dq,J=13.2,5.6,4.8Hz,2H),1.51–1.42(m,2H).

[0292] Step 2: 7-Bromo-6-((tetrahydro-2H-pyran-2-yl)oxy)-1H-indole (intermediate S4b)

[0293] Intermediate S4a (7.4 g, 24.5 mmol) was dissolved in 70 mL of tetrahydrofuran. The reaction system was placed under an inert atmosphere and stirred at -50 °C. Vinyl magnesium bromide (1 M in THF) solution (123 mL, 123 mmol) was added dropwise, and the reaction was allowed to proceed for 2 h. After the reaction was completed, the reaction system was poured into an ice-cold saturated ammonium chloride solution and extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride, concentrated under reduced pressure, and subjected to column chromatography to obtain a white solid S4b (4.1 g, 56%).

[0294] LCMS(ESI):[M+H] + =296.08.

[0295] 1 H NMR (400MHz, DMSO-d6) δ11.12(s,1H),7.45(d,J=8.6Hz,1H),7.29(t,J=2.8Hz,1H),6.97(d,J=8.6Hz,1H),6 .49(dd,J=3.1,1.9Hz,1H),5.51(t,J=3.2Hz,1H),3.93–3.83(m,1H),3.58–3.47(m,1H),1.94–1.56(m,6H).

[0296] Step 3: 7-Bromo-1-methyl-6-((tetrahydro-2H-pyran-2-yl)oxy)-1H-indole (intermediate S4c)

[0297] Intermediate S4b (4.1 g, 13.8 mmol) was dissolved in 30 mL of tetrahydrofuran. Sodium hydride (1.66 g, 41.5 mmol) was added under ice bath conditions. After stirring for one hour, iodomethane (2.6 mL, 41.5 mmol) was added, and the reaction was allowed to proceed for 30 min. After the reaction was complete, the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride, concentrated under reduced pressure, and subjected to column chromatography to obtain a white solid, S4c (3.5 g, 81%).

[0298] 1 H NMR (600MHz, DMSO-d6) δ7.45(dd,J=8.6,1.8Hz,1H),7.24(t,J=2.5Hz,1H),6.98(dd,J=8.6,1.9Hz,1H),6.40(t,J=2.5H z,1H),5.51(t,J=3.0Hz,1H),4.10(s,3H),3.46–3.37(m,2H),2.05–1.97(m,2H),1.90–1.81(m,2H),1.68–1.61(m,2H).

[0299] Step 4: 7-Bromo-1-methyl-1H-indole-6-ol (intermediate S4d)

[0300] Intermediate S4c (3.5 g, 11.3 mmol) was dissolved in 25 mL of methanol, and aluminum trifluoromethanesulfonate (203 mg, 1.13 mmol) was added. The mixture was reacted at room temperature for 30 min. After the reaction was complete, the mixture was purified by reverse column chromatography to obtain a white solid S4d (1.7 g, 66%).

[0301] LCMS(ESI):[M+H] +=226.06.

[0302] 1 H NMR (400MHz, DMSO-d6) δ9.67 (s, 1H), 7.29 (d, J = 8.3Hz, 1H), 7.09 (d, J = 3.2Hz, 1H), 6.73 (d, J = 8.4Hz, 1H), 6.31 (d, J = 3.1Hz, 1H), 4.05 (s, 3H).

[0303] Step 5: Tert-butyl 4-(((7-bromo-1-methyl-1H-indol-6-yl)oxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylic acid ester (intermediate S4e)

[0304] Triphenylphosphine (2.96 g, 11.3 mmol) was dissolved in tetrahydrofuran, and diethyl azodicarbonate (2.05 mL, 11.3 mmol) was slowly added dropwise. The reaction system was kept at room temperature for 1 h. Menthol (2.41 g, 11.3 mmol) dissolved in tetrahydrofuran and intermediate S4d (1.7 g, 7.52 mmol) were added to the reaction system sequentially. The mixture was stirred at room temperature for 1 h. After the reaction was completed, the mixture was concentrated under reduced pressure and purified by column chromatography to obtain a white solid S4e (1.7 g, 53%).

[0305] LCMS(ESI):[M-Boc+H] + =321.28.

[0306] 1 H NMR(400MHz,Chloroform-d)δ7.43(d,J=8.5Hz,1H),6.91(d,J=3.2Hz,1H),6.79(d,J=8.6Hz,1H),6.38(d,J=3.2H z,1H),5.84(s,1H),4.51(s,2H),4.15(s,3H),3.95(s,2H),3.57(t,J=5.8Hz,2H),2.40–2.20(m,2H),1.47(s,9H).

[0307] Step 6: Tert-butyl-1-methyl-1H,7H-spiro[furano[2,3-g]indole-8,4'-piperidine]-1'-carboxylic acid ester (intermediate S4f)

[0308] Intermediate S4e (1.00 g, 2.37 mmol) was dissolved in toluene (10 mL), and azobisisobutyronitrile (0.58 g, 3.56 mmol) and tributyltin hydride (2.07 g, 7.12 mmol) were added. The mixture was reacted overnight at 110 °C. The reaction mixture was concentrated, and the crude product was purified by column chromatography to give intermediate S4f (0.72 g, 89%) as a white solid.

[0309] LC-MS(ESI):[M+H] + =343.29.

[0310] 1 H NMR(400MHz,Chloroform-d)δ7.40(d,J=8.4Hz,1H),6.84(d,J=3.2Hz,1H),6.70(d,J=8.4Hz,1H),6.46(d,J=3.2Hz,1H), 4.50(s,2H),4.34–4.09(m,2H),3.95(s,3H),2.95–2.67(m,2H),2.47–2.27(m,2H),1.88(d,J=13.7Hz,2H),1.50(s,9H).

[0311] Step 7: Tert-butyl 3-iodo-1-methyl-1H,7H-spiro[furan[2,3-g]indole-8,4'-piperidine]-1'-carboxylic acid ester (intermediate S4g)

[0312] Intermediate S4f (0.72 g, 2.10 mmol) was dissolved in DMF (10 mL), and N-iodosuccinimide (1.42 g, 6.31 mmol) was added at 0 °C. The reaction was allowed to proceed overnight at room temperature. The reaction mixture was concentrated, and the crude product was purified by column chromatography to give intermediate S4g (0.97 g, 98%) as a white solid.

[0313] LC-MS(ESI):[M+H] + =468.20.

[0314] Step 8: Tert-butyl 3-(3-(3,4-dimethylbenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-methyl-1H,7H-spiro[furan[2,3-g]indole-8,4'-piperidine]-1'-carboxylate (intermediate S4h)

[0315] Compound S4g (100 mg, 0.21 mmol) and 3-(3,4-dimethylbenzyl)dihydropyrimidine-2,4(1H,3H)-dione (68 mg, 0.26 mmol) were dissolved in dioxane (10 mL). Then, trans-(1R,2R)-N,N'-dimethyl-1,2-cyclohexanediamine (12 mg, 0.09 mmol), cuprous iodide (8 mg, 0.04 mmol), and cesium carbonate (208 mg, 0.64 mol) were added sequentially. The reaction was carried out under nitrogen protection at 120 °C for 16 hours. The crude product was concentrated under reduced pressure and purified by column chromatography to give a yellow solid compound S4h (70 mg, 54%).

[0316] LC-MS(ESI):[M+H] + =605.58

[0317] 1 H NMR(400MHz,Chloroform-d)δ7.17–7.10(m,2H),6.90(s,1H),6.72(d,J=8.5Hz,1H),6.44(d,J=2.0Hz,2H),5.02(s,2H),4.50(s,2H),4.33 –4.06(m,4H),3.90(s,3H),3.81(s,3H),3.78(s,3H),2.92(t,J=6.6Hz,2H),2.81(s,2H),2.34(s,2H),1.86(d,J=13.6Hz,2H),1.49(s,9H).

[0318] Step 9: 1-(1-methyl-1H,7H-spiro[furan[2,3-g]indol-8,4'-piperidin]-3-yl)dihydropyrimidine-2,4(1H,3H)-dione (intermediate S4)

[0319] Compound S4h (200 mg, 0.33 mmol) was dissolved in trifluoroacetic acid (2 mL), followed by the addition of trifluoromethanesulfonic acid (0.2 mL). The reaction was carried out under nitrogen protection at 70 °C for 3 hours. The crude product was concentrated under reduced pressure and purified by high performance preparative chromatography to obtain a yellow solid compound S4 (12 mg, 10%).

[0320] LC-MS(ESI):[M+H] + =355.20.

[0321] 1 H NMR (400MHz, DMSO-d6) δ10.34(s,1H),7.27(d,J=8.5Hz,1H),7.18(s,1H),6.65(d,J=8.4Hz,1H),4.54(s,2H),3.96(s,3 H),3.68(t,J=6.7Hz,2H),3.42(s,2H),3.15–2.95(m,2H),2.74(t,J=6.7Hz,1H),2.46–2.29(m,3H),2.05–1.88(m,3H).

[0322] Example 4: Synthesis of Compound 1

[0323] Step 1: (2,4-Difluoro-5-nitrophenyl)methanol (Intermediate 1a)

[0324] 2,4-Difluoro-5-nitrobenzoic acid (1 g, 4.92 mmol) was dissolved in 25 mL of tetrahydrofuran, and then a dimethyl sulfide solution of borane (7.39 mL, 14.77 mmol, 2 M) was added dropwise at 0 °C under N2 protection. The reaction system was stirred at 60 °C for 16 hours. After the reaction was completed, the reaction system was quenched dropwise with methanol at 0 °C. The concentrated reaction solution was purified by normal chromatography to give a pale yellow oily intermediate 1a (953 mg, >99%).

[0325] LC-MS(ESI):[M+H] + =190.14.

[0326] 1 H NMR (400MHz, DMSO-d6) δ8.25(t,J=8.1Hz,1H),7.68(dd,J=11.3,9.9Hz,1H),5.64(t,J=5.7Hz,1H),4.58(dd,J=5.7,0.6Hz,2H).

[0327] Step 2: (4-(cyclopentanamino)-2-fluoro-5-nitrophenyl)methanol (intermediate 1b)

[0328] Cyclopentanylamine (576.09 mg, 6.77 mmol) and N,N-diisopropylethylamine (1.75 g, 13.53 mmol) were added to a 25 mL solution of intermediate 1a (853 mg, 4.51 mmol) in tetrahydrofuran. The reaction mixture was stirred at 60 °C for 16 hours. After the reaction was complete, the concentrated reaction solution was purified by normal chromatography to give intermediate 1b (1 g, 87%), a pale yellow solid.

[0329] LC-MS(ESI):[M+H] + =255.27.

[0330] 1 H NMR (400MHz, DMSO-d6) δ8.17(d,J=8.0Hz,1H),8.06(d,J=6.0Hz,1H),6.89(d,J=13.0Hz,1H),5.30 (t,J=5.7Hz,1H),4.42(d,J=5.7Hz,2H),4.07–3.98(m,1H),2.12–2.01(m,2H),1.76–1.47(m,6H).

[0331] Step 3: Tert-butyl 1-(5-(cyclopentanamino)-2-(hydroxymethyl)-4-nitrophenyl)piperidine-4-carboxylic acid ester (intermediate 1c)

[0332] A mixture of intermediate 1b (877 mg, 3.45 mmol), piperidine-4-carboxylic acid tert-butyl ester (958.54 mg, 5.17 mmol), N,N-dimethylformamide (20 mL), and potassium carbonate (1.43 g, 10.35 mmol) was stirred at 80 °C for 16 hours. After the reaction was complete, the reaction was quenched with water, and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were washed three times with saturated sodium chloride aqueous solution. The residue was purified by normal chromatography to give a pale yellow solid intermediate 1c (420 mg, 29%).

[0333] LC-MS(ESI): [M+H]+=420.49.

[0334] 1 H NMR (400MHz, DMSO-d6) δ8.17(d,J=6.5Hz,1H),8.11(s,1H),6.23(s,1H),5.23(t,J=5.5Hz,1H),4.33(d,J=5.5Hz,2H),4.10–3.99(m,1H),3.33–3 .29(m,2H),2.78(t,J=10.8Hz,2H),2.45–2.36(m,1H),2.12–2.02(m,2H ),1.93–1.85(m,2H),1.76–1.60(m,6H),1.59–1.49(m,2H),1.42(s,9H).

[0335] Step 4: Tert-butyl 1-(5-(cyclopentanamino)-2-formyl-4-nitrophenyl)piperidine-4-carboxylic acid ester (intermediate 1d)

[0336] 2-Iodobenzoic acid (533.97 mg, 1.91 mmol) was added to a 20 mL solution of intermediate 1c (400 mg, 953.47 μmol) in acetonitrile. The reaction mixture was stirred at 60 °C for 1 hour. After the reaction was complete, the reaction system was filtered, and the filtrate was concentrated under reduced pressure to obtain a yellow oily intermediate 1d (423 mg, >99%).

[0337] LC-MS(ESI):[M+H] + =418.59.

[0338] 1H NMR(400MHz, DMSO-d6)δ9.71(s,1H),8.50(s,1H),8.40(d,J=6.6Hz,1H),6.20(s,1H),4.20–4.09(m,1H),3.50–3.40 (m,2H),3.04–2.92(m,2H),2.48–2.41(m,1H),2.15–2.05(m,2H),1.96–1.87(m,2H),1.80–1.53(m,8H),1.42(s,9H).

[0339] Step 5: tert-butyl-1-(5-(cyclopentanamino)-2-(dimethylamino)methyl)-4-nitrophenyl)piperidine-4-carboxylate (intermediate 1e)

[0340] Triethylamine (307.57 mg, 3.04 mmol) was added to a tetrahydrofuran (10 mL) solution of dimethylamine hydrochloride (123.92 mg, 1.52 mmol), and the mixture was stirred at 25 °C for 15 min. Then, intermediate 1d (423 mg, 1.01 mmol) and acetic acid (182.53 mg, 3.04 mmol) were added, and the mixture was stirred at 25 °C for 10 min. Sodium cyanoborohydride (191.01 mg, 3.04 mmol) was then added. The mixture was stirred at 25 °C for 16 h. After the reaction was complete, the concentrated reaction solution was purified by normal chromatography to obtain a pale yellow oily intermediate 1e (488 mg, >99%).

[0341] LC-MS(ESI):[M+H] + =447.49.

[0342] 1 H NMR (400MHz, DMSO-d6) δ8.27(s,1H),8.22(d,J=6.6Hz,1H),6.46(s,1H),4.14–3.89(m,3H),3.22–3.13(m,2H),2.76(t,J=10.8H z,2H),2.61(s,6H),2.45–2.34(m,1H),2.14–2.03(m,2H),1.95–1.90(m,2H),1.83–1.69(m,4H),1.68–1.52(m,4H),1.42(s,9H).

[0343] Step 6: tert-butyl-1-(4-amino-5-(cyclopentylamino)-2-(dimethylamino)methyl)phenyl)piperidine-4-carboxylate (intermediate 1f)

[0344] Intermediate 1e (488 mg, 1.09 mmol) was dissolved in acetic acid (12 mL) and water (1.2 mL). Zinc powder (357.21 mg, 5.46 mmol) was added. The mixture was stirred at 25 °C for 1 hour. After the reaction was complete, most of the acetic acid was concentrated under reduced pressure. The pH was adjusted to >7 with saturated sodium bicarbonate solution, and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were washed twice with saturated sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a yellow oily intermediate 1f (308 mg, 67%).

[0345] LC-MS(ESI):[M+H] + =417.59.

[0346] 1 H NMR(400MHz,DMSO-d6)δ6.49(s,1H),6.27(s,1H),4.59–4.23(m,3H),3.72–3.62(m,1H),3.51(s,2H),2.94–2.85(m,2H),2.63–2.53(m,2H), 2.29(s,6H),2.24–2.14(m,1H),1.98–1.89(m,2H),1.86–1.79(m,2H), 1.72–1.61(m,4H),1.59–1.52(m,2H),1.51–1.43(m,2H),1.41(s,9H).

[0347] Step 7: Tert-butyl 1-(2-amino-1-cyclopentyl-5-((dimethylamino)methyl)-1H-benzo[d]imidazol-6-yl)piperidine-4-carboxylic acid ester (intermediate 1g)

[0348] Intermediate 1f (308 mg, 7393 μmol) was dissolved in methanol / water (7 mL / 7 mL). Then, hydrogen bromide (117.46 mg, dissolved in 2 mL of methanol) was added at 0 °C. The mixture was stirred at 25 °C for 2 hours. After the reaction was complete, no purification was required; the mixture was concentrated under reduced pressure and used directly in the next step.

[0349] LC-MS(ESI):[M+H] + =442.49.

[0350] 1H NMR(400MHz, DMSO-d6)δ8.65(s,2H),7.60(s,1H),7.25(s,1H),4.98–4.87(m,1H),4.37(d,J=5.0Hz,2H),2.96–2.86(m,2H),2.82–2.60 (m,8H),2.43–2.31(m,1H),2.08–2.01(m,4H),1.99–1.96(m,2H),1.93–1.88(m,2H),1.85–1.78(m,2H),1.75–1.69(m,2H),1.43(s,9H).

[0351] Step 8: Tert-butyl 1-(2-(2-bromo-6-fluorobenzamido)-1-cyclopentyl-5-(dimethylamino)methyl)-1H-benzo[d]imidazol-6-yl)piperidine-4-carboxylic acid ester (intermediate 1h)

[0352] 2-Bromo-6-fluorobenzoic acid (113 mg, 515.96 μmol) and N,N-carbonyldiimidazole (92 mg, 567.56 μmol) were added to a dry 50 mL single-necked flask. 1,4-dioxane (5 mL) was added to dissolve the flask, and the mixture was reacted at 95 °C for 2 hours, then cooled to 25 °C. 1 g (227.86 mg, 515.96 μmol) of intermediate and 1-hydroxybenzotriazole (83.66 mg, 619.15 μmol) were slowly added to the mixture, and the mixture was stirred overnight at 95 °C. After the reaction was complete, the mixture was concentrated under reduced pressure and separated by column chromatography to obtain a yellow oily intermediate 1h (170 mg, 51%).

[0353] LC-MS(ESI):[M+H] + =642.37.

[0354] 1 H NMR(400MHz,DMSO-d6)δ7.93(d,J=8.4Hz,1H),7.82(s,1H),7.69–7.62(m,1H ),7.51–7.45(m,2H),5.21–5.09(m,1H),4.14(s,2H),3.04–2.96(m,2H),2.82 –2.72(m,2H),2.61(s,6H),2.42–2.32(m,1H),2.22–2.10(m,2H),2.03–1.93( m,4H),1.90–1.85(m,2H),1.84–1.74(m,2H),1.71–1.63(m,2H),1.43(s,9H).

[0355] Step 9: Tert-butyl 1-(4-bromo-7-cyclopentyl-10-((dimethylamino)methyl)-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)piperidine-4-carboxylic acid ester (intermediate 1i)

[0356] Intermediate 1h (145 mg, 225.64 μmol) and potassium phosphate (71.84 mg, 338.46 μmol) were added to a dry 25 mL reaction tube. N,N-dimethylformamide (4 mL) was then added to the system, and the mixture was stirred at 120 °C for 2 hours. After the reaction was complete, the mixture was cooled to room temperature. Ice water was added to the system, and a solid precipitated. Filtration yielded a yellow solid, intermediate 1i (90 mg, 64%).

[0357] LC-MS(ESI):[M+H] + =622.48.

[0358] 1 H NMR (400MHz, DMSO-d6) δ8.32(d,J=8.2Hz,1H),8.22(s,1H),7.85–7.70(m,2H),7.28(s,1H),5.29–5.17(m,1H),3.58(s,2H),3.23–3. 14(m,2H),2.83–2.74(m,2H),2.44–2.34(m,1H),2.24(s,6H),2.06–1.98(m,4H),1.96–1.89(m,3H),1.81–1.68(m,5H),1.44(s,9H).

[0359] Step 10: 1-(4-bromo-7-cyclopentyl-10-((dimethylamino)methyl)-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)piperidine-4-carboxylic acid (intermediate 1j)

[0360] Intermediate 1i (77 mg, 123.67 μmol) was dissolved in dichloromethane / 1,4-dioxane hydrochloride (2 mL / 2 mL). The mixture was stirred at 25 °C for 1 hour. After the reaction was complete, no purification was required; the mixture was concentrated under reduced pressure and used directly in the next step.

[0361] LC-MS(ESI):[M+H] + =566.38.

[0362] 1H NMR (400MHz, DMSO-d6) δ10.92(s,1H),8.84(s,1H),7.81(d,J=7.8Hz,1H),7.76–7.56(m,2H),7.52(s,1H),5.30–5.18(m,1H),4.47(d,J=5.4H z,2H),3.02–2.96(m,2H),2.87–2.82(m,2H),2.78–2.74(m,6H),2.46– 2.37(m,1H),2.35–2.22(m,2H),2.02–1.89(m,8H),1.76–1.71(m,2H).

[0363] Step 11: 3-(1'-(1-(4-bromo-7-cyclopentyl-10-((dimethylamino)methyl)-5-oxo-5,7-dihydrobenzo[4,5]imidazoline-9-yl)piperidine-4-carbonyl)-1-methyl-2-oxo-1,2-dihydro-3H,7H-spiro[benzofuran[4,5-d]imidazoline-8,4'-piperidine]-3-yl)piperidine-2,6-dione (Compound 1)

[0364] Intermediate S3 (15.69 mg, 42.37 μmol) was added to a solution of intermediate 1j (20 mg, 35.5 μmol) in N,N-dimethylformamide (0.8 mL), followed by HATU (20.14 mg, 52.96 μmol) and N,N-diisopropylethylamine (13.69 mg, 105.91 μmol). The mixture was stirred at 25°C for 1 hour. After the reaction was complete, the mixture was concentrated under reduced pressure and purified by Pre-HPLC to give compound 1 (10.37 mg, 32%) as a yellow solid.

[0365] LC-MS(ESI):[M+H] + =918.55.

[0366] 1H NMR (400MHz, DMSO-d6) δ8.49(s,1H),8.43(d,J=8.5Hz,1H),7.84(d,J=7.9Hz,1H),7.74(t,J=8.1Hz, 1H),7.49(s,1H),6.97–6.89(m,1H),6.56(d,J=8.4Hz,1H),5.35–5.18(m,2H),4.62–4.49(m,3H),4. 45(s,2H),4.10(d,J=11.9Hz,1H),3.49(s,3H),3.29–3.17(m,1H),3.10–3.00(m,2H),2.95–2.85(m, 4H),2.84–2.79(m,6H),2.72–2.57(m,4H),2.29–2.12(m,4H),2.09–1.88(m,8H),1.86–1.68(m,4H).

[0367] Example 5: Synthesis of Compound 2

[0368] Step 1: 1-(tert-butyl)-4-methyl-4-(aminomethyl)piperidine-1,4-dicarboxylic acid ester (intermediate 2a)

[0369] 1-(tert-butyl)-4-methyl-4-cyanopiperidine-1,4-dicarboxylate (5.00 g, 18.63 mmol) was dissolved in acetic acid (50 mL), and then platinum dioxide (0.50 g, 10% wt) was added to the flask to remove oxygen and replace with hydrogen. The mixture was stirred at room temperature for 2 hours. After filtration through diatomaceous earth, the mixture was concentrated under vacuum to obtain an oily liquid intermediate 2a (5.08 g, 99%).

[0370] LC-MS(ESI):[M+H] + =273.35.

[0371] Step 2: 1-(tert-butyl)-4-methyl-4-((dimethylamino)methyl)piperidine-1,4-dicarboxylic acid ester (intermediate 2b)

[0372] Intermediate 2a (5.00 g, 18.36 mmol) was dissolved in methanol (50 mL). Formaldehyde (1.65 g, 55.08 mmol) was then added to the system, and the mixture was stirred at 25 °C for 1 hour. Sodium cyanoborohydride (3.46 g, 55.08 mmol) was then added, and the mixture was stirred at 25 °C overnight. After the reaction was complete, the system was separated by column chromatography to give a yellow solid intermediate 2b (3.52 g, 64%).

[0373] LC-MS(ESI):[M+H] +=301.35.

[0374] 1 H NMR (400MHz, Chloroform-d) δ3.87–3.74(m,2H),3.70(s,3H),3.04–2.84(m,2H),2.69(s,2H),2.33(s,6H),2.12–2.02(m,2H),1.48–1.36(m,11H).

[0375] Step 3: Methyl 4-((dimethylamino)methyl)piperidine-4-carboxylic acid (intermediate 2c)

[0376] Hydrochloric acid / 1,4-dioxane (20 mL, 4 mol / L) and dichloromethane (20 mL) were added to a reaction tube containing intermediate 2b (3.82 g, 12.72 mmol). The system was stirred overnight at room temperature. After the reaction was completed, the mixture was concentrated to obtain a white solid intermediate 2c (1.35 g, 53%).

[0377] LC-MS(ESI):[M+H] + =201.35

[0378] 1 H NMR (400MHz, DMSO-d6) δ3.75(s,3H),3.57–3.50(m,2H),3.29–3.16(m,2H),3.02–2.89(m,2H),2.70(s,6H),2.25–2.14(m,2H),1.99–1.87(m,2H).

[0379] Step 4: Methyl 1-(3-(cyclopentylamino)-4-nitrophenyl)-4-(dimethylamino)methyl)piperidine-4-carboxylic acid (intermediate 2d)

[0380] Intermediate 2c (1.28 g, 6.31 mmol), 5-bromo-N-cyclopentyl-2-nitroaniline (1.20 g, 4.21 mmol), palladium(II) acetate (10%), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthione (10%), cesium carbonate (6.86 g, 21.04 mmol), and 1,4-dioxane (20.0 mL) were added to a 100 mL dry round-bottom flask. The mixture was stirred at 110 °C for 2 hours. After the reaction was complete, the mixture was concentrated under vacuum and then purified by column chromatography to obtain a yellow solid intermediate 2d (1.25 g, 73%).

[0381] LC-MS(ESI):[M+H] + =405.49.

[0382] 1 H NMR(400MHz,Chloroform-d)δ8.03(d,J=9.7Hz,1H),6.19(dd,J=9.8,2.6Hz,1H),5.88(d,J=2.6Hz,1H),3.95–3.85(m,1H),3. 74–3.67(m,5H),3.14–3.04(m,2H),2.51(s,2H),2.30–2.21(m,8H),2.11–2.02(m,2H),1.82–1.74(m,2H),1.72–1.53(m,6H).

[0383] Step 5: Methyl 1-(4-amino-3-(cyclopentylamino)phenyl)-4-((dimethylamino)methyl)piperidine-4-carboxylic acid (intermediate 2e)

[0384] The synthesis method is the same as that for intermediate S1b.

[0385] LC-MS(ESI):[M+H] + =375.49.

[0386] 1 H NMR(400MHz,Chloroform-d)δ6.61(d,J=8.2Hz,1H),6.35(d,J=2.6Hz,1H),6.24(dd,J=8.2,2.5Hz,1H),3.78–3.74(m,1H) ,3.72(s,3H),3.35–3.22(m,2H),2.82–2.72(m,2H),2.56(s,2H),2.28–2.24(m,8H),2.03–1.98(m,2H),1.75–1.48(m,8H).

[0387] Step 6: 1-(2-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yl)-4-((dimethylamino)methyl)piperidine-4-carboxylic acid methyl ester (intermediate 2f)

[0388] The synthesis method is the same as that for intermediate S1c.

[0389] LC-MS(ESI):[M+H] + =400.49.

[0390] 1H NMR(400MHz,Chloroform-d)δ7.12(d,J=8.8Hz,1H),6.76(dd,J=8.9,2.0Hz,1H),6.66(d,J=2.1Hz,1H),5.10–4.98(m,1H),3.79( s,3H),3.43(s,2H),3.39–3.31(m,2H),3.01–2.90(m,2H),2.73(s,6H),2.38–2.30(m,2H),2.23–2.17(m,2H),2.05–1.80(m,8H).

[0391] Step 7: 1-(2-(2-bromo-6-fluorobenzamido)-1-cyclopentyl-1H-benzo[d]imidazol-6-yl)-4-((dimethylamino)methyl)piperidine-4-carboxylic acid ester (intermediate 2g)

[0392] The synthesis method is the same as that for intermediate S1d.

[0393] LC-MS(ESI):[M+H] + =600.08.

[0394] 1 H NMR(400MHz,Chloroform-d)δ7.37(d,J=8.0Hz,1H),7.23(d,J=8.8Hz,1H),7.18–7 .11(m,1H),7.06(t,J=8.5Hz,1H),6.91(dd,J=8.8,1.9Hz,1H),6.85(d,J=2.3Hz,1H ),5.30–5.21(m,1H),3.75(s,3H),3.47–3.39(m,2H),2.89(t,J=11.8Hz,2H),2.64( s,2H),2.38–2.27(m,8H),2.26–2.14(m,4H),2.00–1.90(m,2H),1.80–1.67(m,4H).

[0395] Step 8: 1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)-4-((dimethylamino)methyl)piperidine-4-carboxylic acid methyl ester (intermediate 2h)

[0396] The synthesis method is the same as that for intermediate S1.

[0397] LC-MS(ESI):[M+H] + =580.38.

[0398] 1H NMR(600MHz,Chloroform-d)δ8.10–8.05(m,1H),7.85(d,J=8.9Hz,1H),7.75(dd,J= 7.9,1.0Hz,1H),7.50(t,J=8.1Hz,1H),6.94–6.87(m,2H),5.57–5.47(m,1H),3.75( s,3H),3.55–3.47(m,2H),2.97–2.95(m,2H),2.55(s,2H),2.37–2.30(m,2H),2.26( s,6H),2.22–2.08(m,4H),2.04–1.97(m,2H),1.85–1.78(m,2H),1.75–1.68(m,2H).

[0399] Step 9: 1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)-4-((dimethylamino)methyl)piperidine-4-carboxylic acid (intermediate 2i)

[0400] Tetrahydrofuran (8 mL) was added to a dry 50 mL test tube containing intermediate 2h (70.00 mg, 0.12 mmol) and 4% NaOH aqueous solution (8.0 mL). The system was stirred at 60 °C for 16 hours. After the reaction was completed, a white solid intermediate 2i (49 mg, 71%) was obtained by preparative chromatography.

[0401] LC-MS(ESI):[M+H] + =566.38.

[0402] 1 H NMR (400MHz, DMSO-d6) δ8.40(d,J=8.4Hz,1H),8.19(d,J=9.2Hz,1H),7.77(d, J=7.8Hz,1H),7.66(t,J=8.1Hz,1H),7.12(d,J=2.3Hz,1H),6.99(dd,J=9.2,2. 3Hz,1H),5.27–5.15(m,1H),3.60–3.51(m,4H),3.19–3.08(m,2H),2.83(s,6H ),2.36–2.24(m,2H),2.20–2.10(m,2H),2.05–1.92(m,4H),1.82–1.66(m,4H).

[0403] Step 10: Synthesis of 3-(1'-(1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)-4-((dimethylamino)methyl)piperidin-4-carbonyl)-1-methyl-2-oxo-1,2-dihydro-3H,7H-spiro[benzofurano[4,5-d]imidazo-8,4'-piperidin]-3-yl)piperidin-2,6-dione (Compound 2)

[0404] The synthesis method is the same as that for compound 1.

[0405] LC-MS(ESI):[M+H] + =918.45.

[0406] 1 H NMR (400MHz, DMSO-d6) δ8.36(d,J=8.5Hz,1H),8.19(d,J=9.1Hz,1H),7.78(d,J=7.8Hz,1H),7. 68(t,J=8.1Hz,1H),7.05(d,J=2.3Hz,1H),7.00(d,J=9.1Hz,1H),6.92(d,J=8.4Hz,1H),6.54( d,J=8.4Hz,1H),5.31–5.12(m,2H),4.56–4.15(m,4H),3.60–3.46(m,7H),3.33–3.17(m,2H),2 .96–2.75(m,8H),2.69–2.58(m,2H),2.42–2.28(m,2H),2.26–2.11(m,4H),2.01–1.66(m,12H).

[0407] Example 6: Synthesis of Compound 3

[0408] Step 1: tert-butyl-1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)piperidine-4-carboxylate (intermediate 3a)

[0409] Intermediate S1 (100 mg, 0.2 mmol), tert-butylpiperidine-4-carboxylic acid ester (36.63 mg, 0.26 mmol), Pd2(dba)3 (22.77 mg, 0.04 mmol), Xantphos (18.02 mg, 0.02 mmol), and tBuONa (56.74 mg, 0.06 mmol) were dissolved in 1,4-dioxane (5 mL) and reacted overnight at 100 °C under N2 protection. After the reaction was complete, the system was separated by column chromatography to obtain a yellow solid intermediate 3a (80 mg, 77%).

[0410] LC-MS(ESI):[M+H] + =565.38 / 567.48

[0411] 1 H NMR (400MHz, DMSO-d6) δ8.43(d,J=8.4Hz,1H),8.26(d,J=9.1Hz,1H),7.79(d,J=7.8Hz,1H),7.68(t,J=8.1Hz,1H),7.25(s,1H),7.10(d,J=9.1Hz,1H), 5.27-5.17(m,1H),3.77-3.69(m,2H),3.01(t,J=10.7Hz,2H),2.50–2.43(m ,1H),2.35–2.22(m,2H),2.05-1.93(m,6H),1.80–1.68(m,4H),1.42(s,9H).

[0412] Step 2: 1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)piperidine-4-carboxylic acid (intermediate 3b)

[0413] The synthesis method is the same as that for intermediate 1j.

[0414] LC-MS(ESI):[M+H] + =509.39 / 511.39

[0415] Step 3: 3-(1'-(1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)piperidin-4-carbonyl)-1-(2-(dimethylamino)ethyl)-2-oxo-1,2-dihydro-3H,7H-spiro[benzofurano[4,5-d]imidazo-8,4'-piperidin]-3-yl)piperidin-2,6-dione (compound 3)

[0416] The synthesis method is the same as that of compound 1.

[0417] LC-MS(ESI):[M+H] + =918.85.

[0418] 1H NMR (600MHz, DMSO-d6) δ11.14(s,1H),8.41(d,J=8.4Hz,1H),8.21(d,J=9.1Hz,1H),7.78(d,J=7.8Hz,1H),7.67(t,J=8.1Hz,1H),7 .13(d,J=2.4Hz,1H),7.03–6.98(m,2H),6.63(d,J=8.4Hz,1H),5.40–5.35(m,1H),5.27–5.20(m,1H),4.63(d,J=8.8Hz,1H),4.58( d,J=13.4Hz,1H),4.51(d,J=8.9Hz,1H),4.34–4.25(m,1H),4.23–4.15(m,1H),4.12(d,J=13.1Hz,1H),3.88–3.83(m,4H),3.48–3. 40(m,2H),3.26(t,J=12.9Hz,1H),2.98–2.82(m,8H),2.77–2.59(m,3H),2.33–2.24(m,2H),2.16–1.89(m,9H),1.88–1.60(m,6H).

[0419] Example 7: Synthesis of Compound 4

[0420] Step 1: Methyl(R)-1-(3-amino-6-(2-hydroxyphenyl)pyrazin-4-yl)pyrrolidine-3-carboxylic acid ester (intermediate 4a)

[0421] 2-(6-amino-5-bromopyrazin-3-yl)phenol (0.1 g, 0.3758 mmol) was dissolved in acetonitrile (2 mL), followed by the addition of methyl(R)-pyrrolidine-3-carboxylate (0.07281, 0.5637 mmol) and DIEA (0.24286 g, 1.87901 mmol). The mixture was then stirred at 80 °C for 12 hours. After the reaction was complete, the mixture was concentrated under vacuum. The system was separated by column chromatography to obtain a yellow solid intermediate 4a (66 mg, 55.87%).

[0422] LC-MS(ESI):[M+H] + =315.28

[0423] 1H NMR(600MHz,DMSO-d6)δ14.60(s,1H),7.91(d,J=8.0Hz,1H),7.25–7.20(m,1H),7.11(s,1H),6.89–6.84(m,2H),6.03( s,2H),3.74–3.68(m,2H),3.67(s,3H),3.58–3.48(m,2H),3.27(p,J=7.4Hz,1H),2.28–2.19(m,1H),2.18–2.09(m,1H).

[0424] Step 2: (R)-1-(3-amino-6-(2-hydroxyphenyl)pyrimidin-4-yl)pyrrolidine-3-carboxylic acid (intermediate 4b)

[0425] Intermediate 4a (56 mg, 0.17815 mmol) was dissolved in methanol / water (2 mL / 0.4 mL), followed by the addition of lithium hydroxide hydrate (6 mg, 0.89074 mmol), and then stirred at room temperature for 2 hours. After the reaction was complete, 1 M hydrochloric acid aqueous solution was slowly added to adjust the pH to 5–6. The mixture was then concentrated under vacuum to obtain a yellow solid intermediate 4b (130 mg, 242.98%), which was directly added to the next step without purification.

[0426] LC-MS(ESI):[M+H] + =301.20

[0427] Step 3: 3-(1'-((R)-1-(3-amino-6-(2-hydroxyphenyl)pyrazin-4-yl)pyrrolidine-3-carboxylyl)-1-methyl-2-oxo-1,2-dihydro-3H,7H-spiro[benzofuran[4,5-d]imidazol-8,4'-piperidine]-3-yl)piperidine-2,6-dione (compound 4)

[0428] The synthesis method is the same as that of compound 1.

[0429] LC-MS(ESI):[M+H] + =653.30

[0430] 1H NMR (600MHz, DMSO-d6) δ14.14(s,1H),11.11(s,1H),7.50(d,J=5.8Hz,1H),7.42(t,J=7.6Hz,1H),7.05(d,J=8.2Hz,1H ),7.03–6.98(m,1H),6.97–6.91(m,1H),6.86(d,J=7.7Hz,1H),6.79–6.67(m,2H),6.56(d,J=8.3Hz,1H),5.40–5.26(m, 1H),4.61–4.47(m,3H),4.10(d,J=13.1Hz,1H),4.04–3.94(m,2H),3.90–3.74(m,2H),3.69–3.63(m,1H),3.53–3.49(m, 3H),3.28–3.19(m,1H),2.93–2.83(m,1H),2.77–2.62(m,3H),2.35–2.20(m,2H),2.18–2.05(m,2H),2.03–1.85(m,3H).

[0431] Example 8: Synthesis of Compound 5

[0432] Step 1: 1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)-3-carboxylated cyclobutane methyl ester (intermediate 5a)

[0433] Intermediate S1 (200.00 mg, 0.39 mmol), methyl 3-carboxylate aziridine hydrochloride (90.63 mg, 0.79 mmol), Cs₂CO₃ (385.90 mg, 1.18 mmol), Pd₂(dba)₃ (35.19 mg, 0.08 mmol), Xantphos (91.09 mg, 0.16 mmol), and a dry solution of 1,4-dioxane (10.0 mL) were added to a 100 mL round-bottom flask. The mixture was then purged with nitrogen three times, and the system was stirred at 100 °C for 5 hours. After the reaction was complete, the system was concentrated under vacuum and then separated by preparative chromatography to obtain a yellow solid intermediate 5a (54.00 mg, 19%).

[0434] LC-MS(ESI):[M+H] + =495.29.

[0435] Step 2: 1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)-3-carboxylated azacyclic butaneic acid (intermediate 5b)

[0436] To a dry 25 mL round-bottom flask containing intermediate 5a (52.00 mg, 0.10 mmol) and lithium hydroxide monohydrate (12.60 mg, 0.50 mmol), tetrahydrofuran / methanol / water in a ratio of 2:1:2 (5 mL) was added via syringe. The system was stirred continuously at room temperature for 1 hour. After the reaction was complete, 1 M HCl solution was added to adjust the pH to 4-5. The organic phase was collected by DCM extraction, dried, and evaporated to dryness to obtain a yellow solid intermediate 5b (25 mg, 49%).

[0437] LC-MS(ESI):[M+H] + =481.19.

[0438] Step 3: Synthesis of 3-(1'-(1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]quinazolin-9-yl)azacyclobutane-3-formyl)-1-methyl-2-oxo-1,2-dihydro-3H,7H-spiro[benzofurano[4,5-d]imidazo-8,4'-piperidine]-3-yl)piperidine-2,6-dione (Compound 5)

[0439] The synthesis method is the same as that of compound 1.

[0440] LC-MS(ESI):[M+H] + =833.56.

[0441] 1 H NMR (600MHz, DMSO-d6) δ11.09(s,1H),8.42(d,J=8.5Hz,1H),8.21(d,J=8.9Hz,1H),7.77(d,J=7.8Hz,1H),7.66(t,J=8.1Hz,1H) ,6.93(t,J=8.9Hz,1H),6.65(d,J=2.1Hz,1H),6.55(dd,J=8.4,3.0Hz,1H),6.49(d,J=8.8Hz,1H),5.36–5.30(m,1H),5.27–5.14 (m,1H),4.59–4.48(m,3H),4.25–4.16(m,2H),4.05–3.96(m,2H),3.80–3.72(m,2H),3.53–3.50(m,3H),3.25–3.14(m,1H),2.95 –2.82(m,1H),2.77–2.58(m,3H),2.33–2.20(m,3H),2.18–2.10(m,1H),2.06–1.96(m,5H),1.94–1.83(m,2H),1.79–1.70(m,2H).

[0442] Example 9: Synthesis of Compound 6

[0443] Step 1: Synthesis of (S)-1-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)pyrrolidine-3-carboxylic acid methyl ester (intermediate 6a)

[0444] 2-(6-amino-5-bromopyrazin-3-yl)phenol (93.4 mg, 0.56 mmol, 1.5 eq.) and DIPEA (327.5 μL, 1.88 mmol, 5.0 eq.) were dissolved in acetonitrile (1.5 mL), and the mixture was stirred at room temperature for 30 min. Then, methyl (S)-pyrrolidine-3-carboxylic acid (100 mg, 0.38 mmol, 1.0 eq.) was added, and the mixture was stirred at 80 °C for 12 h. After the reaction was complete, the reaction mixture was concentrated under reduced pressure and then purified by column chromatography (DCM:MeOH = 15:1) to give a pale yellow solid intermediate 6a (76.8 mg, 65%).

[0445] LC-MS(ESI):[M+H] + =314.98.

[0446] 1 H NMR (400MHz, DMSO-d6) δ14.63 (s, 1H), δ7.92 (dd, J=8.2, 1.3Hz, 1H), 7.25–7.20 (m, 1H), 7.12 (s, 1H), 6.89–6.83 (m, 2H), 6. 03(s,2H),3.73–3.68(m,2H),3.67(s,3H),3.56–3.47(m,2H),3.27(p,J=7.4Hz,1H),2.26–2.19(m,1H),2.18–2.09(m,1H).

[0447] Step 2: Synthesis of (S)-1-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)pyrrolidine-3-carboxylic acid (intermediate 6b)

[0448] Intermediate 6a (67.9 mg, 0.22 mmol, 1.0 eq.) was dissolved in MeOH / THF / H2O (2 / 2 / 1, 2.0 mL), and lithium hydroxide monohydrate (91 mg, 2.16 mmol, 10.0 eq.) was added at room temperature. The mixture was stirred at room temperature for 1 hour. After the reaction was complete, the reaction mixture was concentrated under reduced pressure. A suitable amount of water was added to the system, and the pH was adjusted to 3–4 with 2 M hydrochloric acid. The system was extracted three times with a mixed solvent of dichloromethane and methanol (15:1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a yellow solid intermediate 6b (65 mg, >99%).

[0449] LC-MS(ESI):[M+H] + =301.28.

[0450] Step 3: Synthesis of 3-(1'-((S)-1-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)pyrrolidine-3-carbonyl)-1-methyl-2-oxo-1,2-dihydro-3H,7Hspiro[benzofurano[4,5-d]imidazol-8,4'-piperidine]-3-yl)piperidine-2,6-dione (Compound 6)

[0451] The synthesis method is the same as that for compound 1.

[0452] LC-MS(ESI):[M+H] + =653.37

[0453] 1 H NMR (600MHz, DMSO-d6) δ14.13(s,1H),11.10(s,1H),7.49(d,J=6.0Hz,1H),7.41(t,J=7.8Hz,1H),7.04(d,J=8.2Hz,1H),7.02–6.9 7(m,1H),6.96–6.90(m,1H),6.85(d,J=8.0Hz,1H),6.77–6.64(m,2H),6.55(d,J=8.3Hz,1.2Hz,1H),5.39–5.27(m,1H),4.60–4.46 (m,3H),4.09(d,J=12.4Hz,1H),4.04–3.90(m,2H),3.86–3.74(m,2H),3.68–3.60(m,1H),3.52–3.48(m,3H),3.26–3.19(m,1H),2. 92–2.81(m,1H),2.76–2.65(m,2H),2.64–2.57(m,1H),2.32–2.20(m,2H),2.16–2.05(m,2H),1.99–1.94(m,1H),1.93–1.84(m,2H).

[0454] Example 10: Synthesis of Compound 7

[0455] Step 1: Synthesis of methyl 1-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)azacyclobutane-3-carboxylic acid (Intermediate 7a)

[0456] The synthesis method is the same as that for intermediate 6a.

[0457] LC-MS(ESI):[M+H]+ =301.08.

[0458] Step 2: Synthesis of 1-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)azacyclobutane-3-carboxylic acid (intermediate 7b)

[0459] The synthesis method is the same as that for intermediate 6b.

[0460] LC-MS(ESI):[M+H] + =287.28.

[0461] Step 3: Synthesis of 3-(1'-(1-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)azacyclobutane-3-carbonyl)-1-methyl-2-oxo-1,2-dihydro-3H,7Hspiro[benzofurano[4,5-d]imidazol-8,4'-piperidine]-3-yl)piperidine-2,6-dione (Compound 7)

[0462] The synthesis method is the same as that for compound 1.

[0463] LC-MS(ESI):[M+H] + =639.48

[0464] 1 H NMR (600MHz, DMSO-d6) δ14.10(s,1H),11.10(s,1H),7.49(d,J=7.1Hz,1H),7.42(t,J=7.6Hz,1H),7.05(d,J= 8.2Hz,1H),7.01(t,J=7.5Hz,1H),6.97–6.90(m,1H),6.73(s,1H),6.64–6.57(m,2H),6.56(dd,J=8.4,2.4Hz, 1H),5.37–5.30(m,1H),4.90–4.43(m,7H),4.07–3.99(m,1H),3.64(d,J=10.9Hz,1H),3.53–3.49(m,3H),3.23 –3.15(m,1H),2.92–2.83(m,1H),2.68–2.58(m,3H),2.25–2.12(m,2H),2.02–1.94(m,1H),1.92–1.84(m,2H).

[0465] Example 11, Synthesis of Compound 8

[0466] Step 1: 2-Bromo-N-cyclopentyl-5-nitropyridine-4-amine (Intermediate 8a)

[0467] 2,4-Dibromo-5-nitropyridine (4 g, 14.19 mmol) and cyclopentanamine (1.45 g, 17.03 mmol) were dissolved in tetrahydrofuran, and triethylamine (4.31 g, 42.57 mmol) was added. The mixture was then reacted at room temperature for 2 hours. After the reaction was complete, the mixture was poured into water and extracted with EA (50 mL * 3). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under vacuum. The crude product was separated by column chromatography to obtain a yellow solid intermediate 8a (3.65 g, 90%).

[0468] Step 2: Tert-butyl-1-(4-(cyclopentylamino)-5-nitropyridin-2-yl)piperidine-4-carboxylic acid ester (intermediate 8b)

[0469] Intermediate 8a (5 g, 17.47 mmol) was dissolved in DMF (50 mL), followed by the addition of tert-butylpiperidine-4-carboxylic acid ester (3.88 g, 20.96 mmol) and DIEA (6.77 g, 52.42 mmol). The mixture was stirred at 80 °C for 1 hour. After the reaction was complete, the mixture was poured into water and extracted with EA (50 mL * 3). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under vacuum. The crude product was separated by column chromatography to obtain a yellow solid intermediate 8b (4.8 g, 70%).

[0470] LC-MS(ESI): [M+H]+=391.30

[0471] 1 H NMR (600MHz, DMSO-d6) δ8.81(s,1H),7.97(d,J=6.9Hz,1H),5.84(s,1H),4.32(d,J=13.2Hz,2H),4.11–4.03(m,1H),3.14–3.06(m,2 H),2.60–2.52(m,1H),2.11–2.01(m,2H),1.88–1.82(m,2H),1.75–1.66(m,2H),1.65–1.55(m,2H),1.55–1.44(m,4H),1.39(s,9H).

[0472] Step 3: Tert-butyl-1-(5-amino-4-(cyclopentylamino)pyridin-2-yl)piperidine-4-carboxylic acid ester (intermediate 8c)

[0473] Intermediate 8b (4.8 g, 12.29 mmol) was dissolved in methanol (50 mL), followed by the addition of palladium on carbon (2.4 g, 50 wt%). The system was purged with hydrogen three times, and then reacted at room temperature for 12 hours. After the reaction was complete, the mixture was filtered through diatomaceous earth and concentrated under vacuum to obtain a purple solid intermediate 8c (3.8 g, 85.75%). This product was used directly in the next step without purification.

[0474] LC-MS(ESI): [M+H]+=361.25

[0475] Step 4: Tert-butyl 1-(2-amino-1-cyclopentyl-1H-imidazo[4,5-c]pyrimidin-6-yl)piperidine-4-carboxylate (intermediate 8d)

[0476] Intermediate 8c (1.5 g, 4.16 mmol) was dissolved in methanol, and cyanogen bromide (660 mg, 6.2413 mmol) was slowly added. The mixture was stirred overnight at room temperature. After the reaction was complete, the mixture was concentrated under vacuum to obtain a brown solid intermediate 8d (1.6 g, 100%). The product was used directly in the next step without purification.

[0477] LC-MS(ESI):[M+H] + =386.30

[0478] Step 5: Tert-butyl 1-(2-(2-bromo-6-fluorobenzamide)-1-cyclopentyl-1H-imidazo[4,5-c]pyridin-6-yl)piperidine-4-carboxylic acid ester (intermediate 8e)

[0479] 2-Bromo-6-fluorobenzoic acid (0.9 g, 4.15 mmol) and CDI (0.80 g, 4.98 mmol) were dissolved in 1,4-dioxane and stirred at 95 °C for 2 hours. Then, intermediate 8d (1.6 g, 4.15 mmol) and HOBt (610 mg, 4.56 mmol) were added, and the mixture was stirred at 95 °C for another 12 hours. After the reaction was complete, the mixture was concentrated under vacuum and purified by column chromatography to obtain a green solid intermediate 8e (560 mg, 23%).

[0480] LC-MS(ESI):[M+H] + =586.20

[0481] Step 6: Tert-butyl 1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydropyridine[4',3':4,5]imidazo[1,2-a]quinazolin-9-yl)piperidine-4-carboxylic acid ester (intermediate 8f)

[0482] Intermediate 8e (560 mg, 0.95 mmol) and potassium phosphate (192 mg, 1.43 mmol) were dissolved in DMF and stirred at 120 °C for 4 hours. After the reaction was completed, the system was cooled to room temperature and water (20 ml) was added. The solid precipitated out and was filtered. The solid was then slurried with petroleum ether:ethyl acetate = 5:1, filtered and dried to obtain a yellow solid intermediate 8f (170 mg, 31.42%).

[0483] LC-MS(ESI):[M+H] + =566.48

[0484] 1 H NMR (600MHz, DMSO-d6) δ9.01 (s, 1H), 8.26 (d, J = 8.4Hz, 1H), 7.75 (d, J = 7.8Hz ,1H),7.64(t,J=8.1Hz,1H),6.94(s,1H),5.12(p,J=8.7Hz,1H),4.32–4.21( m,2H),3.04–2.97(m,2H),2.56–2.51(m,1H),2.35–2.22(m,2H),2.06–1.94( m,4H),1.90–1.83(m,2H),1.76–1.64(m,2H),1.61–1.49(m,2H),1.40(s,9H).

[0485] Step 7: 1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydropyridineimidazoloquinazolin-9-yl)piperidine-4-carboxylic acid (intermediate 8g)

[0486] Intermediate 8f (160 mg, 0.28 mmol) was dissolved in trifluoroacetic acid and stirred at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated under vacuum to obtain 8 g (230 mg, 144%) of yellow solid intermediate. The product was used directly in the next step without purification.

[0487] LC-MS(ESI):[M+H] + =510.20

[0488] 1H NMR (400MHz, DMSO-d6) δ8.97(s,1H),8.22(d,J=8.4Hz,1H),7.76(d,J=7.7Hz,1H),7.65(t,J=8.1Hz,1H),7.03(s,1H),5.12(p,J =8.6Hz,1H),4.29–4.21(m,2H),3.13–3.01(m,2H),2.60–2.52(m,1H),2.35–2.23(m,2H),2.09–1.84(m,6H),1.76–1.53(m,4H).

[0489] Step 8: 3-(1'-(1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydropyrido[4',3':4,5]imidazo[1,2-a]quinazolin-9-yl)piperidin-4-carboxyl)-1-methyl-2-oxo-1,2-dihydro-3H,7H-spiro[benzuran[4,5-d]imidazo-8,4'-piperidin]-3-yl)piperidin-2,6-dione (Compound 8)

[0490] The synthesis method is the same as that for compound 1.

[0491] LC-MS(ESI):[M+H] + =862.56

[0492] 1 H NMR (600MHz, DMSO-d6) δ11.10(s,1H),8.99(s,1H),8.25(d,J=8.4Hz,1H),7.78(d,J=7.8Hz,1H),7.67(t,J=8.1Hz, 1H),7.04(s,1H),6.96–6.83(m,1H),6.55(d,J=8.3Hz,1H),5.41–5.26(m,1H),5.14(p,J=8.7Hz,1H),4.61–4.44(m ,3H),4.43–4.32(m,2H),4.21–4.08(m,1H),3.49(s,3H),3.29–3.17(m,1H),3.12–3.01(m,3H),2.94–2.80(m,1H), 2.74–2.56(m,3H),2.36–2.27(m,2H),2.26–2.08(m,2H),2.05–1.94(m,5H),1.94–1.83(m,2H),1.82–1.59(m,5H).

[0493] Example 12, Synthesis of Compound 9

[0494] Step 1: Synthesis of tert-butyl 1-(3-(cyclopentylamino)-4-nitrophenyl)piperidine-4-carboxylic acid (intermediate 9a)

[0495] 5-Bromo-N-cyclopentyl-2-nitroaniline (2.98 g, 10.45 mmol), piperidine-4-carboxylic acid tert-butyl hydrochloride (2.90 g, 15.68 mmol), palladium acetate (235 mg, 1.05 mmol), Xantphos (1.21 g, 2.09 mmol), and cesium carbonate (10.22 g, 31.35 mmol) were dissolved in 58 mL of 1,4-dioxane. The system was purged with nitrogen three times and then stirred at 100 °C for 2 hours. After the reaction was complete, the reaction mixture was concentrated under reduced pressure and then purified by column chromatography to obtain a yellow solid intermediate 9a (2.5 g, 61%).

[0496] LC-MS(ESI):[M+H] + =390.19.

[0497] 1 H NMR(600MHz, CDCl3) δ8.46(d,J=5.5Hz,1H),8.03(d,J=9.7Hz,1H),6.20(dd, J=9.8,2.5Hz,1H),5.90(d,J=2.4Hz,1H),3.93–3.86(m,1H),3.83(dt,J=13. 3,3.7Hz,2H),3.10–2.99(m,2H),2.47(tt,J=10.6,4.1Hz,1H),2.12–2.02(m ,2H),2.00–1.94(m,2H),1.84–1.73(m,4H),1.70–1.60(m,4H),1.45(s,9H).

[0498] Step 2: Synthesis of tert-butyl 1-(4-amino-3-(cyclopentylamino)phenyl)piperidine-4-carboxylic acid (intermediate 9b)

[0499] The synthesis method is the same as that for intermediate S3c.

[0500] LC-MS(ESI):[M+H] + =360.49.

[0501] 1H NMR (400MHz, DMSO-d6) δ6.40(d,J=8.2Hz,1H),6.10(d,J=2.4Hz,1H),6.00(dd,J=8.2,2.4Hz,1H),3.74–3.61(m,1H),3.29( dt,J=11.9,3.5Hz,2H),2.58–2.51(m,2H),2.24(tt,J=11.1,3.8Hz,1H),1.98–1.86(m,4H),1.71–1.56(m,8H),1.40(s,9H).

[0502] Step 3: Synthesis of tert-butyl 1-(2-amino-1-cyclopentyl-1H-benzo[d]imidazol-6-yl)piperidine-4-carboxylic acid (intermediate 9c)

[0503] The synthesis method is the same as that for intermediate 8d.

[0504] LC-MS(ESI):[M+H] + =385.49.

[0505] 1 H NMR (400MHz, DMSO-d6) δ6.99(d,J=8.4Hz,1H),6.70(d,J=1.9Hz,1H),6.62(dd,J=8.4,1.9Hz,1H),6.10(s,2H),4.76–4.62(m ,1H),3.44–3.37(m,2H),2.64(td,J=11.6,2.1Hz,2H),2.33–2.25(m,1H),2.08–1.99(m,4H),1.73–1.61(m,8H),1.41(s,9H).

[0506] Step 4: Synthesis of tert-butyl 1-(2-(3-bromo-5-fluoroisonicotinamide)-1-cyclopentyl-1H-benzo[d]imidazol-6-yl)piperidine-4-carboxylic acid (intermediate 9d)

[0507] The synthesis method is the same as that for intermediate 8e.

[0508] LC-MS(ESI):[M+H] + =586.48.

[0509] Step 5: Synthesis of tert-butyl 1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]pyrido[4,3-e]pyrimidin-9-yl)piperidine-4-carboxylic acid (intermediate 9e)

[0510] The synthesis method is the same as that for intermediate 8f.

[0511] LC-MS(ESI):[M+H] + =566.28.

[0512] Step 6: Synthesis of 1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]pyrido[4,3-e]pyrimidin-9-yl)piperidine-4-carboxylic acid (intermediate 9f)

[0513] The synthesis method is the same as that for intermediate 1j.

[0514] LC-MS(ESI):[M+H] + =510.39.

[0515] Step 7: Synthesis of 3-(1'-(1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrobenzo[4,5]imidazo[1,2-a]pyrido[4,3-e]pyrimidin-9-yl)piperidine-4-carbonyl)-1-methyl-2-oxo-1,2-dihydro-3H,7Hspiro[benzofurano[4,5-d]imidazo-8,4'-piperidine]-3-yl)piperidine-2,6-dione (Compound 9)

[0516] The synthesis method is the same as that for compound 1.

[0517] LC-MS(ESI):[M+H] + =862.56.

[0518] 1 H NMR (600MHz, DMSO-d6) δ11.10(s,1H),9.70(s,1H),8.86(s,1H),8.39(d,J=9.0Hz,1H),7.34–7.22(m,1 H),7.18–7.03(m,1H),6.97–6.86(m,1H),6.55(d,J=8.4Hz,1H),5.37–5.31(m,1H),5.25(p,J=8.8Hz,1H ),4.59–4.49(m,3H),4.14–4.08(m,1H),3.89–3.82(m,2H),3.50(s,3H),3.28–3.19(m,1H),3.10–2.94( m,3H),2.90–2.83(m,1H),2.70–2.58(m,3H),2.33–2.20(m,3H),2.18–2.09(m,1H),2.06–1.67(m,13H).

[0519] Example 13, Synthesis of Compound 10

[0520] Step 1: 1-(1'-(1-(4-bromo-7-cyclopentyl-5-oxo-5,7-dihydrophenyl[4,5]imidazo[1,2-a]quinazolin-9-yl)piperidin-4-carbonyl)-1-methyl-1H,7H-spiro[furano[2,3-g]indole-8,4'-piperidin]-dihydropyrimidine-2,4(1H,3H)-dione (Compound 10)

[0521] The synthesis method is the same as that for compound 3.

[0522] LC-MS(ESI):[M+H] + =845.46.

[0523] 1 H NMR (400MHz, DMSO-d6) δ8.39(d,J=8.5Hz,1H),8.24(d,J=9.1Hz,1H),7.79(d,J=7.9Hz,1H), 7.69(t,J=8.1Hz,1H),7.26–7.08(m,3H),6.64(d,J=8.5Hz,1H),5.21(t,J=8.7Hz,1H),4.53 (dd,J=19.9,10.8Hz,2H),4.13(d,J=13.5Hz,1H),3.90–3.78(m,5H),3.70–3.60(m,3H),3.3 0–3.17(m,1H),3.11–2.89(m,3H),2.80–2.61(m,3H),2.37–2.15(m,4H),2.10–1.60(m,13H).

[0524] Example 14: Synthesis of Compound A10

[0525] Step 1: Methyl 5-(benzyloxy)-2-ethoxybenzoate (compound A10a)

[0526] Compound A5d (23.5 g, 90.9 mmol) and potassium carbonate (37.7 g, 272.9 mmol) were dissolved in N,N-dimethylformamide (350 mL). The reaction mixture was cooled to 0 °C, and iodoethane (28.3 g, 181.9 mmol) was added to the reaction system. The mixture was reacted at room temperature for 16 hours. The resulting reaction system was quenched with water, extracted three times with ethyl acetate, washed with brine, and the combined organic phases were dried over anhydrous sodium sulfate. The concentrated solution yielded a yellow solid crude compound A10a.

[0527] 1H NMR(600MHz,Chloroform-d)δ7.47–7.42(m,4H),7.42–7.38(m,2H),7.36–7.32(m,1H),7.10–7.06 (m,1H),6.94–6.90(m,1H),5.04(s,2H),4.09–4.04(m,2H),3.93–3.89(m,3H),1.47–1.38(m,3H).

[0528] Step 2: Methyl 2-ethoxy-5-hydroxybenzoate (compound A10b)

[0529] Compound A10a (55.0 g, 192.0 mmol) was dissolved in methanol (500 mL), and palladium on carbon (11.5 g) was added. The reaction mixture was reacted at room temperature for 16 hours under a hydrogen atmosphere. The reaction mixture was filtered, and the filter cake was washed with methanol. The crude product obtained by concentrating the filtrate was purified by column chromatography to give a yellow oily compound A10b (34.0 g, 90%).

[0530] Step 3: Methyl 4-bromo-2-ethoxy-5-hydroxybenzoate (compound A10c)

[0531] Compound A10b (34.0 g, 173.2 mmol) and N-bromosuccinimide (33.9 g, 190.6 mmol) were dissolved in acetonitrile (350 mL) and trifluoroacetic acid (3.5 mL) and stirred at room temperature for 4 hours. The mixture was quenched with saturated sodium thiosulfate and extracted three times with ethyl acetate. The organic phase was collected. The crude product obtained by concentrating the organic phase was purified by column chromatography to give a yellow solid compound A10c (36.0 g, 775%).

[0532] 1 H NMR (600MHz, Chloroform-d) δ7.48(s,1H),7.11(s,1H),5.48(s,1H),4.05(q,J=7.0Hz,2H),3.90(s,3H),1.45(t,J=6.9Hz,3H).

[0533] LC-MS(ESI):[M+H] + =274.87.

[0534] Step 4: Methyl 4-bromo-6-ethoxy-2-formyl-3-hydroxybenzoate (compound A10d)

[0535] Compound A10c (12.0 g, 43.6 mmol) was dissolved in trifluoroacetic acid (120 mL), and hexamethylenetetramine (24.4 g, 174.4 mmol) was added. The reaction mixture was reacted at 110 °C for 8 hours. After cooling the reaction mixture to room temperature, water was added, and the mixture was extracted with ethyl acetate. The mixture was washed with sodium bicarbonate solution, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to give a yellow solid compound A10d (1.5 g, 11%).

[0536] 1 H NMR (600MHz, Chloroform-d) δ11.71 (s, 1H), 9.89 (d, J = 0.8Hz, 1H), 7.50 (s, 1H), 4.09-4.07 (m, 1H), 3.99 (s, 3H), 1.44-1.38 (m, 3H).

[0537] Step 5: Tert-butyl(S)-5-amino-4-(5-bromo-7-ethoxy-4-hydroxy-1-oxoisoindoline-2-yl)-5-oxovalerate (compound A10e)

[0538] (S)-4,5-diamino-5-oxovalerate tert-butyl hydrochloride (22.7 g, 99.4 mmol) was dissolved in methanol (100 mL). The reaction mixture was cooled to 0 °C, and N,N-diisopropylethylamine (2.0 g, 15.6 mmol) was slowly added to the reaction system, followed by compound A10d (4.3 g, 14.8 mmol) and acetic acid (1.8 g, 29.7 mmol). After reacting at room temperature for 1.5 hours, sodium cyanoborohydride (1.8 g, 29.7 mmol) was slowly added, and the reaction was continued at room temperature for 2 hours. The reaction mixture was quenched with water, extracted with ethyl acetate, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to give a yellow solid compound A10e (6.3 g, 95%).

[0539] 1 H NMR(600MHz,Chloroform-d)δ7.00(s,1H),6.81(s,1H),6.47(s,1H),5.59–5.56(m,1H),4.90(dd,J=9.0,6.1Hz,1H),4.52(d,J=17.9Hz,1H),4.41(d ,J=17.9Hz,1H),4.17–4.12(m,1H),4.12–4.08(m,2H),2.40–2.30(m,2H), 2.29–2.21(m,1H),2.19–2.10(m,1H),1.49(t,J=7.0Hz,3H),1.43(s,9H).

[0540] LC-MS(ESI):[M-tBu+H] + =301.29.

[0541] Step 6: Tert-butyl(S)-4-(((2-(1-amino-5-(tert-butoxy)-1,5-dioxane-2-yl)-5-bromo-7-ethoxy-1-oxoisoindoline-4-yl)oxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylate (compound A10f)

[0542] Compound A10e (4.3 g, 9.4 mmol), compound A5b (2.6 g, 12.2 mmol), and triphenylphosphine (4.9 g, 18.8 mmol) were dissolved in tetrahydrofuran (50 mL). The mixture was stirred at 0 °C for 15 minutes under nitrogen protection. Diethyl azodicarbonate (3.2 g, 18.8 mmol) was then slowly added dropwise to the reaction mixture, which was reacted at room temperature for 2 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to give a yellow oily compound A10f (4.6 g, 75%).

[0543] LC-MS(ESI):[M+H] + =652.47.

[0544] Step 7: Tert-butyl(S)-7-(1-amino-5-(tert-butoxy)-1,5-dioxypentan-2-yl)-5-ethoxy-6-oxo-7,8-dihydro-2H,6H-spiro[furan[2,3-e]isoindole-3,4'-piperidine]-1'-carboxylate (compound A10g)

[0545] Compound A10f (4.65 g, 7.1 mmol) was dissolved in toluene (20 mL), and azobisisobutyronitrile (351 mg, 2.1 mmol) and tributyltin hydride (10.37 g, 35.6 mmol) were added at room temperature. The reaction mixture was reacted at 110 °C for 16 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to give a yellow oily compound A10g (3.3 g, 80%).

[0546] LC-MS(ESI):[M+H] + =573.58.

[0547] Step 8: (S)-3-(5-ethoxy-6-oxo-6,8-dihydro-2H,7H-spiro[furan[2,3-e]isoindole-3,4'-piperidin]-7-yl)piperidin-2,6-dione (compound A10)

[0548] Compound A10 g (3.3 g, 5.7 mmol) was dissolved in acetonitrile (15 mL) and added to a solution of benzenesulfonic acid (2.7 g, 17.2 mmol) in acetonitrile at 90 °C. The reaction was carried out at 90 °C for 12 hours. After cooling the reaction system to room temperature, the system was filtered and the filter cake was washed with acetonitrile. The dried filter cake yielded a white solid compound A10 (1.2 g, 37%).

[0549] 1 H NMR(400MHz,DMSO-d6)δ10.97(s,1H),6.83(s,1H),4.98(dd,J=13.3,5.1Hz,1 H),4.64–4.54(m,2H),4.29(d,J=17.3Hz,1H),4.18–4.07(m,3H),3.30(s,1H), 3.09–2.94(m,2H),2.94–2.82(m,1H),2.64–2.54(m,1H),2.47–2.32(m,1H),2 .20–2.05(m,2H),2.05–1.80(m,3H),1.33(t,J=6.9Hz,3H),1.26–1.14(m,1H).

[0550] LC-MS(ESI):[M+H] + =400.35.

[0551] Example 15: Synthesis of Compound A11

[0552] Step 1: 4-(hydroxymethyl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (compound A5b)

[0553] Compound A5a (10.0 g, 46.9 mmol) was dissolved in toluene (100 mL), and aluminum isopropoxide (12.5 g, 61.0 mmol) was added. The reaction mixture was reacted at 120 °C for 24 hours. The reaction mixture was then cooled to room temperature, and dilute hydrochloric acid (1.0 mol / L, 200 mL) was added. The mixture was extracted three times with ethyl acetate, and the organic phase was collected. The crude product obtained by concentrating the organic phase was purified by column chromatography to give a colorless oily compound A5b (4.7 g, 47%).

[0554] 1 H NMR (600MHz, CDCl3) δ5.67(s,1H),4.07(s,2H),3.98–3.92(m,2H),3.54(dd,J=8.2,4.0Hz,2H),2.15(d,J=6.8Hz,2H),1.49(s,9H).

[0555] LC-MS(ESI):[M-tBu+H] + =158.20

[0556] Step 2: Methyl 5-(benzyloxy)-2-hydroxybenzoate (compound A5d)

[0557] Compound A5c (5.0 g, 29.74 mmol) was dissolved in acetonitrile (50 mL), and potassium carbonate (8.2 g, 59.47 mmol) and benzyl bromide (4.58 g, 26.76 mmol) were added. The mixture was reacted at 40 °C for 12 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to give a white solid compound A5d (5.07 g, 66%).

[0558] 1 H NMR(600MHz,Chloroform-d)δ10.39(s,1H),7.43(d,J=7.3Hz,2H),7.40(dd,J=5.4,2.1Hz,3H),7. 33(t,J=7.2Hz,1H),7.15(dd,J=9.0,3.1Hz,1H),6.92(d,J=9.1Hz,1H),5.02(s,2H),3.95(s,3H).

[0559] Step 3: Methyl 5-(benzyloxy)-2-methoxybenzoate (compound A5e)

[0560] Compound A5d (5.0 g, 19.36 mmol) was dissolved in N,N-dimethylformamide (50 mL), and potassium carbonate (8.03 g, 58.08 mmol) and methyl iodide (5.5 g, 38.72 mmol) were added. The reaction mixture was reacted at room temperature for 12 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic phase was concentrated, and the crude product was purified by column chromatography to give a white solid compound A5e (4.0 g, 76%).

[0561] 1 H NMR(600MHz,Chloroform-d)δ7.48–7.44(m,3H),7.41(t,J=7.5Hz,2H),7.36(t,J=7.3Hz,1H ),7.12(dd,J=9.1,3.2Hz,1H),6.94(d,J=9.0Hz,1H),5.06(s,2H),3.92(s,3H),3.89(s,3H).

[0562] LC-MS(ESI):[M-tBu+H] + =273.27.

[0563] Step 4: Methyl 5-hydroxy-2-methoxybenzoate (compound A5f)

[0564] Compound A5e (4.0 g, 14.7 mmol) was dissolved in methanol (100 mL), and palladium / carbon (1.6 g) was added. The reaction mixture was stirred at room temperature under hydrogen pressure for 12 hours. The reaction mixture was filtered through diatomaceous earth, and the reaction mixture was concentrated under vacuum. The crude product was used directly in the next step without further purification.

[0565] 1 H NMR (600MHz, Chloroform-d) δ7.35(d,J=3.2Hz,1H),7.02(dd,J=8.9,3.2Hz,1H),6.89(d,J=9.0Hz,1H),5.52(s,1H),3.91(s,3H),3.86(s,3H).

[0566] LC-MS(ESI):[M+H] + =253.24.

[0567] Step 5: Methyl 4-bromo-5-hydroxy-2-methoxybenzoate (Compound A5g)

[0568] Compound A5f (2.0 g, 10.98 mmol) was dissolved in acetonitrile (5 mL). Trifluoroacetic acid (0.5 mL) was added under stirring at room temperature, followed by N-bromosuccinimide (1.95 g, 10.98 mmol). The reaction mixture was allowed to react at room temperature for 2 hours. The reaction mixture was concentrated, and the crude product was purified by column chromatography to give a colorless oily compound A5f (1.5 g, 52%).

[0569] 1 H NMR (600MHz, Chloroform-d) δ7.50(d,J=1.3Hz,1H),7.12(d,J=1.3Hz,1H),3.91(d,J=1.3Hz,3H),3.88(d,J=1.3Hz,3H).

[0570] LC-MS(ESI):[M+H] + =263.07.

[0571] Step 6: Methyl 4-bromo-2-formyl-3-hydroxy-6-methoxybenzoate (compound A5h)

[0572] Compound A5 g (1.5 g, 5.75 mmol) was dissolved in trifluoroacetic acid (15 mL), and hexamethylenetetramine (4.0 g, 28.7 mmol) was added. After the addition was complete, the temperature was raised to 110 °C and the reaction was carried out for 16 hours. The reaction system was cooled to room temperature, quenched with 2 M hydrochloric acid, and filtered to give a yellow solid compound A5h (500 mg, 30.10%).

[0573] 1 H NMR (600MHz, Chloroform-d) δ11.67(s,1H),9.89(s,1H),7.50(s,1H),4.00(s,3H),3.88(s,3H).

[0574] LC-MS(ESI):[M-Boc+H] + =288.08

[0575] Step 7: (S)-5-amino-4-(5-bromo-4-hydroxy-7-methoxy-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (compound A5i)

[0576] Compound A5h (500 mg, 1.73 mmol), (S)-4,5-diamino-5-oxovalerate tert-butyl hydrochloride (433 mg, 1.82 mmol), sodium cyanoborohydride (217 mg, 3.46 mmol), acetic acid (109 mg, 1.82 mmol), and N,N-diisopropylethylamine (235 mg, 1.82 mmol) were dissolved in methanol (10 mL) at 0 °C and reacted at 20 °C for 3 hours under nitrogen protection. The reaction mixture was quenched with water and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to give a yellow oily compound A5i (600 mg, 78%).

[0577] 1 H NMR(600MHz,Chloroform-d)δ6.98(s,1H),6.88(s,1H),5.80(s,1H),4.87(dd,J=9.1,5.8Hz,1H),4.54(d,J=18.0Hz,1H),4.41(d,J=18.0 Hz,1H),3.88(s,3H),2.32(ddd,J=13.4,10.9,6.6Hz,2H),2.24(dt,J=13.7,8.6Hz,1H),2.13(td,J=16.0,14.2,6.5Hz,1H),1.43(s,9H).

[0578] LC-MS(ESI):[M+H] +=445.25.

[0579] Step 8: (S)-4-((2-(1-amino-5-(tert-butoxy)-1,5-dioxopentan-2-yl)-5-bromo-7-methoxy-1-oxoisoindole-4-yl)oxy)methyl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (compound A5j)

[0580] Compounds A5i (500 mg, 1.13 mmol) and A5b (313 mg, 1.47 mmol) were dissolved in tetrahydrofuran (10 mL). Triphenylphosphine (591 mg, 2.26 mmol) and diethyl azodicarbonate (393 mg, 2.26 mmol) were added to the system at 0 °C. The system was then heated to room temperature and reacted for 2 hours. The reaction mixture was quenched with water and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to give a yellow oily compound A5j (500 mg, 69.42%).

[0581] 1 H NMR(600MHz,Chloroform-d)δ7.12(s,1H),6.41(s,1H),5.85(s,1H),5.35(s,1H),5.33(s,1H),4.85(dd,J=8.5,6 .5Hz,1H),4.00(s,2H),3.96(s,3H),3.61(s,2H),2.41–2.23(m,6H),2.18–2.11(m,2H),1.51(s,9H),1.44(s,9H).

[0582] LC-MS(ESI):[M-Boc+H] + =538.28.

[0583] Step 9: (S)-7-(1-amino-5-(tert-butoxy)-1,5-dioxopentan-2-yl)-5-methoxy-6-oxo-7,8-dihydro-2H,6H-spiro[furano[2,3-e]isoindole-3,4'-piperidine]-1'-carboxylic acid tert-butyl ester (compound A5k)

[0584] Compound A5j (500 mg, 0.78 mmol) was dissolved in toluene (10 mL), and azobisisobutyronitrile (38 mg, 0.23 mmol) and tri-n-butyltin hydride (684 mg, 2.35 mmol) were added. The reaction mixture was incubated at 110 °C for 2 hours. After cooling to room temperature, the reaction mixture was quenched with a saturated cesium fluoride aqueous solution and extracted with ethyl acetate. The mixture was washed with saturated brine, and the combined organic phases were dried over anhydrous sodium sulfate. The crude product obtained by concentrating the organic phase was purified by column chromatography to give a white solid compound A5k (300 mg, 68.46%).

[0585] 1 H NMR(600MHz,Chloroform-d)δ6.69(s,1H),6.47(s,1H),5.32(s,1H),4.83(dd,J=8.9,6.5Hz,1H),4.51(s,2H),4.37(q,J=17.4Hz,2H),3.95(d,J=4.6Hz,3 H),2.86(s,2H),2.42–2.30(m,3H),2.29–2.20(m,2H),2.16(ddd,J=10.5,8. 9, 6.2Hz, 1H), 1.89 (s, 2H), 1.77 (d, J = 13.4Hz, 2H), 1.51 (s, 9H), 1.44 (s, 9H).

[0586] LC-MS(ESI):[M+H] + =560.58.

[0587] Step 10: 3-(6-oxo-6,8-dihydro-2H,7H-dipyridofurano[2,3-e]isoindol-3,1'-cyclohexane-4',4'-piperidin]-7-yl)piperidin-2,6-dione (compound A5)

[0588] Anhydrous benzenesulfonic acid (283 mg, 1.79 mmol) was dissolved in acetonitrile (5 mL), heated to 80 °C, and compound A5k (500 mg, 0.89 mmol) was added to the system. The reaction was carried out at 80 °C for 12 hours. After cooling the reaction system to room temperature, it was filtered to give a white solid compound A5 (300 mg, 62%).

[0589] 1H NMR(600MHz,DMSO-d6)δ10.97(s,1H),6.83(s,1H),5.02(dd,J=13.3,5.1Hz,1H),4.65–4.56(m,2H) ,4.30(d,J=17.3Hz,1H),4.13(d,J=17.3Hz,1H),4.17(s,1H),3.85(s,3H),3.33(d,J=12.8Hz,2H),3 .05–2.96(m,2H),2.91(ddd,J=17.2,13.7,5.5Hz,1H),2.58(dt,J=15.7,3.0Hz,1H),2.39(qd,J=13 .3,4.5Hz,1H),2.17(td,J=13.8,4.3Hz,2H),1.94(dtd,J=12.7,5.4,2.3Hz,1H),1.91–1.83(m,2H).

[0590] LC-MS(ESI):[M+H] + =386.30.

[0591] Step 11: Compound A5 (0.5 g, 1.3 mmol) was dissolved in dichloromethane (2.5 mL). The reaction mixture was cooled to 0 °C, and boron tribromide (1.9 mL) was added to the reaction system. The reaction was allowed to proceed at room temperature for 8 hours. The resulting reaction system was then quenched with methanol at low temperature. The crude product obtained after concentration was purified by high pressure to give a white solid compound A11 (481 mg, 99%).

[0592] 1 H NMR(600MHz,DMSO-d6)δ10.97(s,1H),9.31–9.16(m,1H),6.72–6.65(m,1H),5.02 (dd,J=13.4,5.1Hz,1H),4.58–4.51(m,2H),4.30(d,J=17.2Hz,1H),4.14(d,J=17 .2Hz,1H),3.33–3.28(m,2H),3.03–2.94(m,2H),2.94–2.86(m,1H),2.62–2.55(m ,1H),2.45–2.35(m,1H),2.15–2.06(m,2H),2.00–1.91(m,1H),1.87–1.79(m,2H).

[0593] LC-MS(ESI):[M+H] + =370.30.

[0594] Biological testing

[0595] Experimental Example 1: Degradation of SMARCA2 / 4 by the compound in HeLa and HEK293 cells

[0596] 1. Cell line construction:

[0597] By inserting the HiBiT tag after the start codon or before the stop codon of the SMARCA2 and SMARCA4 genes, the degradation of SMARCA2 and SMARCA4 proteins can be quantified by detecting the expression level of the HiBiT tag when the compound degrades the SMARCA2 and SMARCA4 proteins.

[0598] Based on the HiBiT insertion site, gRNA and ssDNA for SMARCA2 and SMARCA4 were designed. The amounts of reagents and gRNA required for one electroporation were calculated according to the instructions. Cas9 protein, ssDNA, gRNA, and cells were electroporated together using an electroporator. After 24 hours, the medium was replaced with normal culture medium, and the cells were cultured until day 3 post-electroporation. A portion of the cells were then tested using the Nano Glo HiBiT Lytic Detection System (N3050, Promega). Cells validated by HiBiT detection were seeded in 96-well plates using limiting dilution for further amplification. After 7-14 days, single clones were screened and validated using the Nano Glo HiBiT Lytic Detection System (N3050, Promega). Single clones with high HiBiT fluorescent values ​​were amplified and sequenced to confirm successful HiBiT sequence ligation and homozygosity, making them suitable for subsequent degradation experiments.

[0599] 2. HeLa-HiBiT knock-in cell seeding and compound administration

[0600] The HeLa-HiBiT knock-in cells constructed using the above method were digested and dispersed from the cell culture flask, resuspended in EMEM medium containing 10% FBS, and the cell concentration was adjusted to 5000 cells / well. They were then seeded into 96-well plates and cultured overnight at 37°C and 5% CO2. A 10mM stock solution of the test compound was prepared using DMSO, and a small amount was diluted to 1mM with DMSO for later use. The test compound solution was serially diluted 3-fold at nine different concentrations to treat the cells. The 96-well cell culture plates containing the compound were then cultured at 37°C and 5% CO2 for 24 hours.

[0601] 3. Protein degradation detection

[0602] After 24 hours, the culture medium was aspirated, and 70 μL of reaction solution was added to each well of the 96-well plate. The plate was incubated at room temperature for 15 min, and 50 μL of reaction solution was transferred to a white opaque 96-well plate (Perkinelmer, 6055290). The plate was then scanned and analyzed using a Tecan Spark microplate reader.

[0603] 4. HEK293-HiBiT knock-in cell seeding and compound administration

[0604] HEK293-HiBiT knock-in cells constructed using the above method were digested and dispersed from the cell culture flask, resuspended in EMEM medium containing 10% FBS, and seeded at an adjusted concentration (HEK293-HiBiT knock-in cells, 5000 cells / well) into 96-well plates. The plates were then incubated overnight at 37°C and 5% CO2. A 10mM stock solution of the test compound was prepared using DMSO, and a small amount was diluted to 1mM with DMSO for later use. The test compound solution was serially diluted 3-fold at nine different concentrations to treat the cells. The 96-well cell culture plates containing the compound were then incubated at 37°C and 5% CO2 for 24 hours.

[0605] 5. Protein degradation detection

[0606] After 24 hours, the culture medium was aspirated, and 70 μL of reaction solution was added to each well of the 96-well plate. The plate was incubated at room temperature for 15 min, and 50 μL of reaction solution was transferred to a white opaque 96-well plate (Perkinelmer, 6055290). The plate was then scanned and analyzed using a Tecan Spark microplate reader.

[0607] 6. Degradation of DC 50 calculate

[0608] The protein degradation rate was calculated for each concentration using Excel, with two replicates for each concentration point. Protein degradation curves were generated, and the concentration-degrading rate (DC) was calculated. 50 and D max Protein degradation rate (%) = (OD) ctrl -OD-OD black ) / (OD ctrl –OD black ) OD ctrl = Cells without added compound (control wells) OD black = Cell-free (blank well)

[0609] The degradation rates (%) of the disclosed PROTAC compounds of SMARCA2 / 4 in HeLa cells and HEK-293 cells are shown in Table 1.

[0610] The structure of SMD-3040 (positive control sample) is as follows:

[0611] Table 1: Degradation activity of the PROTAC compound of this application against SMARCA2 / 4 in HeLa cells and HEK293 cells.

[0612] Note: > indicates higher than 1000nM.

[0613] As can be seen from Table 1 above, the exemplary compounds of this disclosure can achieve the degradation of SMARCA2 / 4 in HeLa and HEK293 cells; some of the exemplary compounds of this disclosure can achieve the selective degradation of SMARCA2 in HeLa and HEK293 cells.

[0614] Experimental Example 2: Determination of the Proliferation Inhibition Activity of the Disclosed PROTAC Compound in Various Cell Types

[0615] NCI-H838, SK-MEL-5, HeLa, and SW1573 cells were seeded at a density of 500 cells / well in 96-well plates and cultured at 37°C in a 5% CO2 incubator for 24 h. On day 2, cells were treated with different concentrations of compounds and incubated at 37°C in a 5% CO2 incubator for 7 days. Cell viability was assessed using a CCK-8 assay kit (Beyotime, Product number: C0040) according to the manufacturer's instructions. The IC50 of each compound after 7 days was calculated using GraphPad Prism software. 50 value.

[0616] Conclusion: The exemplary compounds disclosed herein can exert strong inhibition on the proliferation of SMARCA4 mutant cell lines SK-MEL-5 and NCI-H838, while exerting weak inhibition on SMARCA4 wild-type cell lines HeLa and SW1573.

[0617] Experimental Example 3: Binding activity of the disclosed E3 ligase inhibitor on the E3 ubiquitin ligase CRBN

[0618] The binding activity of the E3 ligase inhibitor and positive control samples lenalidomide and pomalidomide to the E3 ubiquitin ligase CRBN is determined by the competitive binding of the E3 ligase inhibitor, lenalidomide and pomalidomide to the CRBN protein with thalidomide labeled XL665, thereby preventing fluorescence resonance energy transfer (FRET).

[0619] CRBN binding activity assay kit (CEREBLON BINDING KITS (PE, 64BDCRBNPEG)).

[0620] The detection is based on homogeneous time-resolved fluorescence (HTRF) technology. When the donor and acceptor are close, the donor can transfer energy to the acceptor, exciting it and causing it to emit light at 665 nm.

[0621] The donor used in this kit is a europium-labeled GST antibody (GST Eu Cryptate Antibody), and the receptor is thalidomide (Thalidomide-Red reagent) labeled with XL665. The donor binds to the GST-tagged CRBN protein. The E3 ligase inhibitors disclosed in this invention, as well as lenalidomide and pomalidomide, competitively bind to the CRBN protein against thalidomide. The binding activity of the compounds is determined based on the fluorescence value emitted by the receptor at 665 nm. The stronger the binding affinity of the compound, the weaker the signal.

[0622] The donor and acceptor were diluted 50-fold using the PROTAC binding buffer 1 provided in the kit. The CRBN protein was diluted 45-fold. The 8 mM solution of the compound disclosed in this invention was diluted 10-fold using the 1X diluent provided in the kit, followed by a 5-fold serial dilution, for a total of 7 dilutions.

[0623] Add 5 μl of the compound, 5 μl of diluted CRBN protein, and 10 μl of donor-receptor mixture to the wells of a white 384-well plate (PE, Part number: 6008280). Incubate at room temperature for 3 hours.

[0624] Calculate the ratio of the acceptor to the donor emitted signal for each individual pore.

[0625] Ratio = (665nm signal value / 620nm signal value) * 10 4

[0626] Calculate the coefficient of variation (CV) as follows: (Standard deviation (SD) / Ratio) * 100

[0627] Using GraphPad Prism, calculate IC based on compound concentration, ratio, and coefficient of variation. 50 value.

[0628] Table 2. IC50 of the disclosed E3 ligase inhibitors, lenalidomide, and pomalidomide. 50 value.

[0629] Conclusion: The E3 ligase inhibitor disclosed herein can bind well to CRBN protein, and the exemplary E3 ligase inhibitor has a better binding ability to CRBN than the positive control samples lenalidomide and pomalidomide.

[0630] Experimental Example 4: Mouse Pharmacokinetic Study

[0631] 1. Test materials

[0632] ICR mice were randomly divided into two groups, with six mice in each group. Group 1 received a tail vein injection of the compound, with a solvent of DMSO:PEG200:physiological saline = 1:7:2, at a dose of 1 mg / kg and a volume of 5 mL / kg. Blood samples were collected from the retro-orbital venous plexus at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 24 h after intravenous administration. Group 2 mice were fasted but administered the compound via gavage, with a solvent of DMSO:PEG200:physiological saline = 1:7:2, at a dose of 10 mg / kg and a volume of 10 mL / kg. Blood samples were also collected from the retro-orbital venous plexus at 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 24 h after gavage. Whole blood was collected in anticoagulant tubes containing EDTA, centrifuged at 4000 rpm for 10 min at 4°C, and plasma was stored at -80°C for later analysis.

[0633] 3. Sample processing and bioanalysis

[0634] Before analysis, remove the sample plasma and blank plasma and thaw them on ice or in a 4°C freezer.

[0635] Standard curve sample preparation: The test compounds were diluted with DMSO to the required concentration. 5 μL of the compound solution was added to 45 μL of mouse blank plasma. 200 μL of internal standard acetonitrile (1500 rpm, 50 nM labetalol and 500 nM terfenadine) was added to precipitate the protein. The mixture was centrifuged at 3200 rpm for 40 min. 8-10 concentration gradients were set for the standard curve.

[0636] Quality control samples were prepared according to the standard curve preparation method. Four quality control samples with lower limit of quantitation and high, medium and low concentrations were set, and each quality control sample was replicated in triplicate.

[0637] Take 50 μL of plasma from samples taken at different time points and add 200 μL of internal standard acetonitrile to precipitate proteins.

[0638] After centrifugation of standard curve samples, quality control samples, and plasma samples at different time points, 100L of the supernatant was diluted 1:1 with water and analyzed by LC-MS / MS. The blood concentrations of the compound at different time points were calculated using Excel.

[0639] 4. Data Processing

[0640] Pharmacokinetic parameters were calculated using the statistical moment method of non-compartmental models in Phoenix WinNonlin 8.0 software.

[0641] The compounds disclosed in this application have good in vivo pharmacokinetic properties and considerable oral bioavailability.

[0642] The present invention has been described through the above embodiments. However, it should be understood that the above embodiments are for illustrative purposes only and are not intended to limit the invention to the scope of the described embodiments. Furthermore, those skilled in the art will understand that the present invention is not limited to the above embodiments, and many more variations and modifications can be made based on the teachings of the present invention, all of which fall within the scope of protection claimed by the present invention. The scope of protection of the present invention is defined by the appended claims and their equivalents.

Claims

1. A compound having the structure of Formula I: PTM-L-ULM (Formula I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, or polymorph thereof, wherein: L is a chemical linking moiety that links the ULM and the PTM; wherein: W3 is, at each occurrence, independently C(=0) or C(=S); G1, and G2 are each independently selected at each occurrence from O, S, and Se; R3, R4, R5, and R6 are each independently selected at each occurrence from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, hydroxyalkyl, nitro, cyano, amino, alkylamino, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy cycloalkyl, heterocyclyl, aryl, amino, and heteroaryl groups is independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl; m3 is independently at each occurrence 0, 1, 2, 3, 4, 5, 6, or 7, m4 is independently at each occurrence 0, 1, 2, 3, 4, 5, 6, 7, or 8, and m3 + m4 < 8; m5 is independently at each occurrence 0, 1, 2, 3, 4 5, 6, or 7, m6 is independently at each occurrence 1, 2, 3, 4, 5, 6, or7, and m5 + m6 < 7; m9, m10, and m11 are each independently selected at each occurrence from 0, 1, 2, and 3, and m9 + m10 + m11 < 3; n is independently at each occurrence 0, 1, 2, or 3; with the proviso that:

2. A compound having the structure of Formula III: PTM-L-ULM (Formula III), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solv ate, or polymorph thereof, wherein: L is a chemical linking moiety that links the U LM and the PTM; wherein: W3 is, at each occurrence, independently C(=0), or C(=S); G1, and G2 are each independently selected at each occurrence from 0, S, and Se; R3, R4, R5, and R6 are selected at each occurrence from hydrogen, deuterium, halogen, alkyl, deuteriated alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy haloalkyl, haloalkoxy, hydroxyl, hydroxyalkyl, nitro cyano, amino, alkylamino, cycloalkyl, heterocyclyi, aryl, and heteroaryl, wherein each of the alkyl, heteroalkyi, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, amino, and heteroaiyl groups is independently optionally substituted with one or more substituents selected from halogen, alkyl heteroalkyl, alkoxy, haloalkyl, hydroxyl, hydroxyaiyl, cyano, amino, nitro, cycloalkyl, heterocyclyi, alkenyl, alkynyl, alkylamino, aryl, and heteroa ryi; m3 is independently at each occurrence 0, 1, 2, 3, 4, 5, 6, or 7, m4 is 0, 1, 2, 3, 4, 5, 8, and m3 + m4 < 8; ​ ​ ​ ​ The PTM is selected from the following structures: ​ R b2 is N or CR a2 ; R b3 is N or CR a3 ; R b4 is N or CR a4 ; R b5 is N or CR a5 ; R a7 , R a8 , and R a9 are each independently selected for each occurrence from N and CR b ; R b , R a1 , R a2 , R a3 , R a4 , and R a5 are each independently selected for each occurrence from hydrogen, deuterium, halogen, nitro, amino, cyano, hydroxyl, alkyl, alkoxy, haloalkyl, haloalkoxy, deuterium- substituted alkyl, heteroalkyl, alkenyl, alkynyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C 1-6 alkylene-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)2, -C 1-6 alkylene-N(C 1-6 alkyl)H, and -O-cycloalkyl; ULM is selected from the following structures: ​ ​ Z is independently at each occurrence N or CR m ; ​ ​ A1, A2, A3, A4, A5, and A6are each independently for each occurrence C(R m )2, NR m , C(=0), O, or S; X is, at each occurrence, independently N or CR m ; ​ ​ ​ R m each occurrence is selected independently from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of said alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl; R1, R2, and R8are each independently, at each occurrence, selected from hydrogen, halogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy, hydroxyl, 3-7 membered cycloalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, -C 1-6 alkylene-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)2, and -C 1-6 alkylene-N(C 1-6 alkyl)H; and ​ ​ 1) when PTM is selected from Formula 1-1, ULM is selected from Formula 2-11, Formula 2-12, and Formula 2-13, at least one H on the compound of Formula I is replaced with R aa , R aa is -C 1-6 alkylene-N(C 1-6 alkyl)2, -O-C 1-6 alkylene-N(C 1-6 alkyl)2, -C 1-6 alkylene-O-C 1-6 alkylene-N(C 1-6 alkyl)2, or -C 1-6 alkylene-3-7 membered heterocyclyl containing 1, 2, or 3 N, O, or S heteroatoms; or When the PTM is selected from Formula 1-1, the ULM is selected from Formula 2-11, Formula 2-12, and Formula 2-13, and Formula 2-12 has the structure shown in Formula 2-12a below, L is selected from When PTM is selected from Equation 1-1 and ULM is selected from Equations 2-11, 2-12 and 2-13, R b3 R b4 R b5 R a7 or R a8 One and only one of them is selected from the N atom; or 2) when PTM is selected from Formula 1-2, ULM is selected from Formula 2-11, Formula 2-12, and Formula 2-13, L is selected from ​ ​ ​ ​ ​ The PTM is selected from the following structures: ​ R b2 is N or CR a2 ; R b3 is N or CR a3 ; R b4 is N or CR a4 ; R b5 is N or CR a5 ; R a7 , R a8 , and R a9 are each independently selected for each occurrence from N and CR b ; R b , R a1 , R a2 , R a3 , R a4 , and R a5 are each independently selected for each occurrence from hydrogen, deuterium, halogen, alkyl, haloalkyl, deuterated-alkyl, heteroalkyl, alkenyl, alkynyl, amino, haloalkoxy, hydroxyalkyl, alkoxy, cyano, hydroxyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C 1-6 alkylene-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)2, -C 1-6 alkylene-N(C 1-6 alkyl)H, and -O-cycloalkyl; ULM is selected from the following structures: ​ ​ Z is independently at each occurrence N or CR m ; ​ ​ A1, A2, A3, A4, A5, and A6are each independently for each occurrence C(R m )2, NR m , C(=0), O, or S; X is, at each occurrence, independently N or CR m ; ​ m5 is, at each occurrence, independently 0, 1, 2, 3, 4, 5, 6, or 7, m6 is, at each occurrence, independently 1, 2, 3, 4, 5, 6, or 7, and m5+m6 < 7; m9, m10, and m11 are, at each occurrence, independently selected from 0, 1, 2, and 3, and m9+m10+m11 < 3; R m is independently selected at each occurrence from hydrogen, deuterium, halogen, alkyl, deuterated alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, alkylamino, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of said alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl; R1, R2, and R8are each independently, at each occurrence, selected from hydrogen, halogen, deuterium, C 1-6 alkyl, C 1-6 alkoxy, hydroxyl, 3-7 membered cycloalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, -C 1-6 alkylene-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)2, and -C 1-6 alkylene-N(C 1-6 alkyl)H; and n is, at each occurrence, independently 0, 1, 2, or 3; provided that: 1) when PTM is selected from Formula 1-1, ULM is selected from Formula 2-1, Formula 2-2, and Formula 2-3, at least one H in said Formula III compound is replaced by R aa aa 1-6 alkylene-N(C 1-6 alkyl)2, -0-C 1-6 alkylene-N(C 1-6 alkyl)2, -C 1-6 alkylene-0-C 1-6 alkylene-N(C 1-6 alkyl)2, or -C 1-6 alkylene-3-7 membered heterocyclyl containing 1, 2, or 3 N, O, or S heteroatoms; or​​ 2) when PTM is selected from Formula 1-1, ULM is selected from Formula 2-1, Formula 2-2, and Formula 2-3, L is selected from 3) when PTM is selected from Formula 1-1, ULM is selected from Formula 2-1, Formula 2-2, and Formula 2-3, R b3 , R b4 , R b5 , R a7 , or R a8 is selected from N atom; 4) when PTM is selected from Formula 1-2, ULM is selected from Formula 2-1, Formula 2-2, and Formula 2-3, L is selected from 3. The compound of claim 1 or 2, wherein, L is a covalent bond or is -(B L ) q -; q is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; preferably, q is 1, 2, 3, 4, 5, 6, or B L Each time it appears, it is selected independently from CR. L1 R L2 O, S, S(O), S(O)2, NR L1 C(O)NR L1 C(O), a monocyclic alkyl group, a monoheterocyclic alkyl group, a monoheterocyclic partially unsaturated cyclic hydrocarbon group, a bridged cyclic group, a heterobridged cyclic group, a spirocyclic group, a heterospirocyclic group, an aryl group, and a heteroaryl group, wherein the monocyclic alkyl group, a monoheterocyclic alkyl group, a monoheterocyclic partially unsaturated cyclic hydrocarbon group, a bridged cyclic group, a heterobridged cyclic group, a spirocyclic group, a heterospirocyclic group, a monocyclic aryl group, and a monocyclic heteroaryl group are optionally selected by 1, 2, 3, 4, 5, or 6 independently selected from R L1 Group substitution; preferably, B L Each occurrence is independently selected from: CR L1 R L2 O, S, S(O), S(O)2, NR L1 C(O)NR L1 C(O), 3-8 membered monocycloalkylene, 3-8 membered monoheterocycloalkylene, 3-8 membered monoheterounsaturated cycloalkylene, 5-15 membered bridged cycloalkylene, 5-15 membered heterobridged cycloalkylene, 5-15 membered spirocycloalkylene, 5-15 membered heterospirocycloalkylene, 6-15 membered arylene and 5-15 membered heteroarylene, wherein the 3-8 membered monocycloalkylene, 3-8 membered monoheterocycloalkylene, 3-8 membered monoheterounsaturated cycloalkylene, 5-15 membered bridged cycloalkylene, 5-15 membered heterobridged cycloalkylene, 5-15 membered spirocycloalkylene, 5-15 membered heterospirocycloalkylene, 6-15 membered arylene and 5-15 membered heteroarylene are optionally selected independently by 1, 2, 3 or 4 members from R L1 The group substitution; the 3-8 membered heterocyclic alkyl group, the 3-8 membered heterocyclic partially unsaturated cyclic hydrocarbon group, the 5-15 membered heterobridged cyclic group, the 5-15 membered heterospirocyclic group, and the 5-15 membered heteroaryl group contain 1, 2, 3, 4 or 5 heterocyclic atoms each independently selected from N, O, and S. R L1 and R L2 each independently at each occurrence is selected from hydrogen, halogen, C 1-8 alkyl, -O-C 1-8 alkyl, -S-C 1-8 alkyl, -NH-C 1-8 alkyl, -N(C 1- 8alkyl)2, 3-11 membered cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, 3-11 membered heterocycloalkyl, -O-3-8 membered cycloalkyl, -O-3-11 membered heterocyclyl, -O-6-10 membered aryl, -O-5-10 membered heteroaryl, -S-3-8 membered cycloalkyl, -NH-3-8 membered cycloalkyl, -N(3-8 membered cycloalkyl)(C 1-8 8alkyl), -NH-3-8 membered heterocyclyl, -N(3-8 membered heterocyclyl)(C 1-8 8alkyl), -NH-6-10 membered aryl, -N(6-10 membered aryl)(C 1-8 8alkyl), -NH-5-10 membered heteroaryl, -N(5-10 membered heteroaryl)(C 1-8 8alkyl), -OH, -NH2, -SH, -SO2 P(O)(O-C 1-8 8alkyl)(C 1-8 8alkyl), -P(O)(O-C 1-8 8alkyl)2, -C≡C-C 1-8 8alkyl, -C≡CH, -CH=CH-(C 1-8 8alkyl), -C(C 1-8 8alkyl)=CH-(C 1-8 8alkyl), -C(C 1-8 8alkyl)=C(C 1-8 8alkyl)2, -Si(OH)3, -Si(C 1-8 8alkyl)3, -Si(OH)(C 1-8 8alkyl)2, -C(O)-C 1-8 8alkyl, -C(O)OH, -CN, -CF3, -CHF2, -CH2F, -NO2, -SO2H, -SF5, -S(O)2NH-C 1-8 8alkyl, -S(O)2N(C 1-8 8alkyl)2, -S(O)NH-C 1-8 8alkyl, -S(O)N(C 1-8 8alkyl)2, -C(O)NH-C 1-8 8alkyl, -C(O)N(C 1-8 8alkyl)2, -N(C 1-8 8alkyl)C(O)NH(C 1-8 8alkyl), -N(C 1-8 8alkyl)C(O)N(C 1-8 alkyl), -NHC(O)NH(C 1-8 alkyl), -NHC(O)N(C 1-8 alkyl)2, -NHC(O)NH2, -N(C 1-8 alkyl)S(O)2NH(C 1-8 alkyl), -N(C 1-8 alkyl)S(O)2N(C 1-8 alkyl)2, -NHS(O)2NH(C 1-8 alkyl), -NHS(O)2N(C 1-8 alkyl)2, and -NHS(O)2NH2, said C 1-8 alkyl, 3-11 membered cycloalkyl, 3-11 membered heterocycloalkyl, 6-10 membered aryl, and 5-10 membered heteroaryl are each independently and optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, halocycloalkyl, haloheteroalkyl, -N(C 1-6 alkyl)2, 6-10 membered aryl, 5-10 membered heteroaryl, haloC 6-10 aryl, and halo 5-10 membered heteroaryl; preferably, R L1 , and R L2 each occurrence is independently selected from hydrogen, halogen, C 1-6 alkyl, -O-C 1-6 alkyl, -C(O)-C 1-6 alkyl, -C(O)OH, -CN, -CF3, -CHF2, -CH2F, -NO2, -SO2, 3-6 membered cycloalkyl, and 3-6 membered heterocycloalkyl, said C 1-6 alkyl, C 3-6 cycloalkyl, and 3-6 membered heterocycloalkyl are each independently substituted with one or more substituents selected from halogen, C 1-6 alkyl, C 2-6 heteroalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, hydroxy, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, cyano, amino, nitro, 3-6 membered cycloalkyl, 3-6 membered heterocyclyl, 3-6 membered halocycloalkyl, 3-6 membered haloheteroalkyl, -N(C 1-3 alkyl)2, 6-10 membered aryl, 5-10 heteroaryl, 6-10 membered haloaryl, and 5-10 membered haloheteroaryl; and / or R a7 , R a8 , and R a9 each occurrence is independently selected from N, CH, -C 1-6 alkylene-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)H, and -C 1-6 alkylene-N(C 1-6 alkyl)2; preferably, R a7 , R a8 , and R a9 each occurrence is independently selected from N, CH, CH2N(CH3)2, and (CH2)2-N(CH3)2; preferably, R a7 is CH; R a8 is selected from N, CH, and CH2N(CH3)2; R a9 is CH; and / or R b , R a1 , R a2 , R a3 , R a4 , and R a5 each occurrence is independently selected from hydrogen, halogen, deuterium, cyano, nitro, amino, carboxyl, hydroxyl, C 1- 6alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, 3-7 membered heterocycloalkyl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, 3-6 membered cycloalkyl, -O-3-5 membered cycloalkyl, -C 1-6 alkylene-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)2, and -C 1-6 alkylene-N(C 1-6 alkyl)H; preferably, R b , R a1 , R a2 , R a3 , R a4 , and R a5 each occurrence is independently selected from hydrogen, F, Cl, Br, I, deuterium, nitro, cyano, amino, carboxyl, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, 3-7 membered heterocycloalkyl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, 3-6 membered cycloalkyl, -O-3-5 membered cycloalkyl, -C 1-3 alkylene-NH2, -C 1-3 alkylene-N(C 1-3 alkyl)2, and -C 1-3 alkylene-N(C 1-3 alkyl)H; and / or G1 and G2 are both O; and / or W3 is C(=O); and / or Z is N or CH; and / or R3, R4, R5, and R6are each independently at each occurrence selected from hydrogen, deuterium, halogen, C 1-6 alkyl, C 1-6 deuterated alkyl, C 2-6 heteroalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, hydroxyl, C 1-6 hydroxyalkyl, nitro, cyano, amino, C 1-6 alkylamino, 3-7 membered cycloalkyl, 3-7 membered heterocyclyl containing 1, 2, or 3 heteroatoms each independently selected from N, O, and S, 6-8 membered aryl, and 6-8 membered heteroaryl containing 1, 2, or 3 heteroatoms each independently selected from N, 0, and S, wherein said C 1-6 alkyl, C 2-6 heteroalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, 3-7 membered cycloalkyl, 3-7 membered heterocylyl, 6-8 membered aryl, amino, and 6-8 membered heteroaryl are each independently optionally substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkoxy, haloalkyl, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkylamino, aryl, and heteroaryl; preferably, R3, R4, R5, and R6are each independently at each occurrence selected from 1-6 alkyl, C 1-6 alkoxy, hydroxyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, -NH-C 1-3 alkyl, -NH-C(O)-C 1-3 alkyl, and C 1-6 hydroxyalkyl; more preferably, R3, R4, R5, and R6are each independently at each 1-3 alkyl, C 1-3 alkoxy, hydroxyl, C 1-3 haloalkyl, C 1- haloalkoxy, -NH-C 1-3 alkyl, -NH-C(O)-C 1-3 alkyl, and C 1-3 hydroxyalkyl; and / or A1, A2, A3, A4, A5, and A6are each independently for each occurrence C(R m )2, NR m , C(=O), or -O-; and / or X is, at each occurrence, independently N; and / or m3 is, at each occurrence, independently 0, 1, 2, 3, or 4, m4 is, at each occurrence, independently 0, 1, 2, 3,4, or 5, and m3+m4 < 5; preferably, m3 is, at each occurrence, independently 0, 1, 2, or 3, m4 is, at each occurrence, independently 0, 1, 2,3, or 4, and m3+m4 = 2, m3+m4 = 3, or m3+m4 = 4; and / or m5 is, at each occurrence, independently 0, 1, 2, 4, or 5, m6 is, at each occurrence, independently 1, 2, 3, or 4, and m5+m6 < 4; preferably, m5 is, at each occurrence, independently 0, 1, 2, or 3, R m independently at each occurrence selected from hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, -NH-C 1-3 alkyl, and C 1-6 hydroxyalkyl; preferably, R m independently at each occurrence selected from hydrogen, F, Cl, Br, I, C 1-3 alkyl, C 1-3 alkoxy, hydroxyl, C 1-3 haloalkyl, C 1-3 haloalkoxy, -NH-C 1-3 alkyl, and C 1-3 hydroxyalkyl; more preferably, R m independently at each occurrence selected from H, F, Cl, Br, I, C 1-3 alkyl, C 1-3 alkoxy, hydroxyl, C 1-3 haloalkyl, and C 1-3 hydroxyalkyl; more preferably, R m independently at each occurrence selected from H and methyl; R1, R2are each independently at each occurrence selected from the group consisting of H, F, CI, Br, I, C 1-3 alkyl, C 1-3 alkoxy, hydroxy, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, -C 1-3 alkylene-NH2, -C 1-3 alkylene-N(C 1-3 alkyl)2, and -C 1-3 alkylene-N(C 1-3 alkyl)H; and / or R8is independently at each occurrence selected from H, -C 1-3 alkyl, -C 1-3 alkylene-NH2, -C 1-3 alkylene-N(C 1-6 alkyl)H and -C 1-3 alkylene-N(C 1-6 alkyl)2; preferably, R8is independently at each occurrence selected from H, -CH3, -CH2N(CH3)2and -(CH2)2-N(CH3)2; and / or n is 0 or 1; preferably, n is 1; and / or R aa -C 1-3 alkylene-N(C 1-3 alkyl)2, -0-C 1-3 alkylene-N(C 1-3 alkyl)2, -C 1-3 alkylene-0-C 1-3 alkylene-N(C 1-3 alkyl)2, or -C 1-3 alkylene-4-6 membered heterocyclyl containing 1, 2 or 3 N, O or S heteroatoms; preferably, R aa is selected from:

4. The compound of any one of claims 1-3, wherein, R b is H; R a1 is cyclopentyl; R b2 is C-Br; R b3 is CH; R b4 is CH; R b5 is CH; R a7 is CH; R a8 is CH; R a9 is CH; and / or A1, A2, A3, A4, A5, and A6 are, at each occurrence, independently CH2.

5. The compound of any one of claims 1-4, wherein, The ULM is selected from the following structures:

6. The compound of any one of claims 1-5, wherein, L is a covalent bond or is -(B L ) q -; B L independently for each occurrence, is a divalent linker selected from one or more of the following groups: -0-, -S-, -S(O)-, -S(0)2-, -CH2-, -C(O)-, -NH-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 7-azaspiro[3.5]nonane, 6-azaspiro[4.4]octane, 2-azaspiro[4.5]decane, 2-azaspiro[3.3]heptane, 3-azaspiro[5.5]undecane, spiro[3.5]nonane, spiro[4.4]octane, spiro[4.5]decane, spiro[3.3]heptane, spiro[5.5]undecane, 2,5-diazabicyclo[2.2.2]octane, 2-oxa-4,9-diazaspiro[5.5]undecane, 3-azabicyclo[3.1.0]hexane, 1-oxa-8-azaspiro[4.5]decane, 4-azaspiro[2.5]octane, 3-azabicyclo[3.2.1]octane, 8-azabicyclo[3.2.1]octane, 6-azabicyclo[3.1.1]heptane, 3-azabicyclo[3.1.1]heptane, 2-azabicyclo[2.2.2]octane, and phenylene; wherein the divalent linker is optionally substituted with one or more groups selected from R L1 ; Preferably, the divalent linker is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, fluorosubstituted C 1-6 alkoxy, C 3-6 cycloalkyl, and 3- to 6-membered oxacycloalkyl; more preferably, the divalent linker is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of fluorine, chlorine, cyano, hydroxyl, methyl, ethyl, isopropyl, methoxy, ethoxy, difluoromethoxy, cyclopropyl, and oxetanyl; Preferably, B L Selected from one or more of the following structural segments: -O-, -S-, -S(O)-, -S(O)2-, -CH2-, -C(CH3)2-, -C(O-, -NH-, q is 1, 2, 3, 4, 5, 6 or 7; preferably, q is 1, 2, 3, 4, 5 or 6; and is a point of attachment.

7. The compound of claim 6, wherein L is selected from the following structures: covalent bond, -C(O)-, -C(O)-(CH2) ja -, ja -, pa -NH-(CH2) sa -, ya -NH-(CH2) ja -NH-(CH2) sa -, pa -C(O)-(CH2) sa -, pa -O-(CH2) sa -, ya -C(O)-(CH2) ja -C(O)-(CH2) sa -, ya -O-(CH2) ja -O-(CH2) sa -, ya -O-(CH2) ja -C(O)-(CH2) sa -, ya -C(O)-(CH2) ja -O-(CH2) sa -, pa -NH-(CH2) ya -O-(CH2) ja -C(O)-(CH2) sa -, ya -C(O)-(CH2) ja -O-(CH2) sa -NH-(CH2) pa -, ja, pa, sa, and ya are, at each occurrence, independently selected from 1, 2, 3, and 4.

8. The compound of any one of claims 1-7, wherein, The PTM is selected from the following structures:

9. The compound of any one of claims 1-8, wherein the compound is selected from the group consisting of compounds of Formula 3-1, Formula 3-2, Formula 3-3, Formula 3-4, and Formula 3-5: wherein R b , R b2 , R b3 , R b4 , R b5 , R a1 , R a7 , R a8 , R a9 , L, R3, R4, R5, R6, R8, R1, n and R2 are as defined in any one of claims 1 to 8; provided that: 1) when the compound is selected from Formula 3-1, at least one H in the compound of Formula 3-1 is replaced with R aa , R aa is -C 1-6 alkylene-N(C 1-6 alkyl)2, -O-C 1-6 alkylene-N(C 1-6 alkyl)2, -C 1-6 alkylene-O-C 1-6 alkylene-N(C 1-6 alkyl)2, or -C 1-6 alkylene-3-7 membered heterocyclyl containing 1, 2, or 3 N, O, or S heteroatoms; 2) when PTM is selected from Formula 3-2, L is selected from Preferably, R b2 is CBr; R b3 , R b4 , R b5 , R a7 , R a8 and R a9 are each CH; R a1 is cyclopentyl; R5, R6, R1and R2are H; R8is CH3; n is 1 ; preferably, 1) when the compound is selected from Formula 3-1, the compound has at least one H replaced by R aa substituted, R aa is selected from or when the compound is selected from Formula 3-1, L is selected from 2) when PTM is selected from Formula 3-2, L is selected from 10. A compound of Formula 3-6, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, or polymorph thereof, wherein R is selected from the group consisting of hydrogen, F, CI, Br, I, deuterium, nitro, cyano, amino, carboxyl, hydroxyl, C a1 alkyl, C 1-6 alkyl, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, 3-7 membered heterocycloalkyl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, 3-6 membered cycloalkyl, and -O-3-5 membered cycloalkyl; R b2 is CR a2 ; R b3 is CR a3 ; R b4 is CR a4 ; R b5 is CR a5 ; R a2 , R a3 , R a4 and R a5 are each independently selected from hydrogen, F, Cl, Br, I, deuterium, nitro, cyano, amino, carboxyl, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy and C 1-6 hydroxyalkyl; R8is selected from H and -C 1-6 alkyl; R5and R6are each independently for each occurrence selected from hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, -NH-C 1-3 alkyl, -NH-C(O)-C 1-3 alkyl, and C 1-6 hydroxyalkyl; n is 1; L is selected from B L3 -B L4 wherein, B L3 and B L4 each independently is selected from C(O), C 1-6 alkylene, 3-8 membered alonoheterocycloalkylene, 5-15 membered heterobicycloalkylene, Preferably, R a1 is cyclopentyl; R b2 is CH; R b3 is CH; R b4 is CH; R b5 is CH; R a7 is CH; R a9 is CH; R8is methyl; R5is H; R6is H; and / or L is selected from 3-8 membered alkylenemonoheterocycloalkyl-C(O); preferably, L is selected from 11. The compound of any one of claims 1-10, wherein, The compound is selected from:

12. A compound, or an isomer, isotopic derivative, polymorph, prodrug, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is selected from any one of the following structures:

13. A compound having the structure of Formula II: CLM a — L a — PTM a (Formula II), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, or polymorph thereof, wherein: PTM a is a target protein binding moiety; L a is a covalent linkage CLM a and said PTM a a chemical linking moiety, and CLM a is a cereblon (CRBN) binding moiety selected from any one of the following structures: indicates a CLM a with L a the attachment site.

14. The compound of claim 13, wherein, L a is a bond or is -(B La ) qa -; B La at each occurrence, the same or different, and each is independently selected from CR L1a R L2a , O, S, SO, SO2, NR L3a , SO2NR L3a , SONR L3a , C(O)NR L3a , NR L3a C(O)NR L4a , NR L3a SO2NR L4a , C(O), CR L1a =CR L2a , C≡C, SiR L1a R L2a , P(O)R L1a , P(O)OR L1a , NR L3a C(=NCN)NR L4a , NR L3a C(=NCN), NR L3a C(=CNO2)NR L4a , cycloalkylene, heterocyclylene, arylene, or heteroarylene, wherein the cycloalkylene, heterocyclylene, arylene, and heteroarylene are optionally substituted with 1, 2, 3, 4, 5, or 6 R L1a and / or R L2a groups; R L1a , R L2a , R L3a , and R L4a are independently at each occurrence selected from H, halogen, C 1-8 alkyl, O-C 1-8 alkyl, S-C 1-8 alkyl, NH-C 1-8 alkyl, N(C 1-8 alkyl)2, C 3-11 cycloalkyl, aryl, heteroaryl, C 3-11 heterocycloalkyl, O-C 3-8 cycloalkyl, O-C 3-11 heterocycloalkyl, O-aryl, O-heteroaryl, S-C 3- 8cycloalkyl, NH-C 3-8 cycloalkyl, N(C 3-8 cycloalkyl)2, N(C 3-8 cycloalkyl)(C 1-8 alkyl), NH-C 3-8 heterocycloalkyl, N(C 3-8 heterocycloalkyl)2, N(C 3-8 heterocycloalkyl)(C 1-8 alkyl), NH-aryl, N(aryl)(C 1-8 alkyl), NH-heteroaryl, N(heteroaryl)(C 1-8 alkyl), OH, NH2, SH, SO2 P(O)(O-C 1- 8alkyl)(C 1-8 alkyl), P(O)(O-C 1-8 alkyl)2, C≡C-C 1-8 alkyl, C≡CH, CH=CH-(C 1-8 alkyl), C(C 1-8 alkyl)=CH-(C 1-8 alkyl), C(C 1-8 alkyl)=C(C 1-8 alkyl)2, Si(OH)3, Si(C 1-8 alkyl)3, Si(OH)(C 1-8 alkyl)2, C(O)-C 1-8 alkyl, C(O)OH, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NH-C 1-8 alkyl, SO2N(C 1-8 alkyl)2, SONH-C 1-8 alkyl, SON(C 1-8 alkyl)2, C(O)NH-C 1-8 alkyl, C(O)N(C 1- 8alkyl)2, N(C 1-8 alkyl)2, NHC(O)NH(C 1-8 alkyl), N(C 1-8 alkyl)2, NHC(O)N(C 1-8 alkyl)2, NHC(O)NH(C 1-8 alkyl), NHC(O)N(C 1-8 alkyl)2, NHC(O)NH2, N(C 1-8 alkyl)SO2NH(C 1-8 alkyl), N(C 1-8 alkyl)SO2N(C 1-8 alkyl)2, NHSO2NH(C 1-8 alkyl), NHSO2N(C 1- alkyl)2, and NHSO2NH2, optionally, said C 1-8 alkyl, C 3-11 cycloalkyl, C 3-11 heterocyclyl, C 6-10 aryl, and C 5-10 heteroaryl are each independently substituted with one or more substituents selected from halogen, alkyl, heteroalkyl, alkenyl, alkynyl, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, halocycloalkyl, haloheteroalkyl, alkylamino, aryl, heteroaryl, haloaryl, and haloheteroaryl; and qa is an integer greater than or equal to 1; preferably 1, 2, 3, 4, 5, 6, 1, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 2 0.

15. The compound of claim 14, wherein, B La selected from one or more of the following structures: -O-, -S-, -S(O)-, -S(O)2-, -CH2-, -C(O)-, -NH-, is a point of attachment.

16. The compound of any one of claims 13-15, wherein L a is selected from the following structures: covalent bond, -(CH2) j - -(CH2) p -NH-(CH2) s - -(CH2) y -NH-(CH2) j -NH-(CH2) s - -(CH2) p -C(O)-(CH2) s - -(CH2) p -O-(CH2) s - -(CH2) y -C(O)-(CH2) j -C(O)-(CH2) s - -(CH2) y -O-(CH2) j -O-(CH2) s - -(CH2) y -O-(CH2) j -C(O)-(CH2) s - -(CH2) y -C(O)-(CH2) j -O-(CH2) s - -(CH2) p -NH-(CH2) y -O-(CH2) j -C(O)-(CH2) s - -(CH2) y -C(O)-(CH2) j -O-(CH2) s -NH-(CH2) p -, wherein, j is 1, 2, 3, 4, 5, 6,7, 8, 9, or 10; k, s, p, and y are 0, 1, 2, 3, 4, 5, 1, 7, 8, 9, or 10; CLM a or PTM a of connection points; Preferably, L a -(CH2-CH2-O)3-CH2-CH2-NH-, -NH-(CH2-CH2-O)-CH2-CH2-NH-, -NH-(CH2-CH2-O)2-CH2-CH2-NH-, -NH-(CH2-CH2-O)3-CH2-CH2-NH-, -C(O)-NH-(CH2-CH2-O)-CH2-CH2-NH-, -C(O)-NH-(CH2-CH2-O)2-CH2-CH2-NH-, -C(O)-NH-(CH2-CH2-O)3-CH2-CH2-NH-, -(CH2-CH2-O)-CH2-CH2-C(O)-, -(CH2-CH2-O)2-CH2-CH2-C(O)-, -(CH2-CH2-O)3-CH2-CH2-C(O)-, -NH-(CH2-CH2-O)-CH2-CH2-C(O)-, -NH-(CH2-CH2-O)2-CH2-CH2-C(O)-, -NH-(CH2-CH2-O)3-CH2-CH2-C(O)-, -C(O)-NH-(CH2-CH2-O)-CH2-CH2-C(O)-, -C(O)-NH-(CH2-CH2-O)2-CH2-CH2-C(O)-, -C(O)-NH-(CH2-CH2-O)3-CH2-CH2-C(O)-, -(CH2-CH2-O)-CH2-CH2-NH-C(O)-, -(CH2-CH2-O)2-CH2-CH2-NH-C(O)-, -(CH2-CH2-O)3-CH2-CH2-NH-C(O)-, -NH-(CH2-CH2-O)-CH2-CH2-NH-C(O)-, -NH-(CH2-CH2-O)2-CH2-CH2-NH-C(O)-, -NH-(CH2-CH2-O)3-CH2-CH2-NH-C(O)-, -C(O)-NH-(CH2-CH2-O)-CH2-CH2-NH-C(O)-, -C(O)-NH-(CH2-CH2-O)2-CH2-CH2-NH-C(O)-, -C(O)-NH-(CH2-CH2-O)3-CH2-CH2-NH-C(O)-, -(CH2-CH2-O)-CH2-CH2-C(O)-NH-, -(CH2-CH2-O)2-CH2-CH2-C(O)-NH-, -(CH2-CH2-O)3-CH2-CH2-C(O)-NH-, -NH-(CH2-CH2-O)-CH2-CH2-C(O)-NH-, -NH-(CH2-CH2-O)2-CH2-CH2-C(O)-NH-, -NH-(CH2-CH2-O)3-CH2-CH2-C(O)-NH-, -C(O)-NH-(CH2-CH2-O)-CH2-CH2-C(O)-NH-, -C(O)-NH-(CH2-CH2-O)2-CH2-CH2-C(O)-NH-, -C(O)-NH-(CH2-CH2-O)3-CH2-CH2-C(O)-NH-, -(CH2-CH2-O)-CH2-CH2-NH-C(O)-NH-, -(CH2-CH2-O)2-CH2-CH-C(O)-NH-(CH2-CH2-O)3-CH2-CH2-NH-, -CH2-CH2-(O-CH2-CH2)-, -CH2-CH2-(O-CH2-CH2)2-, -CH2-CH2-(O-CH2-CH2)3-, -NH-CH2-CH2-(O-CH2-CH2)-, -NH-CH2-CH2-(O-CH2-CH2)2-, -NH-CH2-CH2-(O-CH2-CH2)3-, -C(O)-NH-CH2-CH2-(O-CH2-CH2)-, -C(O)-NH-CH2-CH2-(O-CH2-CH2)2-, -C(O)-NH-CH2-CH2-(O-CH2-CH2)3-, -CH2-CH2-(O-CH2-CH2)-NH-, -CH2-CH2-(O-CH2-CH2)2-NH-, -CH2-CH2-(O-CH2-CH2)3-NH-, -NH-CH2-CH2-(O-CH2-CH2)-NH-, -NH-CH2-CH2-(O-CH2-CH2)2-NH-, -NH-CH2-CH2-(O-CH2-CH2)3-NH-, -NH-CH2-CH2-O-CH2-CH2-C(O)-, -C(O)-CH2-CH2-O-CH2-CH2-NH-, -NH-(CH2)4-C(O)-, -NH-(CH2)5-C(O)-, -NH-(CH2)6-C(O)-, -C(O)-(CH2)4-NH-, -C(O)-(CH2)5-NH-, -C(O)-(CH2)6-NH-, -NH-(CH2-CH2-O)-(CH2)3-, -NH-(CH2-CH2-O)-(CH2)4-, -NH-(CH2-CH2-O)-(CH2)5-, -NH-(CH2-CH2-O)-(CH2)6-, -(CH2)3-(O-CH2-CH2)-NH-, -(CH2)4-(O-CH2-CH2)-NH-, -(CH2)5-(O-CH2-CH2)-NH-, -(CH2)6-(O-CH2-CH2)-NH-, -CH2-CH2-O-(CH2)2-C(O)-, -CH2-CH2-O-(CH2)3-C(O)-, -CH2-CH2-O-(CH2)4-C(O)-, -C(O)-(CH2)2-O-CH2-CH2-, -C(O)-(CH2)3-O-CH2-CH2-, -C(O)-(CH2)4-O-CH2-CH2-, -C(O)-(CH2)2-, -C(O)-(CH2)3-, -C(O)-(CH2)4-, -C(O)-(CH2)5-, -C(O)-(CH2)6-,-(CH2)2-C(O)-, -(CH2)3-C(O)-, -(CH2)4-C(O)-, -(CH2)5-C(O)-, -(CH2)6-C(O)-, -C(O)-(CH2)2-C(O)-, -C(O)-(CH2)3-C(O)-, -C(O)-(CH2)4-C(O)-, -C(O)-(CH2)5-C(O)-, -C(O)-(CH2)6-C(O)-, -CH2-C(O)-CH2-, -CH2-C(O)-(CH2)2-, -CH2-C(O)-(CH2)3-, -CH2-C(O)-(CH2)4-, -(CH2)2-C(O)-CH2-, -(CH2)2-C(O)-(CH2)2-, -(CH2)2-C(O)-(CH2)3-, -(CH2)2-C(O)-(CH2)4-, -(CH2)3-C(O)-CH2-, -(CH2)3-C(O)-(CH2)2-, -(CH2)3-C(O)-(CH2)3-, -(CH2)3-C(O)-(CH2)4-, -(CH2)4-C(O)-CH2-, -(CH2)4-C(O)-(CH2)2-, -(CH2)4-C(O)-(CH2)3-, -(CH2)4-C(O)-(CH2)4-, -CH2-O-CH2-, -CH2-O-(CH2)2-, -CH2-O-(CH2)3-, -CH2-O-(CH2)4-, -(CH2)2-O-CH2-, -(CH2)2-O-(CH2)2-, -(CH2)2-O-(CH2)3-, -(CH2)2-O-(CH2)4-, -(CH2)3-O-CH2-, -(CH2)3-O-(CH2)2-, -(CH2)3-O-(CH2)3-, -(CH2)3-O-(CH2)4-, -(CH2)4-O-CH2-, -(CH2)4-O-(CH2)2-, -(CH2)4-O-(CH2)3-, -(CH2)4-O-(CH2)4-, 17. The compound of any one of claims 13-16, wherein, PTM is a moiety that binds to a target protein or polypeptide, wherein the target protein is selected from the group consisting of B7.1, B7, TNFR2, NADPH oxidase, other partners in the Bcl / Bax and apoptosis pathways, C5a receptor, HMG-CoA reductase, PDE5 (phosphodiesterase type 5), PDE4 (phosphodiesterase type 4), PDE1, PDE2, PDE3, squalene epoxidase, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclooxygenase 1, cyclooxygenase 2, 5-HT receptor, dopamine receptor, G protein (e.g., Gq), histamine receptor, 5-lipoxygenase, tryptase serine protease, thymidylate synthetase, purine nucleoside phosphorylase, trypanosomal GAPDH, glycogen phosphorylase, carbonic anhydrase, chemokine receptor, JAK, STAT, RXR and analogs thereof, HIV-1 protease, HIV-1 integrase, influenza neuraminidase, hepatitis B reverse transcriptase, sodium channel, multiple drug resistance-associated protein P-glycoprotein, tyrosine kinase, CD23, CD124, tyrosine kinase p56lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-α receptor, ICAM-1, calcium channel (Ca2+ channel), VCAM, VLA-4 integrin, selectin, CD40 / CD40L, inosine monophosphate dehydrogenase, p38 MAP kinase, Ras / Raf / MEK / ERK pathway, interleukin-1 beta converting enzyme, caspase, HCV NS3 protease, HCV NS3 5A protease, HCV NS4A protease, HCV NS4B protein, HCV NS5A protein, HCV NS5B polymerase, HCV El protein, HCV E2 protein, HCV E3 protein, HCV E4 protein, HCV E5 protein, HCV E6 protein, HCV E7 protein, HCV E8 protein, HCV E9 protein, HCV E10 protein, HCV E11 protein, HCV E12 protein, HCV E13 protein, HCV E14 protein, HCV E15 protein, HCV E16 protein, HCV E17 protein, HCV E18 protein, HCV E19 protein, HCV E20 protein, HCV E21 protein, HCV E22 protein, HCV E23 protein, HCV E24 protein, HCV E25 protein, HCV E26 protein, HCV E27 protein, HCV E28 protein, HCV E29 protein, HCV E30 protein, HCV E31 protein, HCV E32 protein, HCV E33 protein, HCV E34 protein, HCV E35 protein, HCV E36 protein, HCV E37 protein, HCV E38 protein, HCV E39 protein, HCV E40 protein, HCV E41 protein, HCV E42 protein, HCV E43 protein, HCV E44 protein, HCV E45 protein, HCV E46 protein, HCV E47 protein, HCV E48 protein, HCV E49 protein, HCV E50 protein, HCV E51 protein, HCV E52 protein, HCV E53 protein, HCV E54 protein, HCV E55 protein, HCV E56 protein, HCV E57 protein, HCV E58 protein, HCV E59 protein, HCV E60 protein, HCV E61 protein, HCV E62 protein, HCV E63 protein, HCV E64 protein, HCV E65 protein, HCV E66 protein, HCV E67 protein, HCV E68 protein, HCV E69 protein, HCV E70 protein, HCV E71 protein, HCV E72 protein, HCV E73 protein, HCV E74 protein, HCV E75 protein, HCV E76 protein, HCV E77 protein, HCV E78 protein, HCV E79 protein, HCV E80 protein, HCV E81 protein, HCV E82 protein, HCV E83 protein, HCV E84 protein, HCV E85 protein, HCV E86 protein, HCV E87 protein, HCV E88 protein, HCV E89 protein, HCV E90 protein, HCV E91 protein, HCV E92 protein, HRNA helicase, glutamine ribonucleotide formyltransferase, rhinovirus 3C protease, herpes simplex virus-1 (HSV-1) protease, cytomegalovirus (CMV) protease, poly(ADP-ribose) polymerase, cyclin-dependent kinase 4 / 6, vascular endothelial growth factor, oxytocin receptor, microsomal triglyceride transfer protein, bile acid transport protein, 5a-reductase, angiotensin II, glycine receptor, norepinephrine reuptake receptor, endothelin receptor, neuropeptide Y and its receptors, adenosine receptors, adenosine kinase, AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyl transferase, geranylgeranyl transferase, NGF receptor TrkA, beta-amyloid, VEGF receptor Flk-1 / KDR, vitronectin receptor, integrin receptor, Her-2 / neu, telomerase, cytosolic phospholipase A2, EGF receptor tyrosine kinase, ecdysone 20-monooxygenase, GABA-gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, chloride channel, acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, enolpyruvyl shikimate phosphate synthetase, MYC protein, androgen receptor, estrogen receptor, aurora kinase A, Bcr-Abl protein, epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Bruton's tyrosine kinase (BTK), bromodomain-containing protein 4 (BRD4), SMARCA2 / 4, IRAK4 protein, STAT6, IKZF2, IRF5, CDK2, ActR II, and KAT6.

18. The compound of any one of claims 13-17, wherein, PTM a selected from the group consisting of structures that bind SMARCA2 / 4; Preferably, the PTM a selected from the group consisting of: R b2 is N or CR a2 ; preferably, R b2 is CH; R b3 is N or CR a3 ; preferably, R b3 is CH; R b4 is N or CR a4 ; preferably, R b4 is N or CH; R b5 is N or CR a5 ; preferably, R b5 is CH; R a7 , R a8 , and R a9 are each independently selected from N and CR b ; preferably, R a7 , R a8 , and R a9 are each independently selected from N, CH, -C 1-6 alkylene-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)H, and -C 1-6 alkylene-N(C 1-6 alkyl)2; preferably, R a7 , R a8 , and R a9 are each independently selected from N, CH, CH2N(CH3)2, and (CH2)2-N(CH3)2; preferably, R a7 is CH; R a8 is selected from N, CH, and CH2N(CH3)2; R a9 is CH; R b , R a1 , R a2 , R a3 , R a4 , R a5 each occurrence is independently selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, deuterated alkyl, heteroalkyl, alkenyl, alkynyl, amino, haloalkoxy, hydroxyalkyl, alkoxy, cyano, hydroxyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C 1-6 alkylene-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)2, -C 1-6 alkylene-N(C 1-6 alkyl)H, and -O-cycloalkyl; preferably, R b , R a1 , R a2 , R a3 , R a4 , and R a5 each occurrence is independently selected from hydrogen, halogen, deuterium, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, nitro, amino, carboxyl, hydroxyl, 3-7 membered heterocycloalkyl containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, 3-6 membered cycloalkyl, -O-3-5 membered cycloalkyl, -C 1-6 alkylene-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)2, and -C 1-6 alkylene-N(C 1-6 alkyl)H; preferably, R b , R a1 , R a2 , R a3 , R a4 , R a5 each occurrence is independently selected from hydrogen, F, Cl, Br, I, deuterium, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, nitro, amino, carboxyl, hydroxyl,3-7 membered heterocycloalkyl containing 1, 2, or3 heteroatoms independently selected from N, O, and S, C 1-6 haloalkyl, C 1-6 hydroxyalkyl 3-6 membered cycloalkyl, -O-3-5 memberedcycloalkyl, -C 1-3 alkylene-NH2, -C 1-3 alkylene-N(C 1-3 alkyl)2, and -C 1-3 alkylene-N(C 1-3 alkyl)H; Preferably, the PTM is selected from the following structures:

19. A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1-10 and 12-18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

20. Use of a compound of any one of claims 1-10 and 12-18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19, in the manufacture of a medicament for the treatment or prevention of a disease or disorder mediated by SMARCA2 / 4; preferably, the disease or disorder is cancer; preferably, the cancer is lung cancer or cervical cancer.

21. A compound of any one of claims 1-10 and 12-18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19, for use in the treatment or prevention of a disease or disorder mediated by SMARCA2 / 4; preferably, the disease or disorder is cancer; preferably, the cancer is lung cancer or cervical cancer.

22. A method of treating or preventing a disease or disorder mediated by SMARCA2 / 4, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-10 or 12-18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19; preferably, the disease or disorder is cancer; preferably, the cancer is lung cancer or cervical cancer.

23. Use of a compound of claim 12, or an isomer, isotopic derivative, polymorph, prodrug, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment or prevention of a disorder treated by binding to cereblon in vivo.

24. Use of a compound of claim 12, or an isomer, isotopic derivative, polymorph, prodrug, or a pharmaceutically acceptable salt or solvate thereof, as a CRBN binding moiety in the manufacture of a protein degradation targeting chimera (PROTAC) medicament.